

CITATION REPORT

List of articles citing

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program

DOI: 10.1200/jco.1998.16.8.2825

Journal of Clinical Oncology, 1998, 16, 2825-33.

Source: <https://exaly.com/paper-pdf/29797692/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2377	Adaptive immunity in cancer immunology and therapeutics. 2014 , 8, 441		26
2376	Sun Tzu and the Art of BusinessSun Tzu and the Art of Business By McNeillyMark R., Oxford: Oxford University Press, 1996, 225 pages, hard, cover, \$25.00. 1997 , 11, 129-130		1
2375	Rituxan in the Treatment of Cold Agglutinin Disease. 1998 , 92, 3490-3491		107
2374	Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. 1999 , 10, 1525-7		82
2373	Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. <i>Journal of Clinical Oncology</i> , 1999 , 17, 791-5	2.2	224
2372	Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3793-803	2.2	473
2371	Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1851-7	2.2	253
2370	Clinical Investigation of the Monoclonal Anti-CD20 Antibody Rituximab (IDEC-C2B8) in Patients with B Cell Lymphoma. 1999 , 54, 343-360		
2369	Responses in Refractory Hairy Cell Leukemia to a Recombinant Immunotoxin. 1999 , 94, 3340-3348		145
2368	Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8). 1999 , 94, 2217-2224		519
2367	Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. 1999 , 15, 1017-25		24
2366	An array of immunotherapeutic strategies for B-cell lymphomas. 1999 , 8, 2059-2071		
2365	Cancer dormancy and cell signaling: induction of p21(waf1) initiated by membrane IgM engagement increases survival of B lymphoma cells. 1999 , 96, 8711-5		42
2364	Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2. <i>Leukemia and Lymphoma</i> , 1999 , 35, 641-2	1.9	26
2363	Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer. 1999 , 14, 5-10		38
2362	Rituximab immunotherapy. 1999 , 14, 237-40		4
2361	Rituximab immunotherapy for non-Hodgkin's lymphoma. 1999 , 14, 241-50		13

2360	Immunotoxins in cancer therapy. 1999 , 11, 570-8			182
2359	Signaling antibodies in cancer therapy. 1999 , 11, 541-7			115
2358	The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients. 1999 , 3, 271-81			108
2357	The problem of anti-pig antibodies in pig-to-primate xenografting: current and novel methods of depletion and/or suppression of production of anti-pig antibodies. 1999 , 6, 157-68			73
2356	Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K. <i>British Journal of Haematology</i> , 1999 , 106, 47-54	4.5		25
2355	Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation. <i>British Journal of Haematology</i> , 1999 , 106, 545-52	4.5		24
2354	Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma. 1999 , 77, 451-9			26
2353	Do self-perpetuating B lymphocytes drive human autoimmune disease?. 1999 , 97, 188-96			143
2352	A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. 1999 , 17, 276-81			75
2351	Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1999 , 24, 521-6	4.4		33
2350	Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1999 , 24, 1253-8	4.4		33
2349	[Hematology and internal medicine oncology]. 1999 , 40, 356-68			
2348	Detection and relevance of minimal disease in lymphomas. 1999 , 18, 127-42			14
2347	Chimeric monoclonal anti-CD20 antibody (rituximab)--an effective treatment for a patient with relapsing hairy cell leukaemia. 1999 , 16, 221-2			18
2346	Behandlung von malignen Lymphomen mit dem mono-klonalen anti-CD20 Antikörper Rituximab (IDEC-C2B8). 1999 , 5, 532-540			0
2345	Einsatz mono- und bispezifischer Antikörper in der Tumorthherapie. 1999 , 5, 679			1
2344	Clinical applications of anti-CD20 antibodies. 1999 , 134, 445-50			90
2343	Autologous hematopoietic cell transplantation in non-Hodgkin's lymphoma. 1999 , 13, 889-918			11

2342 Rituximab is a new option for patients with relapsed indolent non-Hodgkin's lymphoma. **1999**, 14, 1-5

2341 Monoclonal antibodies in cancer treatment: a review of recent progress. **1999**, 12, 209-36

6

2340 [Hematology]. **1999**, 20, 74-80

2339 Rituximab. **1999**, 58, 79-88; discussion 89-90

98

2338 Malignancy: Current Clinical Practice: Treatment of Hairy Cell Leukemia at the Close of the 20th Century. **1999**, 4, 283-303

1

2337 Limited stage I and II follicular non-Hodgkin's lymphoma: the Nebraska Lymphoma Study Group experience. *Leukemia and Lymphoma*, **1999**, 34, 273-85

1.9 18

2336 Antibody therapy has arrived. Now where does it fit?. **1999**, 10, 619-21

5

2335 Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy. **1999**, 10, 1249-50

14

2334 A new approach to non-Hodgkin's lymphoma. **2000**, 39, 197-208

7

2333 Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. *Journal of Clinical Oncology*, **2000**, 18, 1622-36

2.2 379

2332 Lymphoma: a clinical view. **2000**, 1, 64-76

2331 Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing lymphoma. **2000**, 11, 857-60

7

2330 Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas. **2000**, 11, 363-5

30

2329 Improving results of intestinal transplantation. **2000**, 5, 295-299

1

2328 Advances in immunotherapy of hematologic malignancies: cellular and humoral approaches. **2000**, 7, 247-54

5

2327 Chronic lymphocytic leukemia. **2000**, 7, 223-34

84

2326 Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. **2000**, 14, 1675-88

74

2325 Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas. **2000**, 85, 104-12

31

2324	Tumor necrosis factor modulates CD 20 expression on cells from chronic lymphocytic leukemia: a new role for TNF alpha?. 2000 , 50, 251-7		18
2323	Noninvasive localization of tumors by immunofluorescence imaging using a single chain Fv fragment of a human monoclonal antibody with broad cancer specificity. 2000 , 89, 1134-44		42
2322	Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. 2000 , 89, 1835-1844		98
2321	Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes. 2000 , 30, 3165-70		23
2320	Rituximab in cutaneous B-cell lymphoma: a report of two cases. 2000 , 143, 157-61		40
2319	A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. <i>British Journal of Haematology</i> , 2000 , 109, 81-8	4.5	89
2318	In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2000 , 109, 729-35	4.5	72
2317	Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. 2000 , 51, 634-41		221
2316	Advances in the systemic treatment of cancers in the elderly. 2000 , 35, 201-18		12
2315	Follicular lymphomas--a review of treatment modalities. 2000 , 35, 13-32		6
2314	Immunology and immunotherapy of human cancer: present concepts and clinical developments. 2000 , 34, 1-25		59
2313	Aggressive lymphoma in the elderly. 2000 , 33, 119-28		7
2312	Clinical trials of antibody therapy. 2000 , 21, 403-10		243
2311	Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: toxicity, follow-up of minimal residual disease and survival. <i>Bone Marrow Transplantation</i> , 2000 , 26, 1051-6	4.4	11
2310	Monoclonal Antibodies in Chronic Lymphocytic Leukemia. 2000 , 4, 134-144		
2309	Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. 2000 , 24, 411-5		72
2308	Promising approaches in acute leukemia. 2000 , 18, 57-82		4
2307	Expression of a functional mouse-human chimeric anti-CD19 antibody in the milk of transgenic mice. 2000 , 9, 155-9		8

2306	Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. 2000 , 204, 55-63	128
2305	Antibody immunotherapy for leukemia. 2000 , 2, 114-22	7
2304	Biotherapy for lymphoma. 2000 , 2, 157-62	3
2303	IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. 2000 , 79, 493-500	82
2302	Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience. 2000 , 79, 175-82	53
2301	Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD 20 antibody rituximab. 2000 , 79, 332-5	16
2300	Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients. 2000 , 17, 203-10	25
2299	Risk factors for side effects during first infusion of rituximab-definition of a low risk group. 2000 , 17, 218-21	10
2298	Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma. 2000 , 17, 225-8	16
2297	Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. 2000 , 95, 3052-3056	248
2296	Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. 2000 , 95, 3900-3908	477
2295	Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. 2000 , 96, 4055-4063	154
2294	Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. 2000 , 96, 1259-1266	419
2293	Emerging immunotherapies for non-Hodgkin lymphomas: the tortoise approaches the finish line. 2000 , 132, 916-8	4
2292	Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2000 , 38, 91-101	1.9 53
2291	T-cell infiltrate after monoclonal anti-CD20 antibody therapy for B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2000 , 37, 387-91	1.9 1
2290	Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3135-43	2.2 588
2289	Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2603-6	2.2 194

2288	High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. <i>Journal of Clinical Oncology</i> , 2000 , 18, 527-36	2.2	155
2287	The curious case of the baffling biological. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2007-9	2.2	13
2286	European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. <i>Journal of Clinical Oncology</i> , 2000 , 18, 317-24	2.2	404
2285	Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1316-23	2.2	301
2284	Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. 2000 , 133, 275-9		115
2283	Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma?. 2000 , 11, 374-5		60
2282	Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates. 2000 , 11, 399-408		59
2281	Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells. 2000 , 83, 1375-9		32
2280	Pretargeted radioimmunotherapy of non-Hodgkin's lymphoma: best of both worlds?. 2000 , 15, 1-5		1
2279	Treatment advances in non-Hodgkin's lymphoma. 2000 , 1, 451-66		4
2278	Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response. 2000 , 11, S117-S121		44
2277	The effect of Rituximab on patients with follicular and mantle-cell lymphoma. 2000 , 11, S123-S126		40
2276	Acute Toxicity of Mitoxantrone, Chlorambucil and Prednisolone (MCP) versus MCP plus Rituximab in Low-Grade Non-Hodgkin's Lymphoma - Interim Results of a Phase III Trial. 2000 , 23, 164-166		1
2275	Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens. 2000 , 11, S107-S111		17
2274	Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. 2000 , 1, 1-9		102
2273	Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. 2000 , 11, S113-S116		168
2272	Immunotoxins. 2000 , 1, 1117-29		24
2271	Follicular lymphoma: Have we made any progress?. 2000 , 11, S23-S27		43

2270	Diffuse large-cell lymphoma. 2000 , 11, S29-S33	6
2269	Follicle centre cell lymphoma: optimal use of therapeutic options. 2000 , 11 Suppl 3, 111-5	3
2268	Monoclonal antibody therapy in lymphoid malignancies. 2000 , 5, 376-84	49
2267	Hematologic malignancies: selected abstracts and commentary. 2000 , 5, 280-4	
2266	Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia. 2000 , 6, 81-7	30
2265	Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. 2000 , 165, 5954-61	105
2264	Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. 2000 , 26, 133-43	181
2263	Monoclonal antibody therapy for solid tumors. 2000 , 26, 269-86	125
2262	Recent advances in immunotherapy and monoclonal antibody treatment of cancer. 2000 , 16, 2-12	18
2261	[Lymphomas in children infected with HIV-1]. 2000 , 7, 738-44	8
2260	Physics for practitioners: the use of radiolabeled monoclonal antibodies in B-cell non-Hodgkin's lymphoma. 2000 , 37, 2-8	7
2259	Monoclonal antibodies in lymphoid neoplasia: principles for optimal combined therapy. 2000 , 37, 17-26	10
2258	Investigation of monoclonal antibody therapy with conventional and high-dose treatment: current clinical trials. 2000 , 37, 27-33	4
2257	Monoclonal antibody-based therapy of lymphoid neoplasms: what's on the horizon?. 2000 , 37, 34-42	2
2256	A perspective on monoclonal antibody therapy: where we have been and where we are going. 2000 , 37, 43-6	14
2255	In vitro and in vivo purging of B lymphoma cells from stem-cell products using anti-CD20 Abs. 2000 , 2, 445-53	2
2254	Prolonged disease-free survival after autografting for chemosensitive non-bulky low grade non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2000 , 39, 283-90	1.9 3
2253	Therapeutic uses of MAbs directed against CD20. 2000 , 2, 455-61	1

2252	Rituximab/CHOP Induction Therapy in Newly Diagnosed Patients with Mantle-Cell Lymphoma1. 2000 , 1, 27-28	17
2251	The 41st annual meeting of the American Society of Hematology. New Orleans, LA. December 3-7, 1999. 2000 , 1, 17-26	1
2250	The expanding frontier of radioimmunotherapy of relapsed Non-hodgkin's lymphoma. 2000 , 1, 158-9	
2249	Commentary on "Excellent Tolerance of Rituximab When Given After Mitoxantrone/Cyclophosphamide: An Effective and Safe Combination for Indolent Non-Hodgkin's Lymphoma" 2000 , 1, 152-153	3
2248	European Society of Medical Oncology (ESMO). Hamburg, Germany. October 13-17, 2000. American Society of Hematology. San Francisco, CA. December 1-5, 2000. 2000 , 1, 173-8	
2247	Commentary on "Rituximab Therapy of B-Cell Neoplasms" 2000 , 1, 195-196	3
2246	Progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem-cell transplantation: changing the natural history with monoclonal antibody therapy. 2000 , 1, 62-6	6
2245	36th annual American Society of Clinical Oncology meeting. New Orleans, LA. May 20-23, 2000. 2000 , 1, 93-100	
2244	The history of the development of vaccines for the treatment of lymphoma. 2000 , 1, 129-39; discussion 140	29
2243	Excellent tolerance of rituximab when given after mitoxantrone/cyclophosphamide: an effective and safe combination for indolent non-Hodgkin's lymphoma. 2000 , 1, 146-51; discussion 152-3	11
2242	Rituximab therapy of B-cell neoplasms. 2000 , 1, 186-94; discussion 195-6	25
2241	Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. 2000 , 11, 611-20	108
2240	37th Annual American Society of Clinical Oncology Meeting. San Francisco, CA. May 12-15, 2001. 2001 , 2, 11-7	
2239	6th European Hematology Association Meeting. Frankfurt, Germany. June 21-24, 2001. 2001 , 2, 74-9	
2238	Meeting highlights from 43rd annual meeting of the American Society of Hematology, December 7-11, 2001, Orlando, Florida and First International Congress on Monoclonal Antibodies, August 30-September 2, 2001, Banff, Alberta, Canada. 2001 , 2, 139-44	1
2237	Current Understanding of Possible Mechanisms of Action and Resistance of Rituximab. 2001 , 2, 145-147	
2236	Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma. 2001 , 1, 177-86	23
2235	Antibody-targeted immunotherapy for treatment of malignancy. 2001 , 52, 125-45	102

2234	Management of AIDS-related non-Hodgkin's lymphomas. 2001 , 61, 1301-15	9
2233	Advances in the therapy of primary central nervous system lymphoma. 2001 , 1, 263-75; discussion 276-7	12
2232	Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells. 2001 , 1, 293-7	6
2231	Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members. 2001 , 2, 164-72	21
2230	Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. 2001 , 41, 1206-14	110
2229	Rituximab-induced vasculitis. 2001 , 203, 83-4	48
2228	Salvage therapy for refractory or relapsed acute lymphocytic leukemia. 2001 , 15, 163-205	57
2227	Tumours: Immunotherapy. 2001 ,	
2226	High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. 2001 , 7, 294-301	64
2225	Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. 2001 , 98, 1326-31	307
2224	Progress in CLL, chemotherapy, antibodies and transplantation. 2001 , 55, 524-8	8
2223	Human therapeutic antibodies. 2001 , 1, 404-8	22
2222	The therapeutic use of antibodies for malignancy. 2001 , 8, 255-9	5
2221	A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2001 , 41, 77-87	1.9 45
2220	Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. 2001 , 97, 3995-7	136
2219	Radioimmunotherapy versus traditional, nontargeted forms of systemic cancer treatment. 2001 , 1, 501-5	1
2218	Radioimmunotherapy: potential as a therapeutic strategy in non-Hodgkin's lymphoma. 2001 , 15, 151-62	8
2217	Prolonged molecular and clinical remission after treatment of a patient with follicular lymphoma with rituximab. <i>Leukemia and Lymphoma</i> , 2001 , 41, 451-5	1.9 4

2216	Chemotherapy plus interferon-alpha2b versus chemotherapy in the treatment of follicular lymphoma. 2001 , 10, 669-74		6
2215	Behandlung indolenter Non-Hodgkin-Lymphome: Neue Akzente für die Praxis. 2001 , 24, I-I		
2214	Some like it hot!. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3908-11	2.2	19
2213	Rituximab: An innovative therapy for non-Hodgkin's lymphoma. 2001 , 58, 215-229		15
2212	Therapeutic immunology. 2001 , 68-86		
2211	Follicular lymphoma. 2001 , 111-125		
2210	Palliative systemic antineoplastic therapy. 2001 , 399-420		
2209	Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2153-64	2.2	450
2208	Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3918-28	2.2	499
2207	Rituximab dose-escalation trial in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2165-70	2.2	527
2206	CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenström's Macroglobulinemia. 2001 , 24, 272-279		134
2205	Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies. 2001 , 24, 263-271		163
2204	Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. 2001 , 19, 833-41		58
2203	Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin's lymphoma and corrected with IVIG. 2001 , 12, 1493-4		11
2202	Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma. 2001 , 12, 457-62		14
2201	Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. 2001 , 12, 109-14		51
2200	Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. 2001 , 97, 1392-8		161
2199	Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. 2001 , 98, 952-7		466

2198	Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. 2001 , 98, 1352-7		189
2197	A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. 2001 , 98, 2535-43		118
2196	Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. 2001 , 98, 2771-7		175
2195	Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2001 , 19, 389-97	2.2	364
2194	Immunotherapy of Non-Hodgkin's lymphomas. 2001 , 2001, 221-40		64
2193	Non-Hodgkin's lymphoma. 2001 , 1, 362-4		
2192	Monoclonal Antibodies: Therapeutic Uses. 2001 ,		
2191	Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotherapy. 2001 , 50, 157-62		4
2190	Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome. 2001 , 80, 170-3		34
2189	Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab. 2001 , 80, 479-81		10
2188	[Clinical use of monoclonal antibodies in malignant lymphomas]. 2001 , 42, 815-6, 819-26		2
2187	[Radioimmunoconjugates: therapy of non-Hodgkin lymphomas and colorectal carcinomas]. 2001 , 42, 860-4, 866-73		3
2186	Antibody-based diagnostic and therapeutic innovations for human cancer. 2001 , 27, 183-94		1
2185	Antikörper, Immuntoxine, Radioimmunkonjugate. 2001 , 7, 1206-1219		1
2184	Autologous peripheral blood stem cell transplantation and anti-B-cell directed immunotherapy for refractory auto-immune haemolytic anaemia. 2001 , 160, 492-6		16
2183	Efficacy of anti-CD20 chimeric Fabâ€fragment on proliferation of B lymphoma cells. 2001 , 46, 1182-1186		2
2182	Re-treatment of relapsed indolent B-cell lymphoma with rituximab. <i>International Journal of Hematology</i> , 2001 , 73, 213-21	2.3	37
2181	Assessment of prognostic factors in follicular lymphoma patients. <i>International Journal of Hematology</i> , 2001 , 73, 363-8	2.3	16

2180	Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. <i>International Journal of Hematology</i> , 2001 , 74, 70-5	2.3	35
2179	Intralesional rituximab for cutaneous B-cell lymphoma. 2001 , 144, 1239-43		61
2178	Pure red cell aplasia in patients with chronic lymphocytic leukaemia treated with cladribine. <i>British Journal of Haematology</i> , 2001 , 112, 1083-5	4.5	9
2177	Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. <i>British Journal of Haematology</i> , 2001 , 114, 800-9	4.5	159
2176	Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. <i>British Journal of Haematology</i> , 2001 , 115, 79-83	4.5	70
2175	Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. <i>British Journal of Haematology</i> , 2001 , 115, 609-11	4.5	83
2174	Complement activation plays a key role in the side-effects of rituximab treatment. <i>British Journal of Haematology</i> , 2001 , 115, 807-11	4.5	230
2173	Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab. 2001 , 37, 13-25		30
2172	Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy. 2001 , 38, 47-61		21
2171	Susceptibility of B-cell lymphoma to human antibodies encoded by the V4-34 gene. 2001 , 39, 59-68		4
2170	Rituximab: perspective on single agent experience, and future directions in combination trials. 2001 , 40, 3-16		61
2169	Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. 2001 , 66, 142-4		146
2168	Humanization and characterization of the anti-HLA-DR antibody 1D10. 2001 , 93, 556-65		55
2167	A novel beta-thalassemia intermedia phenotype containing Nt494+129T-->C and NT494+132C-->A mutations in cis and a Nt168C-->T (beta(o) 39 point) mutation in trans. 2001 , 67, 57-8		2
2166	Normal delta globin gene sequence in carrier of the silent-101 (C-T) beta-thalassemia mutation with normal HbA2 level. 2001 , 67, 58		4
2165	Multiple complications of IVIG therapy in a patient with Guillain-Barr'syndrome. 2001 , 67, 59		14
2164	Refractory autoimmune thrombocytopenic purpura treatment with Rituximab. 2001 , 67, 59-60		24
2163	Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. 2001 , 44, 2836-40		304

2162	Optimizing therapeutic strategies to inhibit circulating soluble target molecules with monoclonal antibodies: example of the soluble IL-6 receptors. 2001 , 31, 259-64		6
2161	Metastatic gastric maltoma: a rare cause of obscure gastrointestinal bleeding. 2001 , 46, 1167-70		
2160	Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study. 2001 , 18, 141-8		17
2159	Trastuzumab: designer drug or fashionable fad?. 2001 , 13, 427-33		1
2158	Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. 2001 , 85, 129-36		54
2157	Rituximab: mechanisms and applications. 2001 , 85, 1619-23		73
2156	New aspects on the pathogenesis, diagnostic procedures, and therapeutic management of chronic lymphocytic leukemia. <i>International Journal of Hematology</i> , 2001 , 73, 32-8	2-3	13
2155	Severe thrombocytopenia and clinical bleeding associated with rituximab infusion in a lymphoma patient with massive splenomegaly without leukemic invasion. 2001 , 15, 186-7		17
2154	CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. 2001 , 15, 1619-26		120
2153	Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. 2001 , 15, 1941-9		42
2152	Improving the efficacy of antibody-based cancer therapies. 2001 , 1, 118-29		687
2151	CORRESPONDENCE. <i>British Journal of Haematology</i> , 2001 , 112, 1083-1085		4-5
2150	Correspondence. <i>British Journal of Haematology</i> , 2001 , 112, 1085-1086		4-5
2149	Correspondence. <i>British Journal of Haematology</i> , 2001 , 112, 1086-1087		4-5
2148	Correspondence. <i>British Journal of Haematology</i> , 2001 , 112, 1087-1088		4-5 2
2147	Correspondence. <i>British Journal of Haematology</i> , 2001 , 112, 1089-1089		4-5
2146	Correspondence. <i>British Journal of Haematology</i> , 2001 , 112, 1090-1090		4-5
2145	Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies. 2001 , 248, 103-11		66

2144	Monoclonal antibody therapy for lymphoma: an update. 2001 , 9, 71-80		35
2143	Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab. 2001 , 29, 1410-6		31
2142	Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia. 2001 , 66, 408-11		32
2141	Anti-CD20 monoclonal antibody treatment of human herpesvirus 8-associated, body cavity-based lymphoma with an unusual phenotype in a human immunodeficiency virus-negative patient. 2001 , 8, 993-6		26
2140	Rituximab in combination with interferon-alpha in relapsed and refractory diffuse large B-cell non-Hodgkin's lymphoma. 2001 , 106, 141-2		3
2139	Specific Immunotherapy for Non-Hodgkin's Lymphoma. 2001 , 32, 609-616		
2138	Evaluation on a six-dose treatment of anti CD 20 monoclonal antibody in patients with refractory follicular lymphoma. 2001 , 16, 159-62		3
2137	Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. <i>Leukemia and Lymphoma</i> , 2001 , 42, 1329-37	1.9	21
2136	Recombinant immunotoxins in targeted cancer cell therapy. 2001 , 81, 93-124		41
2135	Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. 2001 , 97, 101-6		457
2134	A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer. 2001 , 85, 152-6		83
2133	Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. 2001 , 40, 205-11		394
2132	High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150. <i>Leukemia and Lymphoma</i> , 2001 , 42, 1255-64	1.9	
2131	Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody. 2001 , 81, 207-8		28
2130	Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2001 , 42, 577-86	1.9	6
2129	Advances in the management of patients with non-Hodgkin's lymphoma. 2001 , 1, 43-52		4
2128	Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2001 , 42, 731-8	1.9	85
2127	Komplette Remission eines langjährig therapierefraktären sekundär hochmalignen Non-Hodgkin-Lymphoms nach Therapie mit Bendamustin und CD 20-Ak (Rituximab). 2001 , 22, 15-19		1

2126	Antibody therapy of lymphoma. 2001 , 2, 953-61		11
2125	Rituximab in the treatment of refractory follicular lymphoma -- six doses are better than four. 2001 , 10, 313-6		11
2124	Monoclonal antibody therapy. 2001 , 56, 369-421		9
2123	Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. 2002 , 17, 621-30		37
2122	In vivo pharmacodynamic effects of Hu1D10 (remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1303-12	1.9	20
2121	High in vivo production of a model monoclonal antibody on adenoviral gene transfer. 2002 , 13, 1483-93		33
2120	Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. 2002 , 99, 4336-42		235
2119	A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug. 2002 , 86, 811-8		30
2118	Therapeutic challenges of AIDS-related non-Hodgkin's lymphoma in the United States and East Africa. 2002 , 94, 718-32		13
2117	Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. 2002 , 13, 928-43		101
2116	Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3885-90	2.2	100
2115	Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4649-54	2.2	53
2114	Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2453-63	2.2	936
2113	Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab. <i>Bone Marrow Transplantation</i> , 2002 , 29, 871-2	4.4	36
2112	Immunophenotypic variability of B-cell non-Hodgkin lymphoma: a retrospective study of cases analyzed by flow cytometry. 2002 , 117, 615-20		21
2111	Immune-based therapies: a review of clinical endpoints used in trials of selected immunologic agents. 2002 , 3, 58-88		2
2110	Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3545-57	2.2	92
2109	Update on epidemiology and therapeutics for non-Hodgkin's lymphoma. 2002 , 2002, 241-62		33

2108	Rituximab in lymphoma with life threatening haemolysis. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1711-2	1.9	1
2107	CHOP plus rituximab--balancing facts and opinion. 2002 , 346, 280-2		35
2106	Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. <i>Bone Marrow Transplantation</i> , 2002 , 29, 769-75	4.4	38
2105	Rituximab: clinical development and future directions. 2002 , 2, 97-110		29
2104	Real-Time t(14;18)(q32;q21) PCR assay combined with high-resolution capillary electrophoresis: a novel and rapid approach that allows accurate quantitation and size determination of bcl-2/JH fusion sequences. 2002 , 15, 448-53		16
2103	Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2002 , 43, 149-51	1.9	53
2102	Engineering antibodies for therapy. 2002 , 3, 237-56		74
2101	Tumours: Targeting of Monoclonal Antibodies for Imaging and Potential for Therapy. 2002 ,		1
2100	[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group]. 2002 , 127, 2253-8		7
2099	In vivo purging and relapse prevention following ASCT. <i>Bone Marrow Transplantation</i> , 2002 , 29 Suppl 1, S5-9	4.4	7
2098	Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2002 , 29 Suppl 1, S14-7	4.4	10
2097	Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. 2002 , 16, 693-9		52
2096	Application of recombinant antibodies in cancer patients. 2003 , 207, 27-53		
2095	Advances in the treatment of non-Hodgkin's lymphoma. 2002 , 13 Suppl 4, 211-6		6
2094	Stevens-Johnson syndrome after treatment with rituximab. 2002 , 13, 1948-50		81
2093	Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. 2002 , 13, 523-30		34
2092	Progress and promise in the treatment of indolent lymphomas. 2002 , 7, 217-25		20
2091	Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4261-7	2.2	353

2090	Necrotizing fasciitis following rituximab therapy. 2002 , 8, 127-129		1
2089	CD20 Expression in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin's Disease: Associations With Presenting Features and Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1278-1287	2.2	31
2088	Cancer vaccines. 2002 , 7 Suppl 3, 20-33		241
2087	Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. 2002 ,		1
2086	Radioimmunotherapy in non-Hodgkin lymphoma. 2002 , 14, 484-9		3
2085	CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. 2002 , 25, 72-81		116
2084	Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation. 2002 , 8, 371-6		21
2083	Using unconjugated antibodies as an immunotherapeutic approach to treatment of B-cell neoplasms. 2002 , 25, 266-73		
2082	Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. 2002 , 99, 67-74		134
2081	The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. 2002 , 99, 1038-43		324
2080	Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. 2002 , 99, 1092-4		75
2079	Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcγ3 gene. 2002 , 99, 754-8		1607
2078	Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). 2002 , 100, 768-73		422
2077	Severe cold hemagglutinin disease (CHD) successfully treated with rituximab. 2002 , 100, 1922-3		27
2076	Pharmacology of PEG-asparaginase in childhood acute lymphoblastic leukemia (ALL). 2002 , 100, 1923-4; author reply 1924-5		5
2075	Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2002 , 29 Suppl 1, S1-4	4.4	8
2074	Rituximab. 2002 , 95, 1209-1212		
2073	Treatment of Waldenström's macroglobulinemia with rituximab. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2327-33	2.2	212

2072	Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3262-9	2.2	556
2071	CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. 2002 , 346, 235-42		4169
2070	VIII International Conference on malignant lymphoma. June 12-15, 2002 Lugano, Switzerland. 2002 , 3, 75-81		
2069	High-dose treatment with autologous haemopoietic progenitor cell support for large B-cell, follicular and mantle-cell lymphoma. 2002 , 15, 467-80		3
2068	Antibody-based therapy of non-Hodgkin's lymphoma. 2002 , 15, 449-65		6
2067	New agents in the treatment of acute lymphocytic leukaemia. 2002 , 15, 771-90		7
2066	Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma. 2002 , 3, 111-6		7
2065	Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia. 2002 , 3, 163-6		60
2064	Chronic Lymphocytic Leukemia. 2002 , 1, 127-143		
2063	Efficacy of plant-produced recombinant antibodies against HCG. 2002 , 17, 2054-61		64
2062	Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation. 2002 , 8, 544-9		10
2061	Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study. <i>Leukemia and Lymphoma</i> , 2002 , 43, 2335-41	1.9	33
2060	Monoclonal antibody therapy of haematological malignancies. 2002 , 16, 283-301		5
2059	Rituximab and other emerging monoclonal antibody therapies for lymphoma. 2002 , 7, 289-302		7
2058	Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lymphoproliferative disease. 2002 , 34, 1178-81		13
2057	Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. 2002 , 100, 3115-20		182
2056	Monoclonal antibody therapies in leukemias. 2002 , 39, 12-9		28
2055	CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy. 2002 , 46, 441-3		23

2054	Current treatment of follicular non-Hodgkin's lymphoma. 2002 , 38, 1167-72		22
2053	Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. 2002 , 17, 445-64		28
2052	Monoclonal Antibody Therapy for Genitourinary Oncology: Promise for the Future. 2002 , 168, 2615-2623		10
2051	Emerging technology and future developments in flow cytometry. 2002 , 16, 477-95, vii-viii		1
2050	Intensive therapies in follicular non-Hodgkin lymphomas. 2002 , 100, 1141-1152		51
2049	Targeted α -particle immunotherapy for myeloid leukemia. 2002 , 100, 1233-1239		378
2048	Rituximab treatment results in impaired secondary humoral immune responsiveness. 2002 , 100, 2257-2259		196
2047	Rituximab in Combination with Chop Improves Survival in Elderly Patients with Aggressive Non-Hodgkin's Lymphoma. 2002 , 88, S26-S28		6
2046	First Isolation of West Nile virus from a patient with encephalitis in the United States. 2002 , 8, 1367-71		83
2045	CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1278-87	2.2	69
2044	Molecular targets in cancer therapy and their impact on cancer management. 2002 , 63 Suppl 1, 1-5		8
2043	Update in hematology. 2002 , 136, 136-43		2
2042	Emerging information on the use of rituximab in chronic lymphocytic leukemia. 2002 , 29, 70-74		46
2041	Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone. 2002 , 29, 48-55		13
2040	Rituximab: Ongoing and future clinical development. 2002 , 29, 105-112		122
2039	Advances in classification and therapy of indolent B-cell malignancies. 2002 , 29, 98-104		17
2038	Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). 2002 , 29, 81-86		53
2037	Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia. 2002 , 29, 75-80		12

2036	Rituximab in the treatment of diffuse large B-cell lymphomas. 2002 , 29, 30-35	42
2035	Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial. 2002 , 29, 25-29	31
2034	Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. 2002 , 29, 10-24	31
2033	Rituximab: Mechanism of action and resistance. 2002 , 29, 2-9	236
2032	Increasing treatment options in indolent non-Hodgkin's lymphoma. 2002 , 29, 2-6	6
2031	Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte colony stimulating factor [corrected]. 2002 , 29, 7-10	25
2030	Immunochemotherapy in indolent non-Hodgkin's lymphoma. 2002 , 29, 11-7	23
2029	Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. 2002 , 29, 18-22	81
2028	Improving outcomes in transplantation. 2002 , 29, 23-6	7
2027	Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy. 2002 , 68, 243-6	24
2026	Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study. 2002 , 69, 21-6	24
2025	Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. 2002 , 69, 129-34	93
2024	Effects of rituximab on a patient with Waldenström's macroglobulinaemia with deletion 13q14. 2002 , 69, 321-3	3
2023	Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients. 2002 , 2, 946-54	57
2022	Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas. 2002 , 70, 181-5	5
2021	Rituximab for the treatment of type II mixed cryoglobulinemia. 2002 , 46, 2252-4; author reply 2254-5	47
2020	Parvovirus B19 infection of cultured skin fibroblasts from systemic sclerosis patients: comment on the article by Ray et al. 2002 , 46, 2262-3; author reply 2263-4	22
2019	Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. 2002 , 46, 2257-8; author reply 2259	22

2018	Reply. 2002 , 46, 2254-2255		4
2017	Reply. 2002 , 46, 2263-2264		2
2016	Reply. 2002 , 46, 2259-2259		
2015	Reply. 2002 , 46, 2257-2257		36
2014	Reply. 2002 , 46, 2260-2260		
2013	Anti-tumor necrosis factor therapy and <i>Listeria monocytogenes</i> infection: report of two cases. 2002 , 46, 2255-7; author reply 2257		64
2012	Criteria for TUNEL labeling in determining apoptosis in human osteoarthritis cartilage: Comment on the article by Aigner et al. 2002 , 46, 2260-1		11
2011	Synovial lymphocyte responses to microbiologic antigen stimulation indicate the etiology of undifferentiated and reactive arthritis, and possibly of rheumatoid arthritis: Comment on the article by Schnarr et al. 2002 , 46, 2259-60; author reply 2260		0
2010	On my knees (Instructions to Authors). 2002 , 46, 2264-2264		
2009	Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted HLA class I/peptide complexes in SCID mice. 2002 , 98, 561-6		17
2008	Monoclonal antibody therapy for B-cell lymphoma. <i>International Journal of Hematology</i> , 2002 , 76, 385-93.	2.3	31
2007	Combination of chemotherapy and monoclonal antibodies for the treatment of lymphoma. <i>International Journal of Hematology</i> , 2002 , 76, 394-400	2.3	6
2006	Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan. <i>International Journal of Hematology</i> , 2002 , 76, 411-9	2.3	21
2005	Heavy chain disease. 2002 , 3, 247-54		23
2004	Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma. 2002 , 3, 275-82		22
2003	Vaccine therapies for non-Hodgkin's lymphoma. 2002 , 3, 307-15		10
2002	[Medicinal therapy of malignant lymphomas]. 2002 , 42, 943-53		1
2001	Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. 2002 , 81, 26-32		62

2000	Intraperitoneal rituximab: an effective measure to control recurrent abdominal ascites due to non-Hodgkin's lymphoma. 2002 , 81, 405-6		11
1999	Rituximab: a useful drug for a repeatedly relapsed hairy cell leukemia patient. 2002 , 81, 736-8		12
1998	Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab. 2002 , 128, 161-6		29
1997	Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. 2002 , 128, 484-92		35
1996	Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer. 2002 , 146, 144-7		28
1995	Skin as a potential organ for ectopic monoclonal antibody production. 2002 , 118, 288-94		10
1994	A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. <i>British Journal of Haematology</i> , 2002 , 116, 229-35	4.5	48
1993	Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2002 , 117, 828-34	4.5	116
1992	Differentiation between non-Hodgkin's lymphoma recurrence and second primary lymphoma by VDJ rearrangement analysis. <i>British Journal of Haematology</i> , 2002 , 118, 809-12	4.5	12
1991	Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. <i>British Journal of Haematology</i> , 2002 , 119, 125-7	4.5	40
1990	Flow cytometry and the study of cerebrospinal fluid in leukaemic patients: additional facts. <i>British Journal of Haematology</i> , 2002 , 116, 725	4.5	
1989	Reversible abnormal chromatin clumping in granulocytes from six transplant patients treated with mycophenolate mofetil: a rare adverse effect mimicking abnormal chromatin clumping syndrome. <i>British Journal of Haematology</i> , 2002 , 116, 726-7	4.5	7
1988	Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment. <i>British Journal of Haematology</i> , 2002 , 116, 727-8	4.5	25
1987	Complete, long-term remission of refractory idiopathic cold haemagglutinin disease after Mabthera. <i>British Journal of Haematology</i> , 2002 , 117, 248-9	4.5	10
1986	Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study. <i>Bone Marrow Transplantation</i> , 2002 , 30, 229-34	4.4	12
1985	CD20-induced B cell death can bypass mitochondria and caspase activation. 2002 , 16, 1735-44		74
1984	Anti-CD20-based therapy of B cell lymphoma: state of the art. 2002 , 16, 2004-15		53
1983	Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. 2002 , 16, 2092-5		113

1982	Antibody evolution beyond Nature. 2002 , 20, 1189-90		38
1981	Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. 2002 , 20, 215-29		46
1980	Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. 2002 , 29, 1276-82		38
1979	Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?. 2002 , 22, 124-30		59
1978	Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. 2002 , 59, 213-6		53
1977	Recombinant antibodies for the diagnosis and treatment of cancer. 2003 , 25, 1-17		11
1976	[B-cell depletion in the treatment of rheumatoid arthritis]. 2003 , 62, 361-6		1
1975	Induction of complete remission of hypoplastic leukemia with antithymocyte globulin. <i>International Journal of Hematology</i> , 2003 , 77, 277-81	2.3	3
1974	Immunotherapy for lymphomas. <i>International Journal of Hematology</i> , 2003 , 77, 444-55	2.3	26
1973	Innovative strategies in lymphoma therapy. 2003 , 115, 462-70		2
1972	New strategies in radioimmunotherapy for lymphoma. 2003 , 5, 364-71		7
1971	B cell depletion therapy in systemic lupus erythematosus. 2003 , 5, 350-6		53
1970	Antibody therapy of non-Hodgkin's B-cell lymphoma. 2003 , 52, 257-80		39
1969	Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan. 2003 , 52 Suppl 1, S90-6		1
1968	Spezifische Immuntherapien zur Behandlung von Krebs im Kindesalter. 2003 , 151, 646-653		
1967	Therapy of non-Hodgkin's lymphoma. 2003 , 30 Suppl 1, S28-36		26
1966	Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma. 2003 , 8, 212-23		11
1965	Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab. 2003 , 13, 223-31		11

1964	Immunotherapy with anti-CD20 compounds. 2003 , 13, 211-22	14
1963	History of antibody therapy for non-Hodgkin's lymphoma. 2003 , 30, 1-5	32
1962	Future directions in radioimmunotherapy for B-cell lymphoma. 2003 , 30, 29-34	18
1961	Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly. 2003 , 30, 21-7	24
1960	First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. 2003 , 30, 9-15	21
1959	Rituximab plus chemotherapy in follicular and mantle cell lymphomas. 2003 , 30, 16-20	53
1958	The mechanisms of action of rituximab in the elimination of tumor cells. 2003 , 30, 3-8	166
1957	Rituximab in chronic lymphocytic leukemia. 2003 , 30, 34-9	18
1956	Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations. 2003 , 30, 248-52	29
1955	CD22 as a target of passive immunotherapy. 2003 , 30, 253-7	53
1954	Radioimmunotherapy for Waldenstrom's macroglobulinemia. 2003 , 30, 258-61	8
1953	Waldenstrom's macroglobulinemia: a retrospective analysis of 40 patients from 1972 to 2001. 2003 , 30, 236-8	5
1952	Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab. 2003 , 30, 434-47	26
1951	Rituximab in B-cell chronic lymphocytic leukemia. 2003 , 30, 483-92	41
1950	CD22-directed monoclonal antibody therapy for lymphoma. 2003 , 30, 457-64	21
1949	Antibodies for the treatment of diffuse large cell lymphoma. 2003 , 30, 448-56	13
1948	Alemtuzumab therapy in B-cell lymphoproliferative disorders. 2003 , 30, 493-501	23
1947	Mitoxantrone-cyclophosphamide-rituximab: an effective and safe combination for indolent NHL. 2003 , 21, 99-108	6

1946	Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximab. 2003 , 73, 37-40		8
1945	The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. 2003 , 48, 455-9		375
1944	Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. 2003 , 48, 2146-54		369
1943	Rituximab in combination with vinorelbine/gemcitabine chemotherapy in patients with primary refractory or early relapsed T cell rich B cell lymphoma. A pilot study. 2003 , 27, 1097-9		2
1942	Monoclonal antibody therapy for lymphoma. 2003 , 17, 143-52		32
1941	Central lymphatic irradiation for stage I-III follicular lymphoma: report from a single-institutional prospective study. 2003 , 57, 316-20		14
1940	Treatment of monomorphic B-cell lymphoma with rituximab after liver transplantation in a child. 2003 , 7, 153-6		12
1939	Anti-CD20 monoclonal antibody (rituximab) therapy in a child with refractory chronic autoimmune haemolytic anaemia. 2003 , 33, 544-5		4
1938	Delayed-onset neutropenia associated with rituximab therapy. <i>British Journal of Haematology</i> , 2003 , 121, 913-8	4.5	102
1937	Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2003 , 122, 457-64	4.5	68
1936	Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2003 , 123, 271-7	4.5	25
1935	Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. <i>British Journal of Haematology</i> , 2003 , 123, 850-7	4.5	44
1934	Clinical use of rituximab in haematological malignancies. 2003 , 89, 1389-94		41
1933	Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2003 , 31, 775-82	4.4	12
1932	Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2003 , 32, 673-9	4.4	89
1931	Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. 2003 , 17, 900-9		110
1930	Costimulatory signals distinctively affect CD20- and B-cell-antigen-receptor-mediated apoptosis in Burkitt's lymphoma/leukemia cells. 2003 , 17, 1164-74		13
1929	Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. 2003 , 17, 1658-64		52

1928	Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. 2003 , 22, 6005-12		86
1927	Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. 2003 , 22, 7359-68		578
1926	Immunotherapy: past, present and future. 2003 , 9, 269-77		455
1925	Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma. 2003 , 17, 25-31		22
1924	Unique aspects of supportive care using monoclonal antibodies in cancer treatment. 2003 , 1, 38-48		34
1923	Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. 2003 , 5, 131-8		51
1922	Introducción al tratamiento oncológico: indicaciones e intención de los tratamientos. 2003 , 100, 133-138		
1921	Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. 2003 , 78, 1340-6		120
1920	Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. 2003 , 63, 803-43		341
1919	Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma. 2003 , 3, 257-9		27
1918	Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody. 2003 , 4, 56-9		11
1917	Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin's lymphoma: an effective and minimally toxic regimen. 2003 , 4, 169-75		16
1916	Overview of antibody therapy in B-cell non-Hodgkin's lymphoma. 2003 , 4 Suppl 1, S5-12		4
1915	Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma. 2003 , 21, 241-52		14
1914	44th annual meeting of the American Society of Hematology. December 7-10, 2002. Philadelphia, Pennsylvania. 2003 , 4, 10-5		
1913	Factors predicting the response to rituximab in indolent lymphoma. 2003 , 4, 19-21		1
1912	Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1746-51	2.2	299
1911	B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. 2003 , 62 Suppl 2, ii55-9		53

1910	Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1951-5	1.9	74
1909	Targeted therapies for the treatment of cancer. 2003 , 186, 264-8		59
1908	Radioimmunotherapy of non-Hodgkin lymphomas. 2003 , 101, 391-8		137
1907	Non-Hodgkin lymphoma. 2003 , 362, 139-46		109
1906	Ligand-targeted liposomal anticancer drugs. 2003 , 42, 439-62		330
1905	Rituximab therapy for multisystem autoimmune diseases in pediatric patients. 2003 , 143, 598-604		43
1904	Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura. 2003 , 143, 670-3		19
1903	Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases. 2003 , 49, 281-7		23
1902	Monoclonal antibody therapy for cancer. 2003 , 54, 343-69		158
1901	Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). 2003 , 101, 6-14		486
1900	Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. 2003 , 9, 505-11		185
1899	Indolent B-cell malignancies: immune recognition and antiself. <i>Leukemia and Lymphoma</i> , 2003 , 44 Suppl 3, S77-83	1.9	
1898	Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis. 2003 , 5 Suppl 4, S12-6		44
1897	Spotlight on Rituximab in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. 2003 , 2, 283-289		
1896	Monoclonal antibodies: the good, the bad, and the ugly. 2003 , 12, 3-6		
1895	Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder. <i>Leukemia and Lymphoma</i> , 2003 , 44, 889-90	1.9	26
1894	Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2003 , 44, 477-81	1.9	26
1893	Adding cytokines to monoclonal antibody therapy: does the concurrent administration of interleukin-12 add to the efficacy of rituximab in B-cell non-hodgkin lymphoma?. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1309-15	1.9	13

1892	An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. 2003 , 14, 520-35		214
1891	Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1263-70	2.2	245
1890	Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3051-9	2.2	219
1889	Treatment of IgM antibody associated polyneuropathies using rituximab. 2003 , 74, 485-9		205
1888	Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. <i>Journal of Clinical Oncology</i> , 2003 , 21, 897-906	2.2	201
1887	Variation in gene expression patterns in follicular lymphoma and the response to rituximab. 2003 , 100, 1926-30		128
1886	Rational approaches to human cancer immunotherapy. 2003 , 73, 3-29		93
1885	Alternative concepts of suicide gene therapy for graft-versus-host disease after adoptive immunotherapy. 2003 , 110, 132-8		2
1884	Skin reactions related to treatment with anticytokines, membrane receptor inhibitors and monoclonal antibodies. 2003 , 2, 467-73		8
1883	Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). <i>Journal of Clinical Oncology</i> , 2003 , 21, 2466-73	2.2	66
1882	Radioimmunotherapy with 131I-rituximab: what we know and what we don't know. 2003 , 18, 489-95		7
1881	Anthrax toxin: structures, functions and tumour targeting. 2003 , 3, 843-53		48
1880	EpCAM: A new therapeutic target for an old cancer antigen. 2003 , 2, 320-6		122
1879	Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?. 2003 , 89, 36-42		56
1878	Monoclonal antibody therapy of chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1874-81	2.2	59
1877	Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation. 2003 , 14, 758-65		27
1876	ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emitters. <i>Leukemia and Lymphoma</i> , 2003 , 44 Suppl 3, S107-13	1.9	15
1875	T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. 2003 , 170, 4397-402		160

1874	Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. 2003 , 14 Suppl 1, i5-10		83
1873	Herpesvirus infections in organ transplant recipients. 2003 , 10, 1-7		37
1872	Ibritumomab tiuxetan: the cancer smart bomb. 2003 , 43, 437-8		
1871	Hematologic Malignancies. 2003 , 487-506		
1870	Rituximab (Rituxan/MabThera): the first decade (1993-2003). 2003 , 3, 767-79		48
1869	Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. 2003 , 26, 351-4		40
1868	Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase. <i>Leukemia and Lymphoma</i> , 2003 , 44, 2165-6	1.9	18
1867	Biology and treatment of chronic lymphocytic leukemia. 2003 , 2003, 153-75		85
1866	Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation. 2003 , 25, 327-9		31
1865	Advances in the therapy of chronic lymphocytic leukemia. 2003 , 10, 297-305		5
1864	Semi-extended, six weekly rituximab infusions in pre-treated advanced low-grade B cell non-Hodgkin's lymphoma: a phase II study. 2003 , 14, 809-15		9
1863	Immunotherapy of lymphoma: update and review of the literature. 2003 , 15, 363-70		2
1862	In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. 2003 , 101, 949-54		294
1861	An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. 2003 , 101, 1071-9		132
1860	Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. 2003 , 101, 466-8		341
1859	Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. 2003 , 101, 3818-26		305
1858	Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. 2003 , 102, 2741-5		324
1857	Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. 2003 , 101, 3857-61		233

1856	Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. 2003 , 102, 810-3	125
1855	Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. 2003 , 102, 3514-20	107
1854	Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. 2003 , 102, 407-8	79
1853	Rituximab in relapsed or refractory hairy cell leukemia. 2003 , 102, 3906-11	127
1852	No clinical evidence for CD4+ cell depletion caused by rituximab. 2003 , 102, 408; author reply 408-9	12
1851	Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia. 2003 , 102, 2309; author reply 2309-10	2
1850	Is sperm protein 17 a useful target for tumor immunotherapy?. 2003 , 102, 2308-9	11
1849	Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. 2003 , 101, 420-4	127
1848	Targeted drugs in oncology: New names, new mechanisms, new paradigm. 2003 , 60, 1233-1243	6
1847	Monoclonal antibodies in the treatment of cancer, Part 1. 2003 , 60, 1531-48	31
1846	Therapeutic idiotype vaccines for non-Hodgkin's lymphoma. 2004 , 51, 271-93	8
1845	Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen. 2004 , 10, 265-95	18
1844	Antibody therapy of lymphoma. 2004 , 51, 229-53	5
1843	Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies. <i>Leukemia and Lymphoma</i> , 2004 , 45, 937-44	1.9 26
1842	Molecular biological design of novel antineoplastic therapies. 2004 , 13, 577-607	4
1841	An update on the management of chronic lymphocytic leukaemia. 2004 , 5, 1535-54	3
1840	Monoclonal antibody therapy of B cell lymphoma. 2004 , 4, 375-85	16
1839	Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. 2004 , 4, 18-26	22

1838	Heterogeneity in the multiple myeloma tumor clone. <i>Leukemia and Lymphoma</i> , 2004 , 45, 857-71	1.9	7
1837	Cardiac toxicity during rituximab administration. <i>Leukemia and Lymphoma</i> , 2004 , 45, 203-4	1.9	14
1836	Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. 2004 , 15, 63-76		81
1835	Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. 2004 , 15, 1109-14		45
1834	Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2654-61	2.2	123
1833	Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. 2004 , 9, 160-72		58
1832	Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. 2004 , 64, 4664-9		356
1831	The radioisotope contributes significantly to the activity of radioimmunotherapy. 2004 , 10, 7792-8		134
1830	Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo. 2004 , 101, 9051-6		32
1829	The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. 2004 , 199, 1659-69		521
1828	Clinical trials for malignant lymphoma in Japan. 2004 , 34, 369-78		19
1827	Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. 2004 , 10, 2253-64		145
1826	Monoclonal antibody therapy in lymphoid leukemias. 2004 , 51, 127-67		2
1825	Radioimmunotherapy with tositumomab and iodine-131 tositumomab for low-grade non-Hodgkin lymphoma: nursing implications. 2004 , 31, 1119-26		
1824	Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. 2004 , 10, 7842-51		101
1823	Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis. 2004 , 111, 221-4		5
1822	Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. 2004 , 279, 53907-14		91
1821	Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1469-79	2.2	96

1820	Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study. 2004 , 15, 504-10		42
1819	The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20x3. 2004 , 173, 6009-16		2
1818	Handbook of Cancer Vaccines. 2004 ,		5
1817	Treatment of SLE with anti-CD20 monoclonal antibody. 2005 , 8, 193-205		32
1816	Empowering targeted therapy: lessons from rituximab. 2004 , 2004, pe30		19
1815	Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. 2004 , 10, 5327-34		200
1814	Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. 2004 , 9, 577-86		74
1813	A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. 2004 , 90, 985-90		135
1812	Gold standard or wrong standard?. 2004 , 19, 271-2		5
1811	Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4711-6	2.2	301
1810	Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. 2004 , 10, 2868-78		157
1809	Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. 2004 , 55, 477-503		181
1808	Radiation safety guidelines for radioimmunotherapy with yttrium 90 ibritumomab tiuxetan. 2004 , 8, 31-4		7
1807	Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. 2004 , 15, 821-30		88
1806	The Natural History of CLL. 2004 , 3-54		1
1805	Fludarabine-induced hemolytic anemia: successful treatment by rituximab. 2004 , 5, 81-3		18
1804	Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. 2004 , 15, 1691-8		92
1803	Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. 2004 , 5, 467-71		19

1802	Idiotype vaccines in the treatment of B-cell non-Hodgkin's lymphoma. 2004 , 22, 97-105		8
1801	Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4717-24	2.2	169
1800	Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases. 2004 , 45, 34-7		12
1799	Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. 2004 , 95, 608-13		59
1798	Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. <i>British Journal of Haematology</i> , 2004 , 127, 519-30	4.5	37
1797	Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2004 , 33, 921-3	4.4	68
1796	A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2004 , 34, 175-9	4.4	19
1795	A novel recombinant bispecific single-chain antibody, bscWue-1 x CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells. 2004 , 18, 636-44		9
1794	Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. 2004 , 18, 616-23		79
1793	The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine. 2004 , 18, 1215-22		46
1792	Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models. 2004 , 91, 1391-8		37
1791	Antibodies to CD20 and MHC class II antigen bound to B-lymphoma cells accumulate in shed cytoplasmic fragments. 2004 , 91, 1500-7		5
1790	Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. 2004 , 4, 1357-60		48
1789	Safety of rituximab therapy during the first trimester of pregnancy: a case history. 2004 , 72, 292-5		103
1788	Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva. 2004 , 73, 258-62		60
1787	A revival of bispecific antibodies. 2004 , 22, 238-44		129
1786	Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. 2004 , 289, 97-109		43
1785	Complement activation and C3b deposition on rituximab-opsinized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab. 2004 , 294, 37-42		6

1784	Advancing Therapy For Chronic Lymphocytic Leukemia-the Role Of Rituximab. 2004 , 31 Suppl 2, 22-26		9
1783	New Treatment Approaches To Indolent Non-Hodgkin's Lymphoma. 2004 , 31 Suppl 2, 27-32		15
1782	Advances in follicular lymphoma. 2004 , 31, 66-71		13
1781	Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression. 2004 , 54, 667-74		18
1780	What is new in lymphoma?. 2004 , 54, 260-72		32
1779	Monoclonal antibodies in the treatment of chronic lymphocytic leukemia. 2004 , 21, 297-304		6
1778	Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone. <i>International Journal of Hematology</i> , 2004 , 79, 311-21	2.3	10
1777	Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study. <i>International Journal of Hematology</i> , 2004 , 80, 267-77	2.3	31
1776	A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002. <i>International Journal of Hematology</i> , 2004 , 80, 341-50	2.3	14
1775	A novel approach for cancer immunotherapy: tumor cells with anchored superantigen SEA generate effective antitumor immunity. 2004 , 24, 294-301		15
1774	Apoptosis induced by molecular targeting therapy in hematological malignancies. 2004 , 111, 107-23		15
1773	Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. 2004 , 19, 794-7		141
1772	Immunotherapy of cancer: from vision to standard clinical practice. 2004 , 130, 367-74		24
1771	[Immunotherapy of malignant diseases--developments and prospects]. 2004 , 154, 235-41		1
1770	CD64 surface expression on neutrophils and monocytes is significantly up-regulated after stimulation with granulocyte colony-stimulating factor during CHOP chemotherapy for patients with non-Hodgkin's lymphoma. <i>International Journal of Hematology</i> , 2004 , 79, 55-62	2.3	14
1769	[Designer-drugs in tumor treatment]. 2004 , 45 Suppl 1, S38-47		
1768	[Monoclonal antibody treatment of malignant lymphoma]. 2004 , 45, 1370-7		0
1767	Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. 2004 , 53, 110-7		64

1766	Remarkable response to rituximab in a patient with atypical CD20(++) mantle cell lymphoma of the bone marrow leading to severe pancytopenia. 2004 , 83, 316-8		3
1765	Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody. 2004 , 83, 319-21		22
1764	Modern diagnostics in chronic myeloproliferative diseases (CMPDs). 2004 , 83 Suppl 1, S59-61		17
1763	Epratuzumab in non-Hodgkin's lymphomas. 2004 , 5, 283-8		15
1762	Advances in the treatment of indolent lymphomas. 2004 , 9, 169-172		
1761	Rituximab as immunotherapy following autologous stem cell transplantation (ASCT) in a 17-year-old boy with diffuse large B cell lymphoma – a case report. 2004 , 9, 179-182		
1760	Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. 2004 , 59, 234-42		91
1759	The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation. 2004 , 8, 9-21		35
1758	B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. 2004 , 50, 2580-9		642
1757	Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases. 2004 , 77, 303-10		31
1756	The role of fludarabine in the treatment of follicular and mantle cell lymphoma. 2004 , 101, 883-93		29
1755	Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. 2004 , 28, 429-42		46
1754	Monoclonal antibodies in the treatment of chronic lymphoid leukemias. <i>Leukemia and Lymphoma</i> , 2004 , 45, 205-19	1.9	45
1753	Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1815-9	1.9	6
1752	Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. 2004 , 103, 777-83		179
1751	Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression. <i>Leukemia and Lymphoma</i> , 2004 , 45, 2057-61	1.9	36
1750	⁹⁰ Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma. 2004 , 4, 1323-31		
1749	From the bench to the bedside: ways to improve rituximab efficacy. 2004 , 104, 2635-42		443

1748	Rituximab-Induced Acute Pulmonary Fibrosis. 2004 , 79, 949-953		47
1747	[Antibodies against cancer]. 2004 , 204, 649-54		2
1746	Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. 2004 , 172, 3280-8		279
1745	Antibody therapy for chronic lymphocytic leukemia: a promising new modality. 2004 , 18, 895-913, ix-x		9
1744	Optimizing the Clinical Benefit of Rituximab in Indolent Non-Hodgkin's Lymphoma. 2004 , 5, 149-151		1
1743	Lymphomes folliculaires. 2004 , 1, 83-105		1
1742	Suicide gene therapy and the control of graft-vs-host disease. 2004 , 17, 453-63		2
1741	A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). <i>Leukemia and Lymphoma</i> , 2004 , 45, 2269-73	1.9	57
1740	Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. 2004 , 64, 1767-77		57
1739	Treatment options in Waldenstrom's macroglobulinemia. 2004 , 5, 155-62		4
1738	Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma. 2004 , 5 Suppl 1, S16-21		10
1737	Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma. 2004 , 5 Suppl 1, S27-32		10
1736	Refractory Chronic Lymphocytic Leukemia. 2004 , 3, 163-178		2
1735	Second primary lymphoma or recurrence: a dilemma solved by VDJ rearrangement analysis. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1539-43	1.9	16
1734	Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. 2004 , 4, 398-402		72
1733	Profiling of internalizing tumor-associated antigens on breast and pancreatic cancer cells by reversed genomics. 2004 , 208, 235-42		10
1732	FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer. 2004 , 40, 707-21, discussion 722-4		54
1731	Monoclonal antibodies in the treatment of colorectal cancer. 2004 , 40, 1292-301		65

1730	Targeted therapy--how successful has it been?. 2004 , 40, 2016-21	1
1729	Rituximab therapy for life-threatening immune hemolytic anemia in a liver transplant recipient: a case report. 2004 , 36, 1492-3	8
1728	Targeted therapy for malignant gliomas. 2004 , 11, 807-18	23
1727	Monoclonal antibodies as therapeutic agents for cancer. 2004 , 5, 292-302	265
1726	Non-Hodgkin lymphoma: an update. 2004 , 5, 341-53	154
1725	Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia. 2004 , 41, 234-45	14
1724	Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). 2004 , 34, 4-9	35
1723	[Role of anti-CD20 monoclonal antibody in association with immunomodulatory agents]. 2004 , 52, 39-42	3
1722	In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. 2004 , 13, 55-62	69
1721	Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. 2004 , 77, 542-8	212
1720	Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma. 2004 , 11, 419-25	8
1719	Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). 2004 , 140, 91-6	96
1718	Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. 2004 , 44, 757-761	19
1717	Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications. 2004 , 15, 189-201	2
1716	Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. 2004 , 103, 1763-9	63
1715	Loss of circulating CD27+ memory B cells and CCR4+ T cells occurring in association with elevated EBV loads in XLP patients surviving primary EBV infection. 2004 , 103, 1625-31	50
1714	Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. 2004 , 103, 1472-4	181
1713	Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. 2004 , 103, 3516-20	29

1712	Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells. 2004 , 103, 1846-54	57
1711	Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. 2004 , 104, 227-36	117
1710	Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. 2004 , 103, 4416-23	474
1709	Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. 2004 , 103, 2925-8	186
1708	Follicular lymphoma international prognostic index. 2004 , 104, 1258-65	1348
1707	Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. 2004 , 104, 3705-11	115
1706	Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. 2004 , 104, 2667-74	249
1705	The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. 2004 , 104, 3064-71	500
1704	Erratum for vol. 102, p. 2173. 2004 , 103, 4423-4423	0
1703	Successful treatment of primary cardiac lymphoma with monoclonal CD20 antibody (rituximab). 2004 , 68, 172-3	25
1702	Anticorps monoclonal anti-CD20 et traitement des maladies auto-immunes. 2004 , 25, 752-754	
1701	Clinical Flow Cytometry. 2004 , 239-257	1
1700	Orbital Lymphoma. 2005 , 133-140	3
1699	Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. 2005 , 27, 785-92	72
1698	CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection. 2005 , 29, 1399-403	15
1697	Current status of therapeutic vaccines for non-Hodgkin's lymphoma. 2005 , 17, 432-40	30
1696	Rituximab: Clinical Development of the First Therapeutic Antibody for Cancer. 2005 , 211-229	
1695	Monoclonal Antibodies: Therapeutic Uses. 2005 ,	

1694	Myelosuppressive side-effects of radioimmunotherapy of non-Hodgkin's lymphoma: is there an increased risk?. 2005 , 26, 1045-7		5
1693	Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody. 2005 , 105, 1231-6		29
1692	Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. 2005 , 105, 489-95		144
1691	CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. 2005 , 105, 1417-23		812
1690	An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. 2005 , 105, 3972-8		73
1689	Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. 2005 , 105, 4576-82		138
1688	Leukemic cell death induced by antithymocyte globulin. 2005 , 29, 821-7		10
1687	Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy. 2005 , 63, 194-201		27
1686	Follicular lymphoma: time for a re-think?. 2005 , 19, 165-78		32
1685	Infections associated with purine analogs and monoclonal antibodies. 2005 , 19, 253-73		18
1684	Overview of monoclonal antibodies in cancer therapy: present and promise. 2005 , 54, 11-29		181
1683	A case of interstitial pneumonia induced by rituximab therapy. <i>International Journal of Hematology</i> , 2005 , 81, 169-70	2.3	26
1682	Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. 2005 , 5 Suppl 1, S37-47		87
1681	Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma. 2005 , 8, 462-70		34
1680	Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorder. 2005 , 19, 644-52		21
1679	Current approaches to treatment of antibody-mediated rejection. 2005 , 9, 408-15		86
1678	Diffuse large B-cell lymphoma on the back of a patient with AIDS: successful treatment by the CD20 monoclonal antibody rituximab. 2005 , 44, 976-8		1
1677	Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma. 2005 , 152, 541-4		37

1676	Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation. 2005 , 153, 167-73	54
1675	Immunotherapy in multiple myeloma--possibility or probability?. <i>British Journal of Haematology</i> , 2005 , 130, 344-62	45 31
1674	Monoclonal antibody therapy of cancer. 2005 , 23, 1147-57	916
1673	Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. 2005 , 24, 2121-43	240
1672	Recombinant approaches to IgG-like bispecific antibodies. 2005 , 26, 649-58	80
1671	B cell depletion in autoimmune rheumatic diseases. 2005 , 4, 436-41	15
1670	T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro. 2005 , 33, 452-9	52
1669	Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets. 2005 , 32, S19-26	19
1668	Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. 2005 , 5, 50-7	70
1667	Pulmonary parenchymal infiltrates in a patient with CD20-positive multiple myeloma. 2005 , 74, 61-5	11
1666	Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice. 2005 , 5, 103	18
1665	Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lymphoma: case report and literature review. 2005 , 25, 1151-5	13
1664	The feasibility of gene expression profiling generated in fine-needle aspiration specimens from patients with follicular lymphoma and diffuse large B-cell lymphoma. 2006 , 108, 10-20	22
1663	The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. 2005 , 104, 2743-52	43
1662	Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. 2005 , 52, 2740-50	399
1661	Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. 2005 , 78, 275-80	94
1660	Expression and characterisation of recombinant human CD48 and isolation of a human anti-CD48 monoclonal antibody by phage display. 2005 , 80, 782-795	3
1659	Liver transplantation for HCV-related cirrhosis in a patient with gastric mucosa-associated lymphoma (MALToma) pretreated with rituximab. 2005 , 11, 839-842	9

1658	Radioimmunotherapy using ¹³¹ I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience. 2005 , 32, 1225-33	14
1657	Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes. 2005 , 54, 867-79	14
1656	A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation. 2005 , 54, 1172-9	18
1655	Cytomegalovirus-associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and rituximab. 2005 , 84, 545-7	12
1654	Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response. 2005 , 84, 526-31	2
1653	Immunotherapie maligner Non-Hodgkin-Lymphome. 2005 , 11, 571-577	
1652	Current status of cancer therapy with radiolabeled monoclonal antibody. 2005 , 19, 355-65	34
1651	Prolymphocytic leukemia. 2005 , 6, 197-208	15
1650	Follicular lymphoma: management options in the era of targeted therapy. 2005 , 6, 297-308	5
1649	Advances in the treatment of chronic lymphocytic leukemia. 2005 , 7, 333-8	3
1648	New developments in immunotherapy for non-Hodgkin's lymphoma. 2005 , 7, 364-71	7
1647	Targeted therapy for hematologic malignancies. 2005 , 12, 82-90	8
1646	Clinical Studies of Immunotherapy With Rituximab (Rituxan [®]) and Radioimmunotherapy With Ibritumomab Tiuxetan (Zevalin [®]) in B-Cell Lymphoid Malignancies. 2005 , 677-709	
1645	Successful treatment of primary cardiac lymphoma with atrioventricular nodal block. 2005 , 46, 927-31	18
1644	Non-Hodgkin-Lymphome. 2005 , 1133-1147	
1643	Therapeutic Monoclonal Antibodies in Oncology. 2005 , 98, 146-152	20
1642	Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates. 2005 , 2005, 335-9	15
1641	Antibodies and Recombinant Cytokines. 2005 ,	

1640	Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. 2006 , 65, 942-5		61
1639	Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus. 2005 , 44, 1462-4		19
1638	Monoclonal antibodies in the treatment of leukemia. 2005 , 5, 663-75		5
1637	Cerebrospinal fluid diffusion of Zevalin after high-activity treatment and stem cell support in a patient affected by diffuse large B-cell non-Hodgkin's lymphoma with central nervous system involvement. 2005 , 16, 1710-1		1
1636	Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5027-33	2.2	759
1635	Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1979-83	2.2	218
1634	Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies. 2005 , 11, 7075s-7079s		18
1633	The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. 2005 , 174, 4389-99		185
1632	Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. 2005 , 11, 7146s-7150s		32
1631	Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. 2005 , 106, 3725-32		1084
1630	Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. 2005 , 102, 15178-83		103
1629	Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 694-704	2.2	131
1628	Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4390-8	2.2	132
1627	Update on rituximab. 2005 , 64 Suppl 4, iv55-7		24
1626	Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. 2005 , 11, 5971-80		65
1625	MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells. 2005 , 11, 7516-22		33
1624	Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. 2005 , 11, 5984-92		145
1623	Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1103-8	2.2	169

1622	Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. 2005 , 106, 1538-43		335
1621	Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma. 2005 , 16 Suppl 2, ii99-104		7
1620	Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 247-8	2.2	46
1619	Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7565-73	2.2	204
1618	[Up-to-date treatment of follicular lymphomas]. 2005 , 130, 2149-54		1
1617	Reactivation of hepatitis B virus with rituximab. 2005 , 4, 599-608		114
1616	Protein Therapeutics. 2005 , 429-446		
1615	Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma. 2005 , 1, 297-306		17
1614	Antibodies for targeted cancer therapy -- technical aspects and clinical perspectives. 2005 , 72, 279-86		34
1613	How does B cell depletion therapy work, and how can it be improved?. 2005 , 64 Suppl 4, iv77-80		22
1612	A review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma. 2005 , 5, 577-88		13
1611	Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisal. 2005 , 1, 47-62		30
1610	Lymphocyte therapy of renal cell carcinoma. 2005 , 5, 1041-51		10
1609	Primary central nervous system lymphoma. 2005 , 5, S63-70		2
1608	Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly. 2005 , 10, 602-12		48
1607	Targeted therapy for epithelial ovarian cancer. 2005 , 9, 501-13		6
1606	Novel immune-based treatment strategies for chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6325-32	2.2	46
1605	Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. <i>Journal of Clinical Oncology</i> , 2005 , 23, 712-9	2.2	218

1604	Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2240-7	2.2	115
1603	Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4079-88	2.2	811
1602	Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein. 2005 , 20, 379-90		25
1601	Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1500-6	2.2	35
1600	Optimizing rituximab in B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1056-8	2.2	9
1599	Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1088-95	2.2	289
1598	Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5044-51	2.2	150
1597	Immunotherapy of hematological malignancies: what is new?. 2005 , 16 Suppl 2, ii53-62		5
1596	Treatment strategies in follicular lymphomas: current status and future perspectives. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6394-9	2.2	72
1595	B cell reductive therapy in the treatment of autoimmune diseases: a focus on monoclonal antibody treatment of rheumatoid arthritis. 2005 , 10, 521-7		2
1594	Effective treatment of indolent non-hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone. 2005 , 28, 73-8		4
1593	[Passive immunotherapy with monoclonal antibodies]. 2005 , 28 Suppl 4, 9-13		1
1592	Multimodality therapies and optimal schedule of antibodies: rituximab in lymphoma as an example. 2005 , 2005, 321-8		10
1591	Therapeutic monoclonal antibodies in oncology. 2005 , 98, 146-52		18
1590	AntiCD20 monoclonal antibody-based radioimmunotherapy of relapsed chemoresistant aggressive post-transplantation B-lymphoproliferative disorder in heart-transplant recipient. 2005 , 6, 629-31		4
1589	Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs). 2005 , 35, 202-11		28
1588	Non-Hodgkin lymphoma: diagnosis and treatment. 2005 , 80, 1087-97		104
1587	Medical Biomethods Handbook. 2005 ,		2

1586	Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on Favld. 2005 , 5, 841-52		22
1585	Monoclonal antibody therapy of leukaemias and lymphomas. 2005 , 5, 1225-43		8
1584	Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model. <i>Leukemia and Lymphoma</i> , 2005 , 46, 1775-84	1.9	35
1583	Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). <i>Journal of Clinical Oncology</i> , 2005 , 23, 705-11	2.2	166
1582	Treatment of elderly cancer patients with chemotherapy. 2005 , 23, 537-47		9
1581	Toward personalized immunotherapy for non-Hodgkin lymphoma: targeting the idiotypic immunoglobulin. 2005 , 19, 289-97		3
1580	The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. 2005 , 19, 309-22		13
1579	Post-transplant lymphoproliferative disorder in children: incidence, prognosis, and treatment options. 2005 , 7, 55-65		37
1578	Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma?. <i>Leukemia and Lymphoma</i> , 2005 , 46, 71-5	1.9	17
1577	Advances in Targeted Cancer Therapy. 2005 ,		
1576	Treatment of primary cutaneous B-cell lymphoma with rituximab. 2005 , 52, 847-53		77
1575	Tolerability and safety of rituximab (MabThera). 2005 , 31, 456-73		369
1574	Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma. 2005 , 8, 27-41		8
1573	[Cutaneous large B-cell lymphoma of the leg]. 2005 , 96, 237-40		7
1572	[Cutaneous marginal zone B-cell lymphoma treated with rituximab]. 2005 , 96, 593-7		3
1571	Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies. 2005 , 32, 33-44		18
1570	CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment. 2005 , 5, 278-81		27
1569	Monoclonal antibodies in the treatment of indolent lymphomas. 2005 , 18, 69-80		10

1568	Conventional allograft and autograft in low grade lymphoma. 2005 , 18, 113-28		3
1567	Radio-immunotherapy in low-grade non-Hodgkin's lymphoma. 2005 , 18, 81-95		9
1566	Monoclonal antibodies and fusion proteins in medicine. <i>Journal of Allergy and Clinical Immunology</i> , 2005 , 116, 721-9; quiz 730	11.5	31
1565	Utilisation thérapeutique des anticorps monoclonaux en hématologie. 2005 , 2, 276-285		0
1564	Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. 2005 , 45, 792-801		156
1563	Diagnosis and management of Waldenstrom's macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1564-77	2.2	180
1562	Rituximab Plus Purine Nucleoside Analogs in the Treatment of Indolent Lymphoid Malignancies. 2005 , 4, 279-292		4
1561	Cancer immunity. 2005 , 129-148		
1560	A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma. 2005 , 20, 457-66		31
1559	B cell non-Hodgkin's lymphoma: rituximab safety experience. 2005 , 7 Suppl 3, S19-25		43
1558	Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. 2006 , 8, R129		170
1557	Review of clinical radioimmunotherapy. 2006 , 6, 445-61		43
1556	[Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus]. 2006 , 133, 53-5		11
1555	Nanoparticle-aptamer bioconjugates for targeted antineoplastic drug delivery. 2006 , 4, 123-130		3
1554	Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. 2006 , 90, 215-41		45
1553	Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia. 2006 , 20, 253-7		10
1552	Anticorps monoclonal anti-CD20 (rituximab) dans les maladies hématologiques et les affections auto-immunes. 2006 , 15, 270-277		1
1551	Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases. 2006 , 6, 943-9		21

1550	Late-onset neutropenia following rituximab. <i>Leukemia and Lymphoma</i> , 2006 , 47, 965-6	1.9	25
1549	Cheung MC, Haynes AE, Stevens A, Meyer RM, Imrie K, et al. Yttrium 90 ibritumomab tiuxetan in lymphoma. <i>Leuk Lymphoma</i> 2006;47:967-977. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1719-1720	1.9	4
1548	Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1830-40	1.9	25
1547	Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1013-7	1.9	112
1546	Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1306-14	1.9	9
1545	Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: case report and review of the literature. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1683-5	1.9	25
1544	High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. 2006 , 17, 1424-7		64
1543	Successful autologous peripheral blood stem cell transplantation with rituximab administration for pediatric diffuse large B-cell lymphoma. 2006 , 23, 19-24		5
1542	Rituximab for the treatment of diffuse large B-cell lymphomas. 2006 , 6, 1175-86		31
1541	Drug insight: rituximab in renal disease and transplantation. 2006 , 2, 221-30		97
1540	42nd annual meeting of the American Society of Clinical Oncology June 2006, Atlanta, GA. 2006 , 7, 16-24		
1539	Monoclonal antibody as therapy for malignant lymphomas. 2006 , 329, 241-54		41
1538	Chronic lymphocytic leukemia: diagnosis and treatment. 2006 , 81, 1105-29		49
1537	Monoclonal antibody therapy for hairy cell leukemia. 2006 , 20, 1125-36		8
1536	B cells in health and disease. 2006 , 81, 377-84		32
1535	Treatment Options for Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. 2006 , 1, 46-56		
1534	B cell-targeted therapy for rheumatoid arthritis: an update on the evidence. 2006 , 66, 625-39		26
1533	Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. 2006 , 66, 791-820		80

1532	B-cell-targeted therapy for systemic lupus erythematosus. 2006 , 66, 1933-48		74
1531	Eastern Cooperative Oncology Group 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT). 2006 , 6, 423-6		11
1530	Salvage chemotherapy in follicular non-Hodgkin's lymphoma: focus on tolerability. 2006 , 7, 115-24		5
1529	Treatment of non-Hodgkin's lymphoma: a look over the past decade. 2006 , 7 Suppl 1, S7-13		27
1528	Targeting lymphoma cells and their microenvironment with novel antibodies. 2006 , 7 Suppl 1, S33-40		2
1527	Therapeutic lymphoma vaccines: importance of T-cell immunity. 2006 , 5, 381-94		16
1526	Radioimmunotherapy for B-cell non-Hodgkin lymphoma. 2006 , 19, 655-68		31
1525	Monoclonal antibody combinations in CLL: evolving strategies. 2006 , 19, 781-93		6
1524	Impact of biologic agents on infectious diseases. 2006 , 20, 931-61, viii		26
1523	Yttrium 90 ibritumomab tiuxetan in lymphoma. <i>Leukemia and Lymphoma</i> , 2006 , 47, 967-77	1.9	18
1522	Rituximab-induced elimination of acquired angioedema due to C1-inhibitor deficiency. 2006 , 119, e3-5		42
1521	Non-transplant-related treatment options in follicular lymphoma. 2006 , 12, 53-8		1
1520	Analyses and perspectives in cancer immunotherapy. 2006 , 60, 621-8		4
1519	Le point sur les anticorps autoris�s en imagerie et en immunoth�rapie. 2006 , 21, 255-263		
1518	Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy. 2006 , 33, 271-9		49
1517	Transplantation of the highly human leukocyte antigen�sensitized patient: long-term outcomes and future directions. 2006 , 20, 146-156		9
1516	Cancer therapy with engineered monoclonal antibodies. 2006 , 1, 147-157		11
1515	Regression of Extensive Colonic Extranodal Marginal Zone B Cell Lymphoma after Treatment with Rituximab. 2006 , 41, 66		2

- 1514 A Case of Autoimmune Hemolytic Anemia Treated with Rituximab in a Child. **2006**, 41, 321 2
- 1513 Monoclonal Antibodies. **2006**,
- 1512 Monoclonal Antibody Therapy of Cancer. **2006**, 487-502
- 1511 Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. **2006**, 107, 2639-42 183
- 1510 The infectious consequences of rituximab addition to fludarabine-containing regimens. **2006**, 107, 3013-4 4
- 1509 Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. **2006**, 108, 705-10 30
- 1508 CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. **2006**, 108, 2384-91 77
- 1507 Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. **2006**, 108, 3295-301 499
- 1506 Antibody Therapy for Non-Hodgkin's Lymphoma. **2006**, 445-455
- 1505 Chronic Lymphocytic Leukemia (CLL). **2006**,
- 1504 Utilisation thérapeutique des anticorps monoclonaux en h matologie. **2006**, 1, 1-7
- 1503 Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies. **2006**, 12, 111-28 18
- 1502 Lymphomes folliculaires. **2006**, 1, 1-15
- 1501 Genetics, gene expression, and targeted therapies in chronic lymphocytic leukemia. **2006**, 7, 1313-27 7
- 1500 Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. **2006**, 29, 558-68 124
- 1499 Radioimmunotherapy of non-Hodgkin's lymphomas. **2006**, 7, 1293-300 21
- 1498 Rituximab but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P-glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts. **2006**, 29, 536-44 22
- 1497 The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines. **2006**, 29, 489-98 13

1496	Optimised Fc variants with enhanced effector function. 2006 , 16, 1449-1452			1
1495	Immunotoxins and Recombinant Immunotoxins in Cancer Therapy. 2006 ,			
1494	Principles of maintenance therapy. 2006 , 30 Suppl 1, S3-10			8
1493	Rituximab maintenance therapy in indolent NHL: a clinical review. 2006 , 30 Suppl 1, S11-5			9
1492	Safety of rituximab maintenance therapy in follicular lymphomas. 2006 , 30 Suppl 1, S16-21			38
1491	Patient benefits of maintenance immunotherapy. 2006 , 30 Suppl 1, S22-6			7
1490	Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. 2006 , 19, 259-69			52
1489	Monoclonal antibodies as targeting and therapeutic agents: prospects for liver transplantation, hepatitis and hepatocellular carcinoma. 2006 , 33, 482-8			17
1488	Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission. 2006 , 20, 179-87			35
1487	Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. 2006 , 155, 1197-200			63
1486	Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device. <i>British Journal of Haematology</i> , 2006 , 132, 42-55	4.5		24
1485	Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. <i>British Journal of Haematology</i> , 2006 , 133, 3-18	4.5		27
1484	The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma. <i>British Journal of Haematology</i> , 2006 , 134, 157-70	4.5		27
1483	Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. 2006 , 97, 305-12			24
1482	Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. 2006 , 12, 7-18			91
1481	Long-term complete responses after ¹³¹ I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. 2006 , 94, 1770-6			27
1480	Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2006 , 38, 433-6	4.4		50
1479	Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. 2006 , 26, 252-5			75

1478	Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA/CMV complexes. 2006 , 20, 1096-102		18
1477	Current controversies in follicular lymphoma. 2006 , 20, 179-200		11
1476	Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma. 2006 , 66, S15-22		10
1475	Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. 2006 , 30, 625-31		68
1474	Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. 2006 , 28, 351-64		52
1473	Late-onset neutropenia in patients treated with rituximab for non-Hodgkin's lymphoma. <i>International Journal of Hematology</i> , 2006 , 84, 242-7	2.3	32
1472	Successful treatment of Helicobacter pylori-negative gastric MALT lymphoma with rituximab. 2006 , 51, 775-8		9
1471	Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma. 2007 , 81, 197-9		38
1470	Aktuelle Therapieoptionen des indolenten Lymphoms. 2006 , 12, 612-618		2
1469	Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies. <i>Clinical and Experimental Medicine</i> , 2006 , 6, 1-12	4.9	37
1468	Immunotherapie des lymphomes. 2006 , 8, 331-335		
1467	Auger radiation targeted into DNA: a therapy perspective. 2006 , 33, 1352-63		118
1466	Monoclonal antibody therapy of chronic lymphocytic leukemia. 2006 , 55, 188-96		39
1465	Immune defects in patients with chronic lymphocytic leukemia. 2006 , 55, 197-209		102
1464	Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. 2006 , 55, 1451-8		40
1463	Update on management of infections in cancer and stem cell transplant patients. 2006 , 85, 345-56		34
1462	Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. 2006 , 85, 257-62		14
1461	CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. 2006 , 58, 35-9		56

1460	[Rheumatology-part 2. Research news concerning pathogenesis, epidemiology, diagnosis, and therapy of connective tissue disease]. 2006 , 101, 127-37	0
1459	Follicular Lymphoma International Prognostic Index. 2006 , 7, 270-5	21
1458	Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma. 2006 , 7, 276-84	4
1457	New aspects of the treatment of chronic lymphocytic leukemia. 2006 , 1, 251-7	
1456	Advances in the treatment of chronic lymphocytic leukemia. 2006 , 1, 43-8	
1455	Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. 2006 , 6, 859-66	403
1454	The therapeutic use of rituximab in non-Hodgkin's lymphoma. 2006 , 78, 5-14	3
1453	Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. 2006 , 77, 300-3	40
1452	Potential adverse events with biologic response modifiers. 2006 , 5, 471-85	21
1451	Infectious complications of chronic lymphocytic leukemia. 2006 , 33, 240-9	131
1450	Initial therapy for patients with chronic lymphocytic leukemia. 2006 , 33, 202-9	16
1449	Monoclonal antibody therapy for B-cell malignancies. 2006 , 33, S2-14	38
1448	Quantitative analysis of protein co-localization on B cells opsonized with rituximab and complement using the ImageStream multispectral imaging flow cytometer. 2006 , 317, 90-9	61
1447	B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. 2006 , 112, 57-70	30
1446	Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. 2006 , 56, 226-43	169
1445	The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. 2006 , 54, 1390-400	795
1444	Development of antibody-based therapeutics for oncology indications. 2006 , 67, 699-728	2
1443	Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. 2006 , 106, 1569-80	441

1442	Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. 2006 , 106, 2412-20	79
1441	Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma. 2006 , 107, 686-95	30
1440	Neoplastic stem cells: a novel therapeutic target in clinical oncology. 2006 , 107, 2512-20	65
1439	A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. 2006 , 107, 2826-32	41
1438	Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. 2006 , 107, 2817-25	18
1437	Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach. 2006 , 24, 47-55	17
1436	Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma. 2006 , 24, 234-7	33
1435	Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. 2006 , 119, 1303-11	88
1434	Immune thrombocytopenic purpura following liver transplantation: a case series and review of the literature. 2006 , 12, 781-91	27
1433	The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia. 2006 , 81, 631-3	13
1432	Delayed reduction in left ventricular function following treatment of non-Hodgkin's lymphoma with chemotherapy and rituximab, unrelated to acute infusion reaction. 2006 , 105, 184-7	15
1431	AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy. 2006 , 99, 811-26	30
1430	Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. 2006 , 45, 1505-13	52
1429	Current and investigational therapies for patients with CLL. 2006 , 2006, 285-94	13
1428	Immunintervention bei neu diagnostiziertem Typ-1-Diabetes - immer noch nur im Rahmen von Studien möglich. 2006 , 1, 379-385	
1427	Abstracts from the Chemotherapy Foundation Symposium XXIV: Innovative Cancer Therapy for Tomorrow, November 8-11, 2006, New York, New York, USA. 2006 , 24 Suppl 1, 1-59	
1426	Metabolism-Directed Optimisation of Antithrombotics: The Prodrug Principle. 2006 , 12, 73-91	23
1425	Haematology. 2006 , 152, 250-65	

1424	Recombinant antibodies in cancer therapy. 2006 , 7, 165-70		6
1423	Immunotherapeutic and immunoregulatory drugs in haematologic malignancies. 2006 , 6, 1657-86		12
1422	Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 174-80	2.2	33
1421	Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3107-12	2.2	83
1420	Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. 2006 , 12, 4027-35		188
1419	A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. 2006 , 12, 7046-53		87
1418	Development of antibodies and chimeric molecules for cancer immunotherapy. 2006 , 90, 83-131		36
1417	Follicular lymphoma: today's treatments and tomorrow's targets. 2006 , 7, 1273-90		6
1416	Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3121-7	2.2	1036
1415	Current treatment strategies in follicular lymphomas. 2006 , 17 Suppl 10, x155-9		2
1414	The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice. 2006 , 66, 1799-808		37
1413	Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4123-8	2.2	174
1412	Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients. 2006 , 12, 6056-63		44
1411	The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. 2006 , 176, 2600-9		173
1410	The biology and treatment of chronic lymphocytic leukemia. 2006 , 17 Suppl 10, x144-54		20
1409	Characterization of antibody-containing vesicles shed from B-lymphoma cell lines: exposure of annexin V binding sites. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2388-99	1.9	2
1408	Recombinant antibodies: from the laboratory to the clinic. 2006 , 21, 285-304		21
1407	A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. 2006 , 35, 93-114		85

1406	Radioimmunotherapy, a new breakthrough in the treatment of follicular non-Hodgkin's lymphoma: the European perspective. 2006 , 21, 1-4		7
1405	Refractoriness to rituximab monotherapy in a child with relapsed/refractory Burkitt non-Hodgkin lymphoma. 2006 , 23, 25-31		6
1404	Rituximab therapy in monoclonal IgM-related neuropathies. <i>Leukemia and Lymphoma</i> , 2006 , 47, 859-64	1.9	45
1403	Sensitivity analysis of cost factors for various therapy options in the treatment of follicular lymphoma. 2006 , 29, 258-64		4
1402	Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. 2006 , 177, 7435-43		119
1401	Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells. 2006 , 21, 645-54		9
1400	Ibritumomab tiuxetan for non-Hodgkin's lymphoma. 2006 , 6, 861-9		13
1399	Epratuzumab in the therapy of oncological and immunological diseases. 2006 , 6, 1341-53		46
1398	Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3880-6	2.2	134
1397	Tailoring antibodies for radionuclide delivery. 2006 , 3, 53-70		82
1396	Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4418-25	2.2	72
1395	Monoclonal antibodies in chronic lymphocytic leukemia. 2006 , 6, 1231-8		2
1394	Is rituximab a safe and effective treatment for patients with active RA, irrespective of methotrexate treatment?. 2006 , 2, 408-9		2
1393	Rituximab in the treatment of peripheral neuropathy associated with monoclonal gammopathy. 2006 , 6, 1267-74		9
1392	Recent advances and current challenges in tumor immunology and immunotherapy. 2007 , 15, 1065-71		27
1391	Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. 2007 , 99, 706-14		299
1390	Cancer du sujet âgé. 2007 ,		
1389	Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas. 2007 , 67, 5921-8		39

1388	Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities. 2007 , 179, 6881-8		43
1387	Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1986-92	2.2	415
1386	Safe administration of iodine-131 tositumomab after repeated infusion-related reactions to rituximab. 2007 , 12, 338-40		5
1385	Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. 2007 , 179, 2815-23		94
1384	Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. 2007 , 7, 257-73		18
1383	Nursing guidelines for managing infections in patients with chronic lymphocytic leukemia. 2007 , 11, 914-24		3
1382	Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 Castlemab Trial. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3350-6	2.2	163
1381	Introduction to B-Cell disorders. 2007 , 11, 3-12		1
1380	The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas. 2007 , 7, 1749-62		7
1379	Rituximab in the treatment of rheumatoid arthritis. 2007 , 3, 17-26		5
1378	TREATMENT OF FOLLICULAR LYMPHOMA – REVIEW. 2007 , 62, 408-418		
1377	Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement. <i>Leukemia and Lymphoma</i> , 2007 , 48, 342-8	1.9	11
1376	Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2007 , 48, 683-90	1.9	31
1375	Komplette Remission eines rezidivierenden Hodgkin-Lymphoms vom Mischzelligen Typ nach Rituximab-Therapie. 2007 , 28, 242-245		
1374	A complete response with rituximab in metastatic diffuse large B-cell lymphoma of the testis: case report. 2007 , 20, 401-3		5
1373	BiovaXID idiotype vaccination: active immunotherapy for follicular lymphoma. 2007 , 6, 307-17		11
1372	Anti-CD25 targeted killing of bicistronically transduced cells: a novel safety mechanism against retroviral genotoxicity. 2007 , 15, 1174-81		6
1371	Iodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma. 2007 , 3, 255-62		5

1370	Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma. 2007 , 125, 1663-7	65
1369	Current treatment options in follicular lymphoma: science and bias. <i>Leukemia and Lymphoma</i> , 2007 , 48, 2098-109	1.9 2
1368	Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia. 2007 , 16, 1799-815	4
1367	Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma. 2007 , 22, 521-30	2
1366	Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. 2007 , 13, 5636s-5642s	11
1365	Role of antibody therapy in lymphoid malignancies. 2007 , 83, 275-90	7
1364	Bevacizumab 5 mg/kg can be infused safely over 10 minutes. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2691-2	43
1363	Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. 2007 , 2, 932-7	111
1362	Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy. 2007 , 67, 2872-80	33
1361	A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. 2007 , 18, 364-9	76
1360	Elevation of activated platelet-dependent chemokines in patients with anti-CD20 monoclonal antibody (rituximab)-treated non-Hodgkin's lymphoma. 2007 , 13, 206-12	3
1359	B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. 2007 , 179, 1369-80	113
1358	Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. 2007 , 67, 10939-47	75
1357	A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study. 2007 , 13, 5652s-5660s	28
1356	Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. 2007 , 46, 29-36	75
1355	The clinical use of antibodies in haematological malignancies. 2007 , 18 Suppl 9, ix51-7	6
1354	Toll-like receptors in tumor immunotherapy. 2007 , 13, 5280-9	101
1353	Immunotherapy of Cancer. 2007 , 211-235	1

1352	BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma. 2007 , 7, 113-22	20
1351	Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. 2007 , 179, 4263-71	54
1350	A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. 2007 , 18, 1216-23	90
1349	Immunologic approaches to ovarian cancer treatment. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2884-93	2.2 39
1348	Complete response to temozolomide treatment in an elderly patient with recurrent primary central nervous system lymphoma--case report. 2007 , 47, 229-32	6
1347	Small intestinal follicular lymphoma with multiple tumor formations diagnosed by double-balloon enteroscopy. 2007 , 46, 705-9	19
1346	[Recent therapeutic strategy for follicular lymphoma]. 2007 , 96, 787-804	
1345	Rituximab maintenance therapy: a step forward in follicular lymphoma. 2007 , 92, 826-33	26
1344	Rituximab for the treatment of autoimmune cytopenias. 2007 , 92, 1589-96	27
1343	B cell-ablative therapy: where are we now?. 2007 , 20, 655-9	1
1342	Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). 2007 , 143, 192-8	65
1341	How I treat indolent lymphoma. 2007 , 109, 4617-26	78
1340	Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas. 2007 , 109, 4980-7	32
1339	Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. 2007 , 109, 4171-3	86
1338	Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. 2007 , 110, 2569-77	120
1337	Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. 2007 , 110, 4037-46	91
1336	Rituximab (Rituxan). 1033-1108	
1335	Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. 2007 , CD003805	48

1334	Defining the role of immunotherapy and radioimmunotherapy in the treatment of low-grade lymphoma. 2007 , 14, 360-8	12
1333	Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma. 2007 , 30, 64-74	25
1332	One step generation of fully chimeric antibodies using Cgamma1- and Ckappa mutant mice. 2007 , 30, 338-49	7
1331	Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group. 2007 , 30, 455-67	26
1330	Rituximab for the treatment of acquired antibodies to factor VIII. 2007 , 92, 66-71	83
1329	Treatment of Benign Orbital Pseudolymphomas With the Monoclonal Anti-CD20 Antibody Rituximab. 2007 , 82, 692-699	27
1328	Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma. 2007 ,	1
1327	The curability of follicular lymphoma. 2007 , 37, 31-5	7
1326	Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults. 2007 , 5, 247-62	11
1325	Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells. 2007 , 1768, 21-9	24
1324	Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario. 2007 , 33, 161-76	52
1323	Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). 2007 , 56, e55-79	88
1322	Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. 2007 , 44, 1331-41	161
1321	Mechanisms of killing by anti-CD20 monoclonal antibodies. 2007 , 44, 3823-37	425
1320	Standard Approaches to Relapsed Indolent Non-Hodgkin's Lymphoma. 2007 , 44, S12-S17	
1319	Overcoming Rituximab Resistance: The US Clinical Experience With Bendamustine. 2007 , 44, S27-S31	1
1318	New Agents in Development for Non-Hodgkin's Lymphoma. 2007 , 44, S18-S21	
1317	Historical Perspective on the Treatment Challenges of Low-Grade Non-Hodgkin's Lymphoma. 2007 , 44, S2-S6	1

1316 Therapy for patients with follicular lymphoma. **2007**, 5, 438-439

1315 Emerging concepts in monoclonal antibody therapy. **2007**, 5, 442-443

1314 Apoptosis, Senescence, and Cancer. **2007**,

6

1313 Selection Strategies I: Monoclonal Antibodies. 18-44

0

1312 General Principles of Tumor Immunotherapy. **2007**,

2

1311 Rituximab-related viral infections in lymphoma patients. *Leukemia and Lymphoma*, **2007**, 48, 1307-12

1.9 209

1310 The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. *Leukemia and Lymphoma*, **2007**, 48, 1931-9

1.9 85

1309 Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2. **2007**, 13, 5528s-5534s

30

1308 Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines. *Leukemia and Lymphoma*, **2007**, 48, 944-56

1.9 12

1307 Head and Neck Manifestations of Systemic Disease. **2007**,

2

1306 Hepatitis B virus reactivation induced by Yttrium-90-ibritumomab-tiuxetan. *Leukemia and Lymphoma*, **2007**, 48, 1866-8

1.9 7

1305 The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation. *Leukemia and Lymphoma*, **2007**, 48, 1961-7

1.9 14

1304 Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. **2007**, 12, 361-70

60

1303 Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors. **2007**, 22, 342-56

8

1302 Infusion of rituximab over 90 minutes on an out-patient basis is safe and improves resource utilization. *Leukemia and Lymphoma*, **2007**, 48, 1875-7

1.9 8

1301 Long-term treatment with rituximab is feasible in selected patients with B-CLL: response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy. *Leukemia and Lymphoma*, **2007**, 48, 905-11

1.9 12

1300 Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. **2007**, 13, 6168-74

102

1299 Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. **2007**, 233-42

75

1298	Use of CFSE to monitor ex vivo regulatory T-cell suppression of CD4+ and CD8+ T-cell proliferation within unseparated mononuclear cells from malignant and non-malignant human lymph node biopsies. 2007 , 36, 629-48		17
1297	Targeting B lymphocytes as therapy for ANCA-associated vasculitis. 2007 , 33, 741-54, v		10
1296	Treatment of Benign Orbital Pseudolymphomas With the Monoclonal Anti-CD20 Antibody Rituximab. 2007 , 82, 692-699		21
1295	Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. 2007 , 67, 3927-35		77
1294	Cancer therapeutic antibodies come of age: targeting minimal residual disease. 2007 , 1, 42-54		43
1293	Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. 2007 , 47, 1119-28		108
1292	Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. 2007 , 67, 333-50		84
1291	Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. 2007 , 7, 406-12		16
1290	Maintenance therapy in lymphoma. 2007 , 7, 507-13		21
1289	Targeted therapies for non-Hodgkin lymphoma: rationally designed combinations. 2007 , 7 Suppl 5, S192-8		3
1288	CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2007 , 48, 2424-36	1.9	29
1287	B-cell depletion in the treatment of mixed cryoglobulinemia. 2007 , 39 Suppl 1, S116-21		10
1286	Rituximab in mixed cryoglobulinemia: increased experience and perspectives. 2007 , 39 Suppl 1, S122-8		29
1285	Chemoimmunotherapy of chronic lymphocytic leukemia. 2007 , 20, 479-98		15
1284	Lymphomes et autres tumeurs h�matologiques. 2007 , 179-206		1
1283	Rituximab maintenance in relapsed or refractory follicular non-Hodgkin's lymphoma: the evidence of its therapeutic value. 2007 ,		
1282	Biological Macromolecules. 2007 , 431-447		0
1281	Management of Haematological Malignancies. 2007 ,		1

1280	Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). 2007 , 57, 310-7		242
1279	Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. 2007 , 25, 127-31		81
1278	Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. 2007 , 110, 121-8		39
1277	Management of symptomatic, untreated chronic lymphocytic leukemia. 2007 , 21, 143-56		7
1276	Pharmacokinetics of rituximab and its clinical use: thought for the best use?. 2007 , 62, 43-52		97
1275	Use of rituximab in patients with follicular lymphoma. 2007 , 19, 38-49		9
1274	Emerging therapies for multiple sclerosis. 2007 , 4, 676-92		23
1273	Acquired immune cytopenias post-cardiac transplantation respond to rituximab. <i>Pediatric Blood and Cancer</i> , 2007 , 48, 339-44	3	30
1272	Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. 2007 , 26, 3704-13		81
1271	Rituximab therapy in malignant lymphoma. 2007 , 26, 3603-13		174
1270	Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab. 2007 , 26, 3614-28		74
1269	Building better magic bullets--improving unconjugated monoclonal antibody therapy for cancer. 2007 , 7, 701-6		60
1268	Septic polyarthritis with <i>Ureaplasma urealyticum</i> in a patient with prolonged agammaglobulinemia and B-cell aplasia after allogeneic HSCT and rituximab pretreatment. <i>Bone Marrow Transplantation</i> , 2007 , 40, 597-8	4.4	30
1267	Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma. <i>Bone Marrow Transplantation</i> , 2007 , 40, 973-8	4.4	20
1266	Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. 2007 , 17, 89-99		47
1265	Intraocular rituximab. 2007 , 21, 1453-4		6
1264	Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. 2007 , 20, 102-5		74
1263	Rituximab for the treatment of post-bone marrow transplantation refractory hemolytic anemia in a child with Omenn's syndrome. 2007 , 11, 552-6		5

1262	Current management of follicular lymphomas. <i>British Journal of Haematology</i> , 2007 , 136, 191-202	4.5	23
1261	Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. <i>British Journal of Haematology</i> , 2007 , 136, 451-61	4.5	208
1260	Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. <i>British Journal of Haematology</i> , 2007 , 137, 409-15	4.5	47
1259	Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2007 , 138, 502-5	4.5	28
1258	High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2007 , 139, 590-9	4.5	36
1257	Partial remission of a newly diagnosed diffuse large B-cell Non-Hodgkin's lymphoma in a hemodialysis patient after administration of immuno-chemotherapy with rituximab-CHOP. 2007 , 29, 469-73		12
1256	Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. 2007 , 66, 476-83		31
1255	Macrophage colony-stimulating factor enhances rituximab-dependent cellular cytotoxicity by monocytes. 2007 , 98, 1368-72		5
1254	Off-label uses of rituximab in dermatology. 2007 , 20, 277-87		29
1253	B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. 2007 , 122, 139-45		137
1252	Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. 2007 , 122, 62-74		193
1251	Successful induction of remission with rituximab for relapse of ANCA-associated vasculitis post-kidney transplant: report of two cases. 2007 , 7, 2821-5		34
1250	The therapeutic use of rituximab in non-Hodgkin's lymphoma. 2007 , 77, 5-14		68
1249	Prolonged remission of pure white cell aplasia (PWCA), in a patient with CLL, induced by rituximab and maintained by continuous oral cyclosporin. 2007 , 79, 271-3		11
1248	Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma. 2007 , 17, 176-83		21
1247	Evaluation of a peptide ELISA for the detection of rituximab in serum. 2007 , 325, 127-39		56
1246	Rituximab: first monoclonal antibody for severe, active RA. 2007 , 18, 19-28		2
1245	The management of posttransplant lymphoproliferative disorder. 2007 , 24, 125-36		52

1244	Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma. 2007 , 28, 179-83	7
1243	Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma--role of radioimmunotherapy. 2007 , 86, 81-7	31
1242	Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. 2007 , 86, 639-45	13
1241	Primary follicular lymphoma of the cervix uteri: a review. 2007 , 86, 623-30	19
1240	Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. 2007 , 60, 129-34	99
1239	Rituximab zur Therapie des Non-Hodgkin-Lymphoms. 2007 , 13, 227-235	0
1238	Rituximab maintenance therapy in follicular lymphoma. 2007 , 2, 213-8	2
1237	Nonmyeloablative stem cell transplantation in follicular B-cell lymphoma. 2007 , 2, 225-31	1
1236	Rituximab maintenance in indolent lymphoma: indications and controversies. 2007 , 9, 378-83	3
1235	The future of biologic agents in the treatment of Sjögren's syndrome. 2007 , 32, 292-7	30
1234	An overview of cancer multidrug resistance: a still unsolved problem. 2008 , 65, 3145-67	335
1233	Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. 2008 , 57, 411-23	163
1232	Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples. 2008 , 61, 1027-35	57
1231	[Treatment of hematological malignancies with monoclonal antibodies]. 2008 , 49, 929-30, 932-4, 936-7	1
1230	Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer. 2008 , 8, 63-8	9
1229	Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. 2008 , 3, 187-93	7
1228	Beyond rituximab: the future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. 2008 , 10, 420-6	2
1227	Radioimmunotherapy âstill experimental? Rational, proven indications and future trends. 2008 , 1, 193-203	2

1226	Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma. 2008 , 25, 437-42		24
1225	Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer. 2008 , 68, 1421-9		54
1224	Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. 2008 , 113, 2714-23		95
1223	Controversies in the front-line management of chronic lymphocytic leukemia. 2008 , 32, 679-88		8
1222	Follicular lymphomas. 2008 , 66, 248-61		37
1221	Effects of ultrasound on apoptosis induced by anti-CD20 antibody in CD20-positive B lymphoma cells. 2008 , 15, 463-471		9
1220	Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. 2008 , 359, 613-26		352
1219	Rituximab in advanced rheumatoid arthritis. 2008 , 7, 5-10		
1218	Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. 2008 , 6, 366-73		114
1217	Empfehlungen für den Einsatz von Rituximab (anti-CD20-Antikörper) bei bullösen Autoimmundermatosen. 2008 , 6, ---		
1216	B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. 2008 , 128, 2859-69		88
1215	Paul Ehrlich's magic bullet concept: 100 years of progress. 2008 , 8, 473-80		811
1214	Protein therapeutics: a summary and pharmacological classification. 2008 , 7, 21-39		1314
1213	Production and characterization of highly tumor-specific rat monoclonal antibodies recognizing the extracellular domain of human L-type amino-acid transporter 1. 2008 , 99, 1000-7		25
1212	Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16. <i>British Journal of Haematology</i> , 2008 , 140, 635-43	4.5	89
1211	Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. <i>British Journal of Haematology</i> , 2008 , 141, 36-40	4.5	65
1210	Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients. <i>British Journal of Haematology</i> , 2008 , 141, 631-40	4.5	40
1209	Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. <i>British Journal of Haematology</i> , 2008 , 142, 179-91	4.5	28

1208	Rituximab in the treatment of autoimmune haematological disorders. <i>British Journal of Haematology</i> , 2008 , 143, 294; author reply 295	4.5	3
1207	Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma. <i>British Journal of Haematology</i> , 2008 , 143, 672-80	4.5	8
1206	The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?. 2008 , 66, 6-19		47
1205	Responses to rituximab vary among follicular lymphoma B cells of different maturation stages. 2008 , 68, 159-68		5
1204	Features of rituximab-induced killing of B lymphocytes. 2008 , 68, 118-9		2
1203	Newer monoclonal antibodies for hematological malignancies. 2008 , 36, 755-68		72
1202	Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity. 2008 , 128, 155-63		8
1201	A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. 2008 , 8, 2607-17		120
1200	B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders. 2008 , 204, 1-12		20
1199	The use of galiximab in non-Hodgkin lymphoma. 2008 , 8, 277-82		12
1198	Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy. 2008 , 8, 356-8		6
1197	Considerations with newer regimens for indolent non-Hodgkin lymphoma. 2008 , 8 Suppl 4, S128-36		2
1196	The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1982-94	1.9	25
1195	CD70 as a therapeutic target in human malignancies. 2008 , 12, 341-51		47
1194	Molecular Biomethods Handbook. 2008 ,		10
1193	Targeted Cancer Therapy. 2008 ,		6
1192	Quelques perspectives concernant le traitement des lymphomes par Zevalin [®] à partir de l'évaluation de l'expérience niçoise. 2008 , 32, 85-95		
1191	Monoclonal antibodies in the treatment of lymphoid malignancies. 2008 , 108, 267-71		8

1190	"It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer. 2008 , 20, 296-300		24
1189	Vaccination with in vitro grown whole tumor cells induces strong immune responses and retards tumor growth in a murine model of colorectal liver metastases. 2008 , 26, 241-9		3
1188	Impact of Polymorphisms on the Clinical Outcomes of Monoclonal Antibody Therapy Against Hematologic Malignancies. 2008 , 203-229		
1187	High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. 2008 , 14, 50-8		87
1186	Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. 2008 , 14, 36-42		60
1185	Antibody therapy for chronic lymphocytic leukemia. 2008 , 45, 95-103		27
1184	Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma. 2008 , 45, 85-9		4
1183	Monoclonal antibodies for the treatment of hematologic malignancies: schedule and maintenance therapy. 2008 , 45, 75-84		7
1182	Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. 2008 , 45, 126-32		14
1181	Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4473-9	2.2	293
1180	Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 204-10	2.2	243
1179	Approved monoclonal antibodies for cancer therapy. 2008 , 8, 1151-8		59
1178	Indolent lymphomas other than follicular and marginal zone lymphomas. 2008 , 22, 903-40, viii		5
1177	Ab therapy of AML: native anti-CD33 Ab and drug conjugates. 2008 , 10, 7-12		6
1176	Follicular lymphoma: clinical features and treatment. 2008 , 22, 863-82, viii		32
1175	Monoclonal antibodies in cancer therapy: 25 years of progress. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1774-7	2.2	162
1174	Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2008 , 49, 227-36	1.9	36
1173	B-cell-targeted therapy for systemic lupus erythematosus: an update. 2008 , 22, 239-49		26

1172	Treatment of follicular lymphoma: current status. <i>Leukemia and Lymphoma</i> , 2008 , 49 Suppl 1, 7-17	1.9	11
1171	Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. 2008 , 26, 431-3		28
1170	Complement and cellular cytotoxicity in antibody therapy of cancer. 2008 , 8, 759-68		64
1169	Imatinib for the treatment of refractory, diffuse systemic sclerosis. 2008 , 47, 735-7		59
1168	Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. 2008 , 181, 822-32		105
1167	Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. 2008 , 181, 2916-24		79
1166	Immunopharmacology. 2008 ,		5
1165	From oncogene to network addiction: the new frontier of cancer genomics and therapeutics. 2008 , 4, 569-77		24
1164	Severe prolonged immunosuppression following fludarabine and rituximab combination therapy. 2008 , 54, 242-4		6
1163	A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. 2008 , 59, 237-50		149
1162	Use of rituximab in multiple sclerosis: current progress and future perspectives. 2008 , 4, 573-82		4
1161	Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. 2008 , 14, 7088-94		79
1160	Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3614-20	2.2	118
1159	Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. 2008 , 180, 7028-38		160
1158	Does rituximab really induce hepatitis C virus reactivation?. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4695-6; author reply 4696	2.2	15
1157	Occurrence of cold agglutinin disease in RA patient during etanercept therapy successfully treated with rituximab. 2008 , 47, 734-5		8
1156	Rituximab treatment of idiopathic membranous nephropathy. 2008 , 73, 117-25		165
1155	Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. 2008 , 5, e64		96

1154	New monoclonal antibodies for non-Hodgkin's lymphoma. 2008 , 19 Suppl 4, iv60-2		3
1153	Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. 2008 , 67, 1724-31		145
1152	Innovative Leukemia and Lymphoma Therapy. 2008 ,		
1151	Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. 2008 , 14, 1550-60		90
1150	Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. 2008 , 68, 2400-8		60
1149	GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1681-92	1.9	16
1148	A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. 2008 , 14, 6697-703		133
1147	Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells. 2008 , 68, 7512-9		25
1146	Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. 2008 , 180, 361-71		260
1145	Antibody-based cancer therapy. 2008 , 3, 441-52		1
1144	Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphoma. <i>Leukemia and Lymphoma</i> , 2008 , 49, 68-74	1.9	9
1143	Signaling in Human B-Lymphoma Rafts. 2008 , 8, 366-374		
1142	A case of non-Hodgkin's lymphoma-associated pemphigus foliaceus and use of rituximab for treatment. 2008 , 19, 1-3		5
1141	Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. 2009 , 24, 179-85		56
1140	Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2725-31	2.2	69
1139	Recombinant antibodies for cancer therapy. 2008 , 8, 1123-41		24
1138	Development of Common Variable Immunodeficiency in an 8-year-old Boy Treated with Rituximab for Idiopathic Thrombocytopenia. 2008 , 21, 99-104		3
1137	Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. <i>Leukemia and Lymphoma</i> , 2008 , 49, 102-12	1.9	55

1136	Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: analysis of remission induction and stem cell mobilization. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1337-44	1.9	7
1135	Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo. 2008 , 111, 1504-11		32
1134	The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. 2008 , 112, 711-20		85
1133	First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. 2008 , 111, 5486-95		223
1132	Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. 2008 , 112, 3312-21		79
1131	Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. 2008 , 112, 2261-71		540
1130	Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. 2008 , 112, 830-5		76
1129	Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. 2008 , 112, 4824-31		270
1128	[Malignant lymphoma. Current topics. 1. Antibody therapy]. 2008 , 97, 1620-6		
1127	15. Treatment of Malignant Lymphoma. 2008 , 97, 2315-2320		
1126	SV40 infection associated with rituximab treatment after kidney transplantation in nonhuman primates. 2008 , 85, 893-902		12
1125	B-cell-targeted therapies: promising new treatments for systemic lupus erythematosus. 2008 , 3, 59-68		0
1124	The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence. 2008 , 20, 17-22		33
1123	Antibodies and hematologic malignancies. 2008 , 14, 184-90		1
1122	Pharmacokinetic properties of rituximab. 2008 , 3, 22-30		12
1121	Rituximab in the treatment of non-Hodgkin's lymphoma. 2008 , 2, 619-33		19
1120	Tumor targeting using liposomal antineoplastic drugs. 2008 , 21		94
1119	Macroglobulinemia de Waldenström - remissão completa após tratamento com rituximabe. 2008 , 30,		

1118	Prediction of clinical outcome in patients with idiopathic thrombocytopenic purpura by evaluating bone marrow clotted CD20+ B lymphocytes and morphological changes of megakaryocytes. 2008 , 48, 11-5		1
1117	B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis. 2009 , 225		
1116	Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphoma. 2009 , 2, 229-42		4
1115	¹³¹ I-tositumomab in Lymphoma. 2009 , 16, 32-47		8
1114	Expanded use of rituximab in the management of non-Hodgkin lymphoma. 2009 , 2, 189-97		3
1113	[Regulatory consequences for the use of monoclonal antibodies]. 2009 , 25, 1183-8		
1112	Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009 , 50, 37-46	1.9	35
1111	Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3036-43	2.2	113
1110	Rapid infusion rituximab changing practice for patient care. 2009 , 15, 183-6		25
1109	Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6101-8	2.2	166
1108	Mobilization of hematopoietic stem cells into the peripheral blood. 2009 , 2, 717-33		26
1107	Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. 2009 , 183, 749-58		200
1106	Rituximab and chemotherapy in diffuse large B-cell lymphoma. 2009 , 9, 719-26		9
1105	Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis. 2009 , 101, 1758-68		23
1104	Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5023-30	2.2	83
1103	CpG ODN enhances the efficacy of rituximab in non-Hodgkin lymphoma. 2009 , 1173, 858-64		3
1102	Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1607-14	2.2	238
1101	Ten years of rituximab in NHL. 2009 , 8, 223-35		75

1100	Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. 2009 , 15, 6446-53		255
1099	[Antibodies: better knowledge for a better use]. 2009 , 25, 1011-9		1
1098	Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. 2009 , 4, 1083-8		64
1097	Targeting CD70 for human therapeutic use. 2009 , 647, 108-19		28
1096	Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3346-53	2.2	136
1095	Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response. 2009 ,		2
1094	Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. 2009 , 50, 1500-8		63
1093	Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies. 2009 , 18, 47-73		36
1092	New and experimental skin-directed therapies for cutaneous lymphomas. 2009 , 22, 322-34		19
1091	Understanding and circumventing resistance to anticancer monoclonal antibodies. 2009 , 1, 222-9		32
1090	Rituximab based therapy followed by autologous stem cell transplantation leads to superior outcome and high rates of PCR negativity in patients with indolent B-cell lymphoproliferative disorders. 2009 , 14, 187-97		1
1089	Therapeutic approaches to non-Hodgkin's lymphoma in the elderly patient. 2009 , 2, 173-82		3
1088	New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. 2009 , 18, 805-19		15
1087	Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies. 2009 , 1, 1015-24		1
1086	Prevention of hepatitis B virus reactivation under rituximab therapy. 2009 , 1, 1053-61		13
1085	Ocrelizumab: a step forward in the evolution of B-cell therapy. 2009 , 9, 889-95		49
1084	Treatment of lymphoma with adoptively transferred T cells. 2009 , 9, 1407-25		13
1083	The preparation of radiolabeled monoclonal antibodies for human use. 2009 , 18, 145-56		3

1082	A case of rituximab-induced interstitial pneumonitis observed in systemic lupus erythematosus. 2009 , 48, 447-8	17
1081	Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. 2009 , 15, 4038-45	51
1080	CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. 2009 , 15, 2739-46	49
1079	Rituximab therapy for membranous nephropathy: a systematic review. 2009 , 4, 734-44	68
1078	Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. 2009 , 32, 689-702	255
1077	Applications of monoclonal antibodies for the treatment of hematological malignancies. 2009 , 9, 207-20	14
1076	Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. 2009 , 15, 6582-94	55
1075	Antibody-based therapy of leukaemia. 2009 , 11, e29	29
1074	In vivo model of follicular lymphoma resistant to rituximab. 2009 , 15, 851-7	32
1073	Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. 2009 , 38, 265-80	54
1072	Serum immunoglobulins and risk of infection: how low can you go?. 2009 , 39, 18-29	84
1071	Combination of granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin (EPO) for the treatment of advanced non-responsive chronic lymphocytic leukemia. 1999 , 63, 325-31	4
1070	FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. 2009 , 82, 143-7	20
1069	Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. 2009 , 83, 365-72	57
1068	Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. 2009 , 9, 1099-107	226
1067	Immunogenicity of rituximab in patients with severe pemphigus. 2009 , 132, 334-41	72
1066	Immunotherapy of cancer. 2009 , 625, 41-54	62
1065	Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon. 2009 , 84, 247-50	49

1064	Myelodysplasia and copper deficiency induced by denture paste. 2009 , 84, 612		2
1063	Postvaccination hyperhemolysis coinciding with remission of Epstein Barr virus (EBV)-associated immune thrombocytopenic purpura (ITP). 2009 , 84, 612-3		3
1062	Pneumatic tube "pseudo tumor lysis syndrome" in chronic lymphocytic leukemia. 2009 , 84, 613-4		13
1061	An unusual presentation of extramedullary biphenotypic lymphoblastic lymphoma. 2009 , 84, 616-7		4
1060	Fatal CMV pneumonitis in a lymphoma patient treated with rituximab. 2009 , 84, 614-6		10
1059	Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. 2009 , 65, 286-93		229
1058	Opportunistic infections and other risks with newer multiple sclerosis therapies. 2009 , 65, 367-77		48
1057	Chronic lymphocytic leukemia: treatment options for patients with refractory disease. 2009 , 115, 3830-41		10
1056	Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. 2009 , 115, 5210-7		68
1055	A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. 2009 , 60, 2156-68		269
1054	Immunomodulation in the treatment of haematological malignancies. <i>Clinical and Experimental Medicine</i> , 2009 , 9, 81-92	4.9	6
1053	Targeting the B cell in vasculitis. 2009 , 24, 1267-75		12
1052	The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis. <i>International Journal of Hematology</i> , 2009 , 89, 326-331	2.3	7
1051	Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. <i>International Journal of Hematology</i> , 2009 , 90, 253-260	2.3	43
1050	Chronic lymphocytic leukemia: new concepts and emerging therapies. 2009 , 10, 16-32		7
1049	Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer. 2009 , 5, 120-125		
1048	Radioimmunotherapy: strategies for the future in indolent and aggressive lymphoma. 2009 , 11, 363-70		4
1047	Targeted therapy for chronic lymphocytic leukemia. 2009 , 4, 11-21		12

1046	[Antibody therapy in hematology and oncology--2]. 2009 , 104, 28-49		0
1045	Side-effects and venous access issues with immune tolerance therapy. 2009 , 15, 494-500		6
1044	Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. 2009 , 100, 158-64		29
1043	Engineered therapeutic antibodies with improved effector functions. 2009 , 100, 1566-72		133
1042	Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma. 2009 , 100, 1951-6		8
1041	Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity. 2009 , 100, 2411-8		34
1040	Haemolytic anaemia following rituximab treatment in a patient with pemphigus vulgaris. 2009 , 161, 205-6		4
1039	Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. <i>British Journal of Haematology</i> , 2009 , 145, 816-24	4-5	59
1038	Rituximab in non-haematological disorders of adults and its mode of action. <i>British Journal of Haematology</i> , 2009 , 146, 233-46	4-5	38
1037	CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. 2009 , 155, 249-56		39
1036	Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy. 2009 , 157, 191-7		42
1035	Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. 2009 , 68, 561-73		17
1034	Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species. 2009 , 23, 59-70		39
1033	Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy. 2009 , 23, 457-66		13
1032	A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. 2009 , 23, 912-8		24
1031	Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. 2009 , 23, 1320-8		24
1030	Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2009 , 43, 121-6	4-4	35
1029	Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. <i>Bone Marrow Transplantation</i> , 2009 , 43, 701-8	4-4	59

1028	Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2009 , 43, 679-84	4.4	15
1027	Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: another autograft or switch to allograft?. <i>Bone Marrow Transplantation</i> , 2009 , 44, 559-69	4.4	7
1026	Serum autoantibodies as biomarkers for early cancer detection. 2009 , 276, 6880-904		238
1025	Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. 2009 , 14, 696-9		38
1024	Successful treatment with rituximab in an elderly patient with acquired factor VIII inhibitor. 2009 , 9, 197-9		13
1023	Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab. 2009 , 50, 202-6		20
1022	Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient. 2009 , 11, 167-70		31
1021	Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma. 2009 , 23, 601-8		23
1020	Rituximab for the treatment of CD20-positive peripheral T-cell lymphoma, unspecified. 2009 , 33, e13-6		18
1019	Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients. 2009 , 33, 792-7		19
1018	CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer. 2009 , 23, 361-75		76
1017	Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2009 , 27, 498-503	2.2	154
1016	Pharmaceutical Perspectives of Cancer Therapeutics. 2009 ,		11
1015	Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects. 2009 , 35, 653-61		23
1014	Nedd4L expression is downregulated in prostate cancer compared to benign prostatic hyperplasia. 2009 , 35, 527-31		36
1013	Siglecs as targets for therapy in immune-cell-mediated disease. 2009 , 30, 240-8		159
1012	[Anti-CD20 in hematologic oncology]. 2009 , 38, 788-98		0
1011	Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy?. 2009 , 69, 1727-37		1

1010	Flavopiridol in chronic lymphocytic leukemia: a concise review. 2009 , 9 Suppl 3, S179-85		36
1009	An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. 2009 , 8, 115		57
1008	R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. 2009 , 2, 14		18
1007	New targets for the treatment of follicular lymphoma. 2009 , 2, 50		16
1006	Selective Recognition of Rituximab-Functionalized Gold Nanoparticles by Lymphoma Cells Studied with 3D Imaging. 2009 , 113, 20252-20258		18
1005	Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1. 2009 , 1173, 721-8		13
1004	The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. 2009 , 182, 3318-26		69
1003	The late adverse events of rituximab therapy--rare but there!. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1083-95		97
1002	Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. <i>Leukemia and Lymphoma</i> , 2009 , 50, 357-65	1.9	81
1001	A simple and safe method for ¹³¹ I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy. 2009 , 24, 103-10		10
1000	Rituximab therapy in nephrotic syndrome due to AH amyloidosis. 2009 , 16, 178-80		3
999	Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. <i>Leukemia and Lymphoma</i> , 2009 , 50, 873-85	1.9	46
998	Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. 2009 , 10, 816-24		385
997	Monoclonal antibodies for cancer immunotherapy. 2009 , 373, 1033-40		214
996	Biology and treatment of follicular lymphoma. 2009 , 2, 533-47		10
995	Longitudinal changes in rheumatoid arthritis after rituximab administration assessed by quantitative and dynamic contrast-enhanced 3-T MR imaging: preliminary findings. 2009 , 19, 2217-24		9
994	Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. 2009 , 23, 949-71, v		33
993	Critical care management of cancer patients: cause for optimism and need for objectivity. 2009 , 21, 318-26		68

992	Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. 2009 , 32, 622-31	33
991	[Molecular-targeted drugs. 1) Indications and the application of molecular-targeted drugs in hematological diseases]. 2009 , 98, 1908-17	
990	Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. 2009 , 113, 3765-72	102
989	Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. 2009 , 113, 4352-61	75
988	Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. 2009 , 113, 18-27	91
987	Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. 2009 , 113, 1412-21	75
986	Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. 2009 , 113, 3773-80	106
985	Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. 2009 , 113, 4144-52	165
984	Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. 2009 , 113, 3809-12	131
983	De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. 2009 , 114, 957-64	134
982	CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. 2009 , 114, 3864-71	53
981	Therapeutic Antibodies in Clinical Use and Leading Clinical Candidates. 711-762	1
980	RESEARCH ADVANCES IN NEUROBLASTOMA IMMUNOTHERAPY. 2009 , 5, 112-117	2
979	Front-line management of diffuse large B cell lymphoma. 2010 , 22, 642-5	22
978	Monoclonal antibody therapy in haematological malignancies. 2010 , 5, 148-59	4
977	A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma. 2010 , 33, 178-84	9
976	Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. 2010 , 89, 308-318	120
975	Successful treatment with rituximab in a patient with stiff-person syndrome complicated by dysthyroid ophthalmopathy. 2010 , 49, 237-41	39

974	Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. 2010 , 115, 5180-90	39
973	Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity. 2010 , 115, 3745-55	31
972	Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. 2010 , 116, 926-34	152
971	Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. 2010 , 115, 2864-71	86
970	Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. 2010 , 115, 5191-201	245
969	Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. 2010 , 12, 33-43	212
968	Application of quantitative pharmacology in development of therapeutic monoclonal antibodies. 2010 , 12, 592-601	30
967	A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. 2010 , 59, 257-65	38
966	Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. 2010 , 89, 255-62	165
965	Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma. 2010 , 89, 263-72	14
964	Bendamustine: something old, something new. 2010 , 66, 413-23	45
963	[Tumor stem cell research - basis and challenge for diagnosis and therapy]. 2010 , 122, 423-36	4
962	Current immunochemotherapy strategies in follicular lymphoma. 2010 , 27, 704-13	2
961	A case of severe acute hepatitis C and delayed antibody production due to rituximab therapy. 2010 , 3, 254-8	1
960	Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms. 2010 , 46, 192-205	13
959	Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. <i>International Journal of Hematology</i> , 2010 , 91, 501-8	2-3 43
958	Targeted treatment and new agents in diffuse large B cell lymphoma. <i>International Journal of Hematology</i> , 2010 , 92, 12-24	2-3 14
957	Challenges in the frontline treatment of patients with chronic lymphocytic leukemia. 2010 , 5, 45-51	3

956	Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data. 2010 , 12, 395-401		5
955	Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. 2010 , 28, 561-74		17
954	Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects. 2010 , 360, 30-8		21
953	Is rituximab safe to use in kidney transplant patients?. 2010 , 10, 8-9		8
952	Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients. 2010 , 85, 502-7		18
951	Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology. 2010 , 85, 147-55		5
950	VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: a multicenter experience. 2010 , 51, 209-15		6
949	Depletion of peripheral blood B cells with Rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma. 2010 , 34, 307-11		7
948	Severe anemia caused by combination of autoimmune hemolysis, pure red cell aplasia and massive bone marrow infiltration in an elderly patient with chronic lymphocytic leukemia: successful treatment with rituximab. 2010 , 34, e140-1		1
947	Novel agents for B-cell non-Hodgkin lymphoma: science and the promise. 2010 , 24, 69-82		13
946	Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada. 2010 , 13, 703-11		19
945	Antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: the evidence for treatment. 2010 , 8, 18-27		0
944	Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope. 2010 , 101, 201-9		35
943	Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. 2010 , 101, 1840-5		48
942	Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results. 2010 , 101, 2579-85		13
941	The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. <i>British Journal of Haematology</i> , 2010 , 149, 3-13	4.5	115
940	Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2010 , 151, 346-53	4.5	57
939	Changing paradigms in the treatment of chronic lymphocytic leukemia. 2010 , 24, 500-11		16

938	Monoclonal antibodies: versatile platforms for cancer immunotherapy. 2010 , 10, 317-27	879
937	Rituximab for the treatment of patients with chronic lymphocytic leukemia. 2010 , 2, 71-81	4
936	Radioimmunotherapy for B-Cell Non-Hodgkin Lymphoma. 2010 , 169-218	
935	. 2010 ,	15
934	Management of non-Hodgkin's lymphoma in older adults. 274-287	
933	Role of rituximab in first-line treatment of chronic lymphocytic leukemia. 2010 , 7, 1-11	7
932	In vivo, multimodal imaging of B cell distribution and response to antibody immunotherapy in mice. 2010 , 5, e10655	16
931	Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system. 2010 , 1, 943-946	2
930	The spectrum of use of rituximab in chronic lymphocytic leukemia. 2010 , 3, 227-46	4
929	Ofatumumab: a novel monoclonal anti-CD20 antibody. 2010 , 3, 51-9	15
928	Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL). 2010 , 1, 115-22	1
927	Galiximab: a review. 2010 , 10, 451-8	20
926	Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events. 2010 , 21, 1699-1705	16
925	High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3709-16 ^{2,2}	93
924	Utility of influenza vaccination for oncology patients. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2481-90	2.2 88
923	A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells. 2010 , 184, 1210-7	34
922	Construction and characterization of a bispecific anti-CD20 antibody with potent antitumor activity against B-cell lymphoma. 2010 , 70, 6293-302	6
921	Hepatitis B reactivation and rituximab in the oncology practice. 2010 , 15, 1113-21	20

920	Rituximab (Rituxan). 2010 , 31, 1178-80		17
919	Immunoglobulin G Fc receptor Fcγ3a 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 279-84	2.2	98
918	Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2085-93	2.2	281
917	A review: the use of rituximab in neuromuscular diseases. 2010 , 12, 91-102		12
916	Radioimmunotherapy: A novel treatment of non-Hodgkin lymphoma. 2010 , 18, 23-29		
915	Rituximab administration and reactivation of HBV. 2010 , 2010, 182067		19
914	Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. 2010 , 2, 14-9		74
913	Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma. 2010 , 51, 150-7		10
912	Liposomes modified by carbohydrate ligands can target B cells for the treatment of B-cell lymphomas. 2010 , 9, 1251-6		8
911	Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. <i>Leukemia and Lymphoma</i> , 2010 , 51, 747-55	1.9	44
910	Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, orelizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus. 2010 , 50, 494-506		33
909	Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. 2010 , 5, 2188-98		186
908	Investigational immunotherapeutics for B-cell malignancies. <i>Journal of Clinical Oncology</i> , 2010 , 28, 884-922		21
907	Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. 2010 , 19, 7-13		26
906	Results of a phase I/II study of orelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. 2010 , 21, 1870-1876		100
905	Antibodies in cancer immunotherapy. 2010 , 6, 291-305		2
904	Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation. 2010 , 21, 1891-1897		12
903	Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives. 2010 , 2010, 428253		18

902	Emerging concepts for the treatment of hematological malignancies with therapeutic monoclonal antibodies. 2010 , 11, 790-800		7
901	Medical treatment of hyperthyroidism: state of the art. 2010 , 118, 678-84		34
900	[Infectious agents in ocular adnexal tumours]. 2010 , 227, 530-7		2
899	The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2010 , 51, 376-89	1.9	30
898	Diversity in antibody-based approaches to non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2010 , 51 Suppl 1, 20-7	1.9	14
897	Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2010 , 51 Suppl 1, 41-9	1.9	5
896	Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. 2010 , 74, 1860-7		159
895	A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells. 2010 , 70, 7600-9		37
894	Emerging biotherapies for Sjögren's syndrome. 2010 , 15, 269-82		10
893	Innovative uses of rituximab in dermatology. 2010 , 28, 547-57		15
892	Infectious complications associated with immunomodulating biologic agents. 2010 , 24, 285-306		65
891	Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. 2010 , 95, 329-32		40
890	Anti-CD20 monoclonal antibodies: historical and future perspectives. 2010 , 95, 135-43		203
889	Central nervous system inflammatory demyelination after rituximab therapy for idiopathic thrombocytopenic purpura. 2010 , 288, 178-81		6
888	Role of Antibodies in Cancer Treatment (An Overview). 2010 , 135-152		2
887	Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. 2010 , 70, 1445-76		144
886	Clinical pharmacokinetics of therapeutic monoclonal antibodies. 2010 , 49, 493-507		441
885	Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study. 2010 , 10, 379-84		9

884	A decade of progress in lymphoma: advances and continuing challenges. 2010 , 10, 414-23		38
883	Role of CD20 monoclonal antibodies in previously untreated chronic lymphocytic leukemia. 2010 , 10 Suppl 1, S27-33		3
882	Infusion reactions: diagnosis, assessment, and management. 2010 , 14, E10-21		136
881	Targeted therapies in cancer. 2010 , 24, 77-88		29
880	Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. 2010 , 363, 211-20		1101
879	The future of CD20 monoclonal antibody therapy in B-cell malignancies. <i>Leukemia and Lymphoma</i> , 2010 , 51, 983-94	1.9	70
878	Ofatumumab, a human anti-CD20 monoclonal antibody. 2010 , 10, 439-49		15
877	Spotlight on rituximab in chronic lymphocytic leukemia, low-grade or follicular lymphoma, and diffuse large B-cell lymphoma. 2011 , 25, 55-61		10
876	Rituximab tolerability when given before or after CHOP. 2011 , 17, 381-6		5
875	Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 178-85	6.1	106
874	Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. 2011 , 186, 6044-55		77
873	SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. 2011 , 17, 6448-58		138
872	The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia. 2011 , 5, 45-53		7
871	Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma. 2011 , 5, 145-56		21
870	Interindividual variability of response to rituximab: from biological origins to individualized therapies. 2011 , 17, 19-30		69
869	Added value of molecular targeted agents in oncology. 2011 , 22, 1703-16		42
868	Hibernation: Poikilotherms. 2011 ,		4
867	Rapid-onset, prolonged bone marrow failure following rituximab therapy of follicular lymphoma. 2011 , 34, 322-4		0

866	Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. 2011 , 96, 567-73	42
865	Eradication of melanomas by targeted elimination of a minor subset of tumor cells. 2011 , 108, 2474-9	91
864	Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. 2011 , 186, 3762-9	156
863	Beyond chemotherapy: new agents for targeted treatment of lymphoma. 2011 , 8, 85-96	70
862	One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. 2011 , 43, 539-49	41
861	Cancer radioimmunotherapy. 2011 , 3, 349-70	96
860	Monoclonal antibodies in hematological malignancies: past, present and future. 2011 , 7, 399-407	12
859	Immunotoxins and other conjugates containing saporin-s6 for cancer therapy. 2011 , 3, 697-720	57
858	Therapy of newly diagnosed follicular lymphoma. <i>Frontiers in Oncology</i> , 2012 , 2, 188	5:3
857	Resistance--the true face of biological defiance. 2012 , 51, 413-22	3
856	A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. 2012 , 23, 2687-2695	23
855	Galiximab signals B-NHL cells and inhibits the activities of NF- κ B-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 572-81	6:1 16
854	Rituximab-based treatment, HCV replication, and hepatic flares. 2012 , 2012, 945950	30
853	Incidence of Non-Neutropenic Infection (NNI) in Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma: The Effects of Rituximab Therapy. 2012 , 22, 220-226	
852	Neutropenia after rituximab treatment: new insights on a late complication. 2012 , 19, 32-8	54
851	What is the best initial therapy for a patient with symptomatic low-grade follicular lymphoma?. 2012 , 18, 383-9	5
850	Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. 2012 , 52, 1918-26	57
849	Anti-tumor monoclonal antibodies in conjunction with β glucans: a novel anti-cancer immunotherapy. 2012 , 19, 4298-305	17

848	Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies. <i>Leukemia and Lymphoma</i> , 2012 , 53, 770-8	1.9	5
847	7th cancer scientific forum of theCancropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France. 2012 , 4, 434-44		1
846	Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma. 2012 , 4, 256-66		5
845	Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma. 2012 , 8, 359-71		6
844	Shining light on nuclear-targeted therapy using gold nanostar constructs. 2012 , 3, 1263-7		21
843	Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia. 2012 , 3, 199-207		5
842	Diagnosis and treatment of diffuse large B-cell lymphoma. 2012 , 142, w13511		21
841	Rapid-infusion rituximab in lymphoma treatment: 2-year experience in a single institution. 2012 , 8, 141-3		3
840	Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs. 2012 , 1, 172-198		22
839	Has single-agent rituximab replaced watch-and-wait for a patient with asymptomatic low-grade follicular lymphoma?. 2012 , 18, 390-5		10
838	Advances in the management of follicular lymphoma. 2012 , 24, 742-7		10
837	Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. 2012 , 97, 1431-8		86
836	Antibody-targeted therapy. 563-581		
835	Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. 2012 , 119, 3698-704		118
834	Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. 2012 , 25, 471-506		282
833	Therapeutic antibodies against cancer. 2012 , 26, 447-81, vii		59
832	Rituximab: emerging treatment strategies of immune-mediated glomerular disease. 2012 , 8, 413-21		7
831	Targeted drug delivery for cancer therapy: the other side of antibodies. 2012 , 5, 70		194

830	Management of indolent lymphoma: where are we now and where are we going. 2012 , 26, 279-88		38
829	Immunotherapy in clinical medicine: historical perspective and current status. 2012 , 96, 421-31, ix		11
828	Non-Hodgkin lymphoma. 2012 , 380, 848-57		401
827	Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma. 2012 , 87, E68-71		1
826	Rituximab-induced direct inhibition of T-cell activation. 2012 , 61, 1233-41		47
825	Positron emission tomography of ⁶⁴ Cu-DOTA-Rituximab in a transgenic mouse model expressing human CD20 for clinical translation to image NHL. <i>Molecular Imaging and Biology</i> , 2012 , 14, 608-16	3.8	24
824	The use of monoclonal antibodies in immune-mediated hematologic disorders. 2012 , 96, 583-619, xi		4
823	Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1757-63	1.9	9
822	Perspective: multimodality radionuclide therapy of progressive disseminated lymphoma and neuroendocrine tumors as a paradigm for cancer control. 2012 , 27, 525-9		1
821	Chronic alloantibody mediated rejection. 2012 , 24, 115-21		41
820	Biological therapy doublets: pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphoma. 2012 , 7, 221-7		4
819	Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1822-8	2.2	261
818	Biological agents for the treatment of uveitis. 2012 , 12, 311-28		25
817	Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicity. 2012 , 287, 31983-93		16
816	A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. 2012 , 18, 5752-60		50
815	Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo. 2012 , 26, 1365-74		38
814	Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice. 2012 , 143, 44-52		35
813	Application of the systematic review and bibliometric network analysis (SeBriNA) methodology contextualizes evidence. Part 2: rituximab for non-Hodgkin's lymphoma. 2012 , 65, 996-1009		4

812	Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. 2012 , 84 Suppl 1, e49-57		28
811	Rituximab: current status as therapy for malignant and benign hematologic disorders. 2012 , 26, 71-82		14
810	Treatment of Lymphoma with 131I-Chimeric Monoclonal Antibodies. 2012 , 527-533		
809	Acupuncture and Moxibustion for Side Effects of Chemotherapy in Cancer Patients. 2012 , 153-181		
808	Risks and untoward toxicities of antibody-based immunoconjugates. 2012 , 64, 1782-99		38
807	Cranio-maxillofacial non-Hodgkin's lymphoma: clinical and histological presentation. 2012 , 40, e211-3		15
806	Radioimmunotherapy in mantle cell lymphoma. 2012 , 25, 201-10		12
805	Polyclonal rabbit antithymocyte globulin induces apoptosis and has cytotoxic effects on human leukemic cells. 2012 , 12, 345-54		12
804	Management of patients with relapsed/refractory follicular lymphoma. 2012 , 9, S61-S67		1
803	Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. 2012 , 27, 107-13		31
802	Trial Watch: Monoclonal antibodies in cancer therapy. 2012 , 1, 28-37		80
801	Rituximab, an Anti-CD20 Monoclonal Antibody. 2012 , 362-377		1
800	Evidence for therapeutic drug monitoring of targeted anticancer therapies. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4017-25	2.2	144
799	Rituximab treatment for Sjogren syndrome-associated non-Hodgkin's lymphoma: case series. 2012 , 32, 3281-4		4
798	Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells. 2012 , 97, 288-96		9
797	Successful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell Transplantation. 2012 , 5, 110-3		7
796	Clinical immunology A prolonged progressive lymphopenia with hypogammaglobulinemia after FCR treatment of chronic lymphocytic leukemia: and literature review. 2012 , 3, 264-269		1
795	Targeted Therapy with Rituximab in Felty's Syndrome: A Case Report. 2012 , 6, 312-4		4

794	B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. 2012 , 119, 2709-20		1110
793	Anti-CD20 antibody therapy for B-cell lymphomas. 2012 , 366, 2008-16		228
792	TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. 2012 , 120, 1613-23	27	
791	High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcR11a polymorphism. 2012 , 24, 477-83		25
790	Notf1le in der gynkologischen Onkologie. 2012 , 45, 199-204		
789	The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. 2012 , 29, 1237-41		36
788	Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. 2012 , 91, 1007-12		68
787	A fully human CD19/CD3 bi-specific antibody triggers potent and specific cytotoxicity by unstimulated T lymphocytes against non-Hodgkin's lymphoma. 2012 , 34, 1183-91		3
786	Better response with conjugate vaccine than with polysaccharide vaccine 12 months after rituximab treatment in lymphoma patients. <i>British Journal of Haematology</i> , 2012 , 156, 407-9	4.5	5
785	Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. <i>British Journal of Haematology</i> , 2012 , 156, 490-8	4.5	56
784	Guidelines on the investigation and management of follicular lymphoma. <i>British Journal of Haematology</i> , 2012 , 156, 446-67	4.5	49
783	The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma. 2012 , 84, 451-8		5
782	Rituximab-induced thrombocytopenia: a cohort study. 2012 , 89, 256-66		23
781	Coiled-coil based drug-free macromolecular therapeutics: in vivo efficacy. <i>Journal of Controlled Release</i> , 2012 , 157, 126-31	11.7	63
780	Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. 2012 , 103, 933-8		56
779	Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma. 2012 , 73, 597-605		19
778	Immunotherapeutic strategies for cancer treatment: a novel protein transfer approach for cancer vaccine development. 2012 , 32, 1197-219		14
777	Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. 2012 , 61, 49-61		26

776	Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma. 2012 , 91, 291-4	6
775	Lymphopenia following the completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma. 2012 , 91, 375-82	19
774	Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. 2012 , 91, 543-51	39
773	The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells. 2013 , 27, 190-201	42
772	Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients. 2013 , 119, 99-106	34
771	Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II trial. 2013 , 11, 160	30
770	Resistance to Immunotherapeutic Antibodies in Cancer. 2013 ,	1
769	Chronic lymphocytic leukemia: inception to cure: are we there?. 2013 , 29, 1-10	4
768	Anti-CD20 monoclonal antibodies: beyond B-cells. 2013 , 27, 217-23	38
767	The optimal management of follicular lymphoma: an evolving field. 2013 , 73, 1395-403	5
766	Acquired C1-inhibitor deficiency and lymphoproliferative disorders: a tight relationship. 2013 , 87, 323-32	43
765	Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. 2013 , 42, 1317-30	49
764	Ibrutinib and novel BTK inhibitors in clinical development. 2013 , 6, 59	166
763	Influenza vaccination in oncology patients. 2013 , 15, 486-90	9
762	Real time analysis of binding between Rituximab (anti-CD20 antibody) and B lymphoma cells. 2013 , 85, 8543-51	19
761	Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials. 2013 , 13, 803-11	43
760	Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1928-33	1.9 7
759	Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia. 2013 , 140, 813-8	15

758	Reversal of cardiomyopathy with tocilizumab in a case of HIV-negative Castleman's disease. 2013 , 91, 273-6		8
757	Rituximab maintenance versus retreatment in follicular lymphoma. 2013 , 31, 171-8		3
756	Phase I study of a modified regimen of ¹²⁵ I-tinidazole-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma. 2013 , 28, 370-9		2
755	Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. 2013 , 5, 826-37		83
754	B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. 2013 , 15 Suppl 1, S2		94
753	Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia. 2013 , 9, 1829-39		15
752	GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2500-5	1.9	48
751	Treatment approaches to asymptomatic follicular lymphoma. 2013 , 6, 747-58		
750	Polymer-drug conjugates: origins, progress to date and future directions. 2013 , 65, 49-59		287
749	Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. 2013 , 13, 106-11		182
748	RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia. 2013 , 73, 683-94		46
747	Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature. 2013 , 68, 499-506		36
746	Targeted therapy in chronic lymphocytic leukemia: past, present, and future. 2013 , 35, 1258-70		31
745	Treatment of Chronic Lymphocytic Leukemia and Related Disorders. 2013 , 103-119		
744	Immunology of the Lymphomas. 2013 , 919-943		
743	Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapy. 2013 , 27, 303-27		9
742	Drug-conjugated antibodies for the treatment of cancer. 2013 , 76, 248-62		116
741	Rituximab biosimilars. 2013 , 13, 1049-62		30

740	Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis. 2013 , 14, 144-55	2
739	Novel antibodies targeting immune regulatory checkpoints for cancer therapy. 2013 , 76, 233-47	31
738	The first antibody therapy for cancer: a personal experience. 2013 , 13, 399-406	1
737	Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance. 2013 , 238, 971-90	38
736	Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. 2013 , 121, 1604-11	218
735	Selection of rituximab dosage in chronic lymphocytic leukemia: where is the evidence?. <i>Leukemia and Lymphoma</i> , 2013 , 54, 934-9	1.9 5
734	Which therapies for which patients?. 2013 , 124-136	
733	Rituximab for the treatment of follicular lymphoma. 2013 , 9, 1283-98	3
732	[Rapid-progressive decrease of cognitive and physical functions in a B-cell non-Hodgkin's lymphoma patient treated with rituximab/bendamustine]. 2013 , 138, 1355-9	1
731	Generation and preclinical characterization of a Fc-optimized GTR-Ig fusion protein for induction of NK cell reactivity against leukemia. 2013 , 21, 877-86	13
730	Construction and characterization of a camelized, human, VH-based peptide vaccine against CD20 antigen. 2013 , 5, 135-41	
729	Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia. 2013 , 98, 1259-63	8
728	A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. 2013 , 98, 964-70	10
727	Cerebral toxoplasmosis after rituximab therapy. 2013 , 173, 924-6	25
726	[Indolent lymphomas: classification, clinical presentation and treatment]]. 2013 , 102, 399-406	
725	Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan. 2013 , 2013, 863909	
724	Helicobacter pylori infection, chronic inflammation, and genomic transformations in gastric MALT lymphoma. 2013 , 2013, 523170	22
723	Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses. 2013 , 2, e26333	116

722	A systematic review of biologics for the treatment of noninfectious uveitis. 2013 , 5, 91-102		16
721	Developments and Challenges for mAb-Based Therapeutics. 2013 , 2, 452-500		95
720	Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma. 2013 , 32, 645-54		2
719	Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. 2013 , 190, 6681-93		61
718	Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer. 2013 , 65, 1351-95		26
717	Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. 2013 , 76, 734-40		46
716	Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. <i>Journal of Clinical Oncology</i> , 2013 , 31, 573-83	2.2	124
715	Trial watch: Monoclonal antibodies in cancer therapy. 2013 , 2, e22789		76
714	Pixantrone: merging safety with efficacy. 2013 , 6, 25-33		3
713	The role of monoclonal antibodies in the treatment of lymphomas. 2013 , 13, 227-39		2
712	Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering. 2013 , 4, 305-12		15
711	Non-Hodgkin Lymphomas: Advanced Diagnostics & Personalized Therapies. 2013 ,		2
710	Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy. 2013 , 37, 563-70		17
709	Hydroxyurea potentiates the caspase-independent killing of B-cell lines by rituximab and GA101. 2012 , 20, 545-55		3
708	Hepatitis B virus reactivation with rituximab-containing regimen. 2013 , 5, 612-20		22
707	Human polyomavirus reactivation: disease pathogenesis and treatment approaches. 2013 , 2013, 373579		51
706	The Effect of Rituximab, Cyclophosphamide, Vincristine, and Prednisolone (R-CVP) Chemotherapy in Patients with Ocular Adnexal Extranodal Marginal Zone B Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. 2013 , 54, 1157		2
705	Rituximab for treatment of inhibitors in haemophilia A. A Phase II study. 2014 , 112, 445-58		34

704	Radiolabeling strategies for tumor-targeting proteinaceous drugs. 2014 , 19, 2135-65		36
703	Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies. 2014 , 2014, 492061		33
702	Current Pathways for Immune Manipulation. 2014 , 219-238		
701	Trial Watch: Radioimmunotherapy for oncological indications. 2014 , 3, e954929		36
700	Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. 2014 , 3, e27048		64
699	Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. 2014 , 3, e27297		86
698	Sustained CD4 T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide. 2014 , 3, e27357		49
697	A first-in-human study of the anti- $\alpha_5\beta_1$ integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. 2014 , 74, 1039-46		27
696	No Mechanism is an Island. 2014 , 257-267		
695	Gene therapy for cancer: present status and future perspective. 2014 , 2, 27		135
694	New antibody approaches to lymphoma therapy. 2014 , 7, 58		44
693	Rituximab: modes of action, remaining dispute and future perspective. 2014 , 10, 2481-92		31
692	Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. 2014 , 107, 821-8		85
691	End of rituximab maintenance for low-tumor burden follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3093-5	2.2	8
690	Historical Roots of Flow Cytometry. 2014 , 3629-3641		
689	Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy. <i>Leukemia and Lymphoma</i> , 2014 , 55, 288-95	1.9	10
688	Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. 2014 , 6, 1300-13		13
687	Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface. 2014 , 26, 451-65		11

686	Rituximab for non-Hodgkin's lymphoma: a story of rapid success in translation. 2014 , 7, 82-6		24
685	Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3096-102	2.2	131
684	Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3 β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies. 2014 , 3, 31		1
683	Thirty-minutes infusion rate is safe enough for bevacizumab; no need for initial prolong infusion. 2014 , 31, 276		1
682	Outcomes after involved-field radiation therapy (IFRT) with or without rituximab in patients with early-stage low-grade non-Hodgkin lymphoma (NHL) staged with CT and PET. 2014 , 37, 35-40		1
681	Lentivector Vaccines. 2014 , 345-361		
680	Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse. 2014 , 6, 1026-37		25
679	Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ^{67}Cu and ^{111}In for domestic radioimmunotherapy and radioscinigraphy of non-Hodgkin's lymphoma. 2014 , 22, 58		10
678	Theranostic applications of antibodies in oncology. 2014 , 8, 799-812		46
677	[Therapy with intravenous gammaglobulins in systemic inflammatory autoimmune diseases: new indications?]. 2014 , 143, 130-3		1
676	Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin. 2014 , 32, 75-86		16
675	Secondary antibody deficiency. 2014 , 10, 583-91		29
674	Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. 2014 , 12, 21		12
673	Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era. 2014 , 123, 3553-62		58
672	Sinonasal lymphoma: case series and review of the literature. 2014 , 4, 670-4		34
671	From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies. 2014 , 41, 661-6		22
670	Influence of ex vivo purging with CliniMACS CD34(+) selection on outcome after autologous stem cell transplantation in non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014 , 164, 555-64	4.5	6
669	Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. 2014 , 83, 142-50		218

668 Rituximab (Rituxan®). **2014**, 1909-2022

667 Obinutuzumab for B-cell malignancies. **2014**, 14, 1197-205

5

666 Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance. **2014**, 41, 667-77

29

665 Selection Strategies for Monoclonal Antibodies. **2014**, 15-42

1

664 Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies. **2014**, 86, 485-91

36

663 Translational medicine in action: anti-CD20 therapy in lymphoma. **2014**, 193, 1519-24

41

662 CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. **2014**, 2, 878-89

42

661 Anti-EGFR antibody conjugated organic-inorganic hybrid lipid nanovesicles selectively target tumor cells. **2014**, 121, 141-9

11

660 A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics. **2014**, 154, 37-46

22

659 A drug safety evaluation of rituximab and risk of hepatitis B. **2014**, 13, 977-87

11

658 Are we nearing an era of chemotherapy-free management of indolent lymphoma?. **2014**, 20, 5226-39

14

657 Rituximab and immune deficiency: case series and review of the literature. **2014**, 2, 594-600

63

656 The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience. **2014**, 14, 364

7

655 Interferon alpha with or without rituximab achieves a high response rate and durable responses in relapsed FL: 17 years' experience in a single centre. **2014**, 93, 147-156

4

654 Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. **2014**, 25, 850-63

147

653 Therapeutic vaccines for cancer: an overview of clinical trials. **2014**, 11, 509-24

522

652 Complement in monoclonal antibody therapy of cancer. **2014**, 59, 203-10

71

651 The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. **2014**, 15, 178

86

650	Ofatumumab (Arzerra [®]): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity. 2014 , 1733-1774		
649	Optimized selection of anti-tumor recombinant antibodies from phage libraries on intact cells. 2014 , 57, 317-22		12
648	Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy. 2014 , 14, 1019-31		22
647	Desensitization Protocols for Organ Transplantation. 2014 , 763-772		
646	Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- β as therapy for previously treated indolent non-Hodgkin lymphoma. 2014 , 123, 3406-13		173
645	Variability in clinical and biological response to rituximab in autoimmune diseases: an opportunity for personalized therapy?. 2014 , 9, 279-293		6
644	Non-Hodgkin's lymphomas. 2014 , 516-544		
643	Toxicity of targeted therapeutic agents in lymphoma and management: part 1: monoclonal antibodies and radioimmunotherapy. 2014 , 3, 41-51		
642	Longitudinal risk of herpes zoster in patients with non-Hodgkin lymphoma receiving chemotherapy: A nationwide population-based study. <i>Scientific Reports</i> , 2015 , 5, 14008	4.9	14
641	Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b. 2015 , 125, 949-58		13
640	Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. 2015 , 125, 82-9		37
639	The role of rituximab in adults with warm antibody autoimmune hemolytic anemia. 2015 , 125, 3223-9		49
638	Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. 2015 , 100, e454-7		7
637	Diagnostic and therapeutic challenges of EBV-positive mucocutaneous ulcer: a case report and systematic review of the literature. 2015 , 5, 13		60
636	Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. 2015 , 121, 3869-76		10
635	The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2015 , 169, 701-10	4.5	23
634	Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and	4.5	68
633	Rituximab for indolent lymphomas before and after allogeneic hematopoietic stem cell transplantation. 2015 , 22, 469-75		

632	The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma. 2015 , 21, 351-6		2
631	Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma. 2015 , 7, 319-30		3
630	Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. 2015 , 6, 202		102
629	Lymphoma Immunotherapy: Current Status. 2015 , 6, 448		32
628	Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response. 2015 , 7, 347-358		17
627	Harnessing the Microbiome to Enhance Cancer Immunotherapy. 2015 , 2015, 368736		41
626	Adverse events of monoclonal antibodies used for cancer therapy. 2015 , 2015, 428169		45
625	Monoclonal Antibodies for the Treatment of Cancer. 2015 , 683-694.e3		
624	Novel Pharmacodynamic Approach to Assess Obatoclox (GX15-070) and Bortezomib (BTZ) Synergism in Non-Hodgkinâs Lymphoma. 2015 , 2, 44-53		
623	Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas. 2015 , 41, 680-9		34
622	Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2357-64	1.9	10
621	Recruitment of Oligoclonal Viral-Specific T cells to Kill Human Tumor Cells Using Single-Chain Antibody-Peptide-HLA Fusion Molecules. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 1327-35	6.1	
620	Co-culture system of human salivary gland epithelial cells and immune cells from primary Sjoren's syndrome patients: an in vitro approach to study the effects of Rituximab on the activation of the Raf-1/ERK1/2 pathway. 2015 , 27, 183-94		8
619	Refractory Sweet's syndrome successfully treated with rituximab. 2015 , 1, 123-5		8
618	Ofatumumab for treating chronic lymphocytic leukemia: a safety profile. 2015 , 14, 1945-59		11
617	Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. 2015 , 20, 129-36		4
616	Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. 2015 , 57, 60-5		170
615	Kinetics of B, T, NK lymphocytes and isoagglutinin titers in ABO incompatible living donor liver transplantation using rituximab and basiliximab. 2015 , 32, 29-34		18

614	Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1659-64	1.9	15
613	Chemotherapy-free treatment in patients with follicular lymphoma. 2015 , 8, 187-203		7
612	Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. 2015 , 67, 46-57		81
611	Monoclonal Antibodies for Cancer Immunotherapy. 2015 , 293-328		2
610	Radiation Dosimetry Study of [(89)Zr]rituximab Tracer for Clinical Translation of B cell NHL Imaging using Positron Emission Tomography. <i>Molecular Imaging and Biology</i> , 2015 , 17, 539-47	3.8	22
609	Tumour inflammatory response: adding fuel to the fire?. 2015 , 22, 7-9		1
608	Immunoreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?. 2015 , 7, 305-28		30
607	Molecular Therapies of Cancer. 2015 ,		8
606	Biobetter Biologics. 2015 , 199-217		4
605	Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma. 2015 , 135-183		
604	The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma. 2015 , 10, 791-808		7
603	Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study. 2015 , 29, 668-76		69
602	Follicular lymphoma patients with a high FLIPI score and a high tumor burden: a risk stratification model. 2015 , 72, 26-32		3
601	Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab. 2015 , 42, 1304-14		58
600	Behandlung folliculärer Lymphome. 2015 , 18, 30-40		
599	Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 42-8	1.9	23
598	Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. <i>British Journal of Haematology</i> , 2015 , 170, 669-78	4.5	69
597	Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma. 2015 , 24, 897-912		10

596	The challenging definition of naïve patient for biological drug use. 2015 , 14, 543-6		6
595	Two courses of four weekly infusions of rituximab with or without interferon- α : final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2598-607	1.9	21
594	Fully human HER2/cluster of differentiation 3 bispecific antibody triggers potent and specific cytotoxicity of T lymphocytes against breast cancer. 2015 , 12, 147-54		7
593	The expanding role of therapeutic antibodies. 2015 , 34, 202-64		15
592	A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas. 2015 , 11, 1327-42		47
591	Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation. 2015 , 12, 1703-16		34
590	Cancer immunotherapy: Strategies for personalization and combinatorial approaches. 2015 , 9, 2043-53		68
589	A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. 2015 , 100, 357-62		49
588	Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma. 2015 , 21, 4391-7		23
587	The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1050-7	1.9	8
586	Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma. 2015 , 17, 41		15
585	The evolution within us. 2015 , 370,		23
584	Lectin-like transcript 1 is a marker of germinal center-derived B-cell non-Hodgkin's lymphomas dampening natural killer cell functions. 2015 , 4, e1026503		25
583	What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?. 2015 , 8, 733-42		8
582	Human lymphocytic B-leukemia cell line treatment with the bacterial toxin listeriolysin O and rituximab (anti-CD20 antibody): Effects of similar localization of their receptors. 2015 , 28, 329-40		1
581	Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). <i>Journal of Clinical Oncology</i> , 2015 , 33, 3635-40	2.2	139
580	Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3467-74	2.2	129
579	Immunotherapy. 2015 , 333-351		

578	Development and Characterization of a New Antipeptide Monoclonal Antibody Directed to Human CD20 Antigen. 2015 , 30, 310-6		3
577	The Role of Biologic Therapies in Dermatology. 2015 , 99, 1183-94		15
576	Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study. 2015 , 39, 1382-8		24
575	Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database Review. 2015 , 15, 578-85		20
574	Novel immunotherapies for hematologic malignancies. 2015 , 263, 90-105		37
573	Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia. 2015 , 94, 99-108		25
572	A Canadian evidence-based guideline for the first-line treatment of follicular lymphoma: joint consensus of the Lymphoma Canada Scientific Advisory Board. 2015 , 15, 59-74		12
571	Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1611-8	1.9	9
570	The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma. 2015 , 10, 15-26		12
569	Pharmaceutical Biotechnology. 2016 ,		5
568	Monoclonal Antibodies as Therapeutic Agents. 2016 , 157-196		1
567	Translational Medicine Case Studies and Reports. 2016 , 135-156		
566	Limited Stage Follicular Lymphoma: Current Role of Radiation Therapy. 2016 , 8, e2016041		11
565	Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate. 2016 , 22, 632-642		19
564	Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance. 2016 , 56, 89-99		26
563	Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma. 2016 , 28, 197-208		4
562	A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. <i>British Journal of Haematology</i> , 2016 , 174, 571-81	4.5	33
561	A visualization method measuring the performance of biomarkers for guiding treatment decisions. 2016 , 15, 152-64		4

560	Chemotherapy-sparing treatment strategies for follicular lymphoma: current options and future directions. 2016 , 23, 371-6		
559	Inflammation Causes Resistance to Anti-CD20-Mediated B Cell Depletion. 2016 , 16, 3139-3149		11
558	Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. <i>British Journal of Haematology</i> , 2016 , 173, 867-75	4.5	23
557	Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies. 2016 , 9, 1557-1569		13
556	Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update. 2016 , 8, 1335-1346		6
555	Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study. 2016 , 13, 824-832		130
554	Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. 2016 , 101, e196-9		13
553	Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1269-80	1.9	4
552	Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2016 , 57, 803-11	1.9	12
551	Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1021-32	1.9	61
550	Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises. 2016 , 8, 569-81		12
549	Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. 2016 , 127, 79-86		59
548	Antibody-Drug Conjugates. 2016 , 149-176		2
547	Bacterial production and structure-functional validation of a recombinant antigen-binding fragment (Fab) of an anti-cancer therapeutic antibody targeting epidermal growth factor receptor. 2016 , 100, 10521-10529		3
546	Radioimmunotherapy and Hematopoietic Cell Transplantation. 2016 , 258-275		
545	Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. 2016 , 173, 1407-24		42
544	New monoclonal antibodies for the treatment of acute lymphoblastic leukemia. 2016 , 49, 13-21		24
543	Anti-CD20 antibody treatment of non-Hodgkin lymphomas. 2016 , 172, 101-104		16

542	Challenges and opportunities for monoclonal antibody therapy in veterinary oncology. 2016 , 218, 40-50	7
541	The safety profile of monoclonal antibodies for chronic lymphocytic leukemia. 2017 , 16, 185-201	3
540	Management of Bleeding Patients. 2016 ,	2
539	Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). 2016 , 122, 2996-3004	27
538	Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment. 2016 , 37, 993-1008	97
537	Influence of R-CHOP Therapy on Immune System Restoration in Patients with B-Cell Lymphoma. 2016 , 91, 302-310	9
536	Adult Acute Lymphoblastic Leukemia. 2016 , 91, 1645-1666	97
535	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation. 2016 , 291, 16659-71	23
534	Immunopharmacology. 2016 ,	3
533	Unintended Immunological Consequences of Biologic Therapy. 2016 , 16, 46	12
532	Inhibition of complement dependent cytotoxicity by anti-CD20 aptamers. 2016 , 6, 12435-12438	3
531	Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia. 2016 , 5, e1132977	10
530	Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma. 2016 , 101, 226-34	26
529	Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1238-47	6.1 9
528	Nodal Follicular Lymphomas: A Clinicopathological Study from a Tertiary Care Centre in South India. 2016 , 32, 182-5	
527	Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. 2016 , 16, 655-74	15
526	Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting. 2016 , 11, 61-70	5
525	Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. 2016 , 94, 783-91	30

524	Use of targeted therapy in cancer patients in the end-of-life period: results from an Australian centre. 2016 , 24, 3023-8	1
523	Chip-based platform for dynamic analysis of NK cell cytotoxicity mediated by a triplebody. 2016 , 141, 2284-95	7
522	SERS detection and targeted ablation of lymphoma cells using functionalized Ag nanoparticles. 2016 ,	2
521	Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. 2016 , 22, 821-6	21
520	Molecular targets on B-cells to prevent and treat antibody-mediated rejection in organ transplantation. Present and Future. 2016 , 20, 859-67	9
519	A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia. 2016 , 9, 235-44	6
518	A review of monoclonal antibody therapies in lymphoma. 2016 , 97, 72-84	33
517	Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions. 2016 , 99, 87-96	48
516	Visceral disseminated varicella zoster virus infection after rituximab treatment for granulomatosis with polyangiitis. 2017 , 27, 155-161	17
515	Hospitalization for Toxicity in Patients Treated With Rituximab. 2017 , 40, 125-132	
514	Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus. 2017 , 56, 107-125	5
513	Use of polyclonal/monoclonal antibody therapies in transplantation. 2017 , 17, 339-352	5
512	A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. 2017 , 34, 324-356	79
511	TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1. 2017 , 129, 1284-1295	29
510	Intralesional anti-CD20 antibody for low-grade primary cutaneous B-cell lymphoma: Adverse reactions correlate with favorable clinical outcome. 2017 , 15, 319-323	3
509	Long-Term Response and Possible Cure of Patients With B-Cell Malignancies With Dose-Escalated Rituximab. 2017 , 5, 2324709617691307	
508	Intralesionale Therapie niedrig maligner primär kutaner B-Zell-Lymphome mit Anti-CD20-Antikörper: Nebenwirkungen korrelieren mit gutem klinischen Ansprechen. 2017 , 15, 319-324	0
507	Evaluation of changes in promoters, use of UCOES and chain order to improve the antibody production in CHO cells. 2017 , 132, 108-115	9

506	Rituximab treatment of myasthenia gravis: A systematic review. 2017 , 56, 185-196		134
505	Precision medicine needs randomized clinical trials. 2017 , 14, 317-323		45
504	Biologic response modifiers: Indications, implications, and insights. <i>Journal of Allergy and Clinical Immunology</i> , 2017 , 139, 1445-1456	11.5	18
503	Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. 2017 , 129, 2616-2623		57
502	Molecular Diagnostics in Cancer. 2017 , 1-14		2
501	Monoclonal Serotherapy. 2017 , 1-23		3
500	Childhood Acute Lymphoblastic Leukemia. 2017 ,		
499	Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Clinical Pharmacology and Therapeutic Results. 2017 , 99-122		
498	CAR T-cell therapy: Balance of efficacy and safety. 2017 , 51, 237-250		4
497	Basic Concepts of Clinical Radiation Oncology. 2017 , 1-14		0
496	Small-Molecule Inhibitors of Bruton's Tyrosine Kinase. 2017 , 75-104		1
495	Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. 2017 , 4, e272-e282		74
494	A novel modified vaccination technique produces IgG antibodies that cause complement-mediated lysis of multiple myeloma cells carrying CD38 antigen. 2016 , 24, 45-51		4
493	Drug discovery and therapeutic delivery for the treatment of B and T cell tumors. 2017 , 114, 285-300		14
492	Phase II study of intensified rituximab induction and maintenance for low grade B cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2845-2851	1.9	
491	Chemotherapy free treatment of indolent lymphoma. 2017 , 35 Suppl 1, 20-24		1
490	Humanization of chimeric anti-CD20 antibody by logical and bioinformatics approach with retention of biological activity. 2017 , 9, 567-577		3
489	Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL. 2017 , 31, 2416-2425		18

488	Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016). 2017 , 13, 1-10		15
487	New targeted therapies for malignant lymphoma based on molecular heterogeneity. 2017 , 10, 39-51		12
486	Construction and characterization of monoclonal antibodies against the extracellular domain of B-lymphocyte antigen CD20 using DNA immunization method. 2017 , 43, 23-32		1
485	Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy. 2017 , 66, 367-378		11
484	Rituximab in the treatment of pemphigus. 2017 , 5, 99-109		1
483	Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. 2017 , 34, 2232-2273		227
482	TNFR2: A Novel Target for Cancer Immunotherapy. 2017 , 23, 1037-1046		63
481	Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 2828-2839	6.1	41
480	HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. 2017 , 130, 1628-1638		25
479	Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. 2017 , 17, 1463-1470		5
478	Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies. 2017 , 17, 834-851		32
477	Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab. 2017 , 36, 352-359		54
476	Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma. 2017 , 15, 1429-1437		10
475	Featured Article: Delivery of chemotherapeutic vcMMAE using tobacco mosaic virus nanoparticles. 2017 , 242, 1405-1411		17
474	Obinutuzumab: what is there to learn from clinical trials?. 2017 , 130, 581-589		61
473	Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia. 2017 , 10, 783-799		4
472	Treatment of membranous nephropathy: time for a paradigm shift. 2017 , 13, 563-579		70
471	Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma. 2017 , 101, 81-88		25

470	A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up. 2017 , 137, 7-14		4
469	Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis. 2017 , 13, 667-676		9
468	Targeting Oncoproteins for Molecular Cancer Therapy. 2017 , 727-756		
467	Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline. 2017 , 29, e13-e28		9
466	Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review. 2017 , 5, 107-113.e1		36
465	Sortase A-Generated Highly Potent Anti-CD20-MMAE Conjugates for Efficient Elimination of B-Lineage Lymphomas. 2017 , 13, 1602267		25
464	Rituximab Hypersensitivity: Evaluation, Desensitization, and Potential Mechanisms. 2017 , 5, 1564-1571		26
463	Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study. <i>Frontiers in Pharmacology</i> , 2017 , 8, 607	5.6	22
462	Recent Advances in the Delivery of Chemotherapeutic Agents. 2017 , 281-298		4
461	Unique therapeutic properties and preparation methodology of multivalent rituximab-lipid nanoparticles. 2017 , 117, 256-269		3
460	Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine. 2017 , 2017, 9620870		32
459	Rituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies. 2017 , 56, 143-156		1
458	RITUXIMAB DELAYS WOUND HEALING AND DECREASES WHITE BLOOD CELL COUNT IN MALE MICE. 2017 , 10, 112		0
457	Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape. 2017 , 9, 131-140		14
456	Cell-Targeted Biologics and Emerging Targets. 2017 , 1020-1043.e4		
455	The role of novel immunotherapies in non-Hodgkin lymphoma. 2017 , 6, 93-103		22
454	How Biophysical Forces Regulate Human B Cell Lymphomas. 2018 , 23, 499-511		19
453	Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome. 2018 , 33, 1013-1018		15

452	A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies. 2018 , 11, 296-304		14
451	Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy. 2018 , 67, 329-339		5
450	Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells. 2018 , 39, 261-274		23
449	Bispecific Antibody Armed T Cells to Target Cancer Cells. 2018 , 1722, 117-126		3
448	Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing. <i>Scientific Reports</i> , 2018 , 8, 124	4-9	21
447	Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas. 2018 , 29, 332-340		12
446	Rituximab in the management of acute lymphoblastic leukemia. 2018 , 18, 221-226		12
445	A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice. 2018 , 67, 605-613		2
444	Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). 2018 , 29, 1354-1365		39
443	Pulmonary MALT lymphoma with underlying interstitial lung disease: A case report and review of the literature. 2018 , 4, 56-59		2
442	Immunology of the Lymphomas. 2018 , 827-852		
441	Treating relapsed follicular lymphoma. 2018 , 11, 403-410		2
440	Antibody therapy targeting CD19 for B-cell non-Hodgkin's lymphoma. 2018 , 29, 1086-1089		10
439	Treatment of Chronic Lymphocytic Leukemia and Related Disorders. 2018 , 117-134		
438	Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study). 2018 , 24, 199-205		2
437	Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1420-1426	1-9	8
436	Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1163-1171	1-9	3
435	Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders. 2018 , 17, 115-124		35

434	Expression of single-domain antibody in different systems. 2018 , 102, 539-551	45
433	Aptamers as potential therapeutic agents for ovarian cancer. 2018 , 145, 34-44	12
432	Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence. 2018 , 18, 309-315	24
431	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. 2018 , 63, 48-60	89
430	Infusion Related Hypersensitivity Reactions with Bio-similar Anti CD-20 Monoclonal Antibody Rituximab in Indian Patients: A Retrospective Study. 2018 , 34, 273-277	2
429	Novel agents for relapsed and refractory follicular lymphoma. 2018 , 31, 41-48	16
428	A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma. 2018 , 18, e51-e60	5
427	Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). 2018 , 9, 766-773	8
426	1 Essentials of Medical Oncology. 2018 ,	
425	Tocilizumab treatment for new onset refractory status epilepticus. 2018 , 84, 940-945	75
424	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. 2018 , 5, e543-e553	38
423	HCV Infection on Lymphoid Neoplasm. 2018 , 06,	
422	Approaches for generation of anti-leukemia specific T cells. 2018 , 7, 40-44	2
421	Cancers of the eye. 2018 , 37, 677-690	29
420	Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL. 2018 , 27, 1470-1478	16
419	An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. 2018 , 18, 508-518.e14	10
418	Biosimilars Have Arrived: Rituximab. 2018 , 2018, 3762864	21
417	Hypersensitivity Reactions: Priming Practice Change to Reduce Incidence in First-Dose Rituximab Treatment. 2018 , 22, 407-414	2

416	Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. 2018 , 10, 1259-1273		66
415	Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	17
414	Clinical Manifestations, Staging, and Treatment of Follicular Lymphoma. 2018 , 1288-1297.e3		
413	Cancer Immunotherapy and the Immune Response in Follicular Lymphoma. <i>Frontiers in Oncology</i> , 2018 , 8, 219	5.3	10
412	Overcoming Resistance of Human Non-Hodgkin's Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors. 2018 , 10,		22
411	Selection and Characterization of Single-Stranded DNA Aptamers Binding Human B-Cell Surface Protein CD20 by Cell-SELEX. 2018 , 23,		23
410	Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real-world analysis from Taiwan Cancer Registry Database. 2018 , 7, 3582-3591		7
409	Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy. <i>Frontiers in Oncology</i> , 2018 , 8, 163	5.3	118
408	Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation. 2018 , 19, 12		3
407	Rituximab-induced Acute Thrombocytopenia in a Patient with Follicular Lymphoma: A Case Report and Review of the Literature. 2018 , 57, 1151-1154		10
406	A tale of two antibodies: obinutuzumab versus rituximab. <i>British Journal of Haematology</i> , 2018 , 182, 29-45		67
405	Complement system's role in cancer and its therapeutic potential in ovarian cancer. 2018 , 88, e12672		12
404	Rituximab as a Therapeutic Option for Steroid-Sensitive Minimal Change Nephrotic Syndrome in Adults. 2018 , 195, 12-19		2
403	Rituximab-induced Acute Thrombocytopenia in Granulomatosis with Polyangiitis. 2018 , 57, 2247-2250		3
402	Anti-CD20 monoclonal antibodies: reviewing a revolution. 2018 , 14, 2820-2841		35
401	Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial. 2018 , 38, 31		4
400	Renewed interest for low-dose radiation therapy in follicular lymphomas: From biology to clinical applications. 2018 , 36, 723-732		3
399	Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies. 2018 , 32, 5063-5077		6

398	The Fab portion of immunoglobulin G contributes to its binding to Fcγreceptor III. <i>Scientific Reports</i> , 2019 , 9, 11957	4.9	23
397	Low-Dose Subcutaneous Anti-CD20 Treatment Depletes Disease Relevant B Cell Subsets and Attenuates Neuroinflammation. 2019 , 14, 709-719		3
396	Targeting Biology in Non-Hodgkin Lymphoma. 2019 , 33, 727-738		1
395	Erythema Migrans: Course and Outcome in Patients Treated With Rituximab. 2019 , 6, ofz292		8
394	Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. <i>Frontiers in Oncology</i> , 2019 , 9, 849	5.3	67
393	Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies. 2019 , 14, 426-438		8
392	Host-Immune Interactions in JC Virus Reactivation and Development of Progressive Multifocal Leukoencephalopathy (PML). 2019 , 14, 649-660		1
391	Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma. 2019 , 10, 2085		6
390	Screening of key genes associated with R-CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B-cell lymphoma. 2019 , 20, 3679-3690		0
389	Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats. 2019 , 8,		26
388	Resistance to Targeted Therapies in Lymphomas. 2019 ,		
387	Commentary: Potential Therapeutic Consequences of an Acid-Sensing Ion Channel 1a-Blocking Antibody. <i>Frontiers in Pharmacology</i> , 2019 , 10, 954	5.6	2
386	Rekombinante Antikörper. 2019 ,		0
385	Current approaches and future perspectives for advanced-stage follicular lymphoma with a low tumor burden. 2019 , 49, 306-310		1
384	Novel Treatments for Lymphoma. 2019 , 49, 903-915		10
383	The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis. 2019 , 30, 690-697		19
382	The Epitope-Specific Anti-human CD4 Antibody MAX.16H5 and Its Role in Immune Tolerance. 2019 , 10, 1035		4
381	Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation. 2019 , 22, 1145-1151		11

380	Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity. 2019 , 10, 999		28
379	Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents. 2019 , 9, 944-961		20
378	Monoclonal Antibodies: From Structure to Therapeutic Application. 2019 , 151-190		
377	CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date. 2019 , 19, 829-843		22
376	How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin's lymphomas. 2019 , 10, 71-84		18
375	Development of β Gal α Antibody Conjugates to Increase Immune Response by Recruiting Natural Antibodies. 2019 , 131, 4574-4578		2
374	A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress. 2019 , 28, 900-909		16
373	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1188-1199	2.2	165
372	Monoclonal Antibodies in Cancer. 2019 , 489-519		
371	Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma. 2019 , 38, 79-91		2
370	Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). <i>British Journal of Haematology</i> , 2019 , 185, 53-64	4.5	6
369	Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobe on malignant lymphoma cells with CD20 overexpression. 2019 , 14, 921-936		18
368	Development of β Gal-Antibody Conjugates to Increase Immune Response by Recruiting Natural Antibodies. 2019 , 58, 4526-4530		11
367	Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer. 2019 , 24, 1013-1021		10
366	Infusion-related reactions to rituximab: frequency, mechanisms and predictors. 2019 , 15, 383-389		25
365	Position of Scientific Oncological Societies Towards Biosimilar Antibodies. 2019 , 14, 5-8		3
364	Chronic Lymphocytic Leukemia. 2019 ,		
363	Immunological Methods to Study Monoclonal Antibody Activity in Chronic Lymphocytic Leukaemia. 2019 , 1881, 173-184		1

362	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway. 2019 , 62, 1715-1730		61
361	In Silico Analysis for Determination and Validation of Human CD20 Antigen 3D Structure. 2019 , 25, 123-135		1
360	Therapeutic Antibodies and Immunologic Conjugates. 2020 , 486-499.e8		1
359	Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma. 2020 , 59, 7-23		
358	Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: An international multicenter randomized trial. 2020 , 38, 67-73		3
357	Non-Hodgkin Lymphomas. 2020 , 1926-1947.e5		
356	Rituximab conjugated iron oxide nanoparticles for targeted imaging and enhanced treatment against CD20-positive lymphoma. 2020 , 8, 895-907		9
355	Chronic Lymphocytic Leukemia. 2020 , 1850-1871.e5		1
354	Antibody and antibody fragments for cancer immunotherapy. <i>Journal of Controlled Release</i> , 2020 , 328, 395-406	11.7	17
353	Analytical and functional similarity of biosimilar ABP 798 with rituximab reference product. 2020 , 68, 79-91		8
352	The Use of 20% Subcutaneous Immunoglobulin Replacement Therapy in Patients With B Cell Non-Hodgkin Lymphoma With Humoral Immune Dysfunction After Treatment With Rituximab. 2020 , 20, e590-e596		2
351	Das molekulare Tumorboard. 2020 , 26, 679-684		
350	Clinical features, treatment and risk factors for interstitial pneumonia in B-cell non-Hodgkin lymphoma patients.. 2020 , 9, 5139-5146		
349	Synthesis and analysis of silver-copper alloy nanoparticles of different ratios manifest anticancer activity in breast cancer cells. 2020 , 11,		6
348	Pharmacogenomics, Pharmacokinetics and Circulating Proteins as Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review. 2020 , 10,		5
347	Monoclonal Antibodies in Cancer Therapy. 2020 , 9,		98
346	Clinical Response and Pattern of B cell Suppression with Single Low Dose Rituximab in Nephrology.. 2020 , 1, 359-367		3
345	Chemotherapy combinations for B-cell lymphoma and chemo-free approach in elderly patients: an update on best practice. 2020 , 13, 851-869		1

344	Rituximab in people living with HIV affected by immune-mediated renal diseases: a case-series. 2020 , 31, 1426-1431	0
343	Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. 2020 , 4, 4091-4101	13
342	How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic. 2020 , 4, e432	15
341	Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer. 2020 , 5, e000753	12
340	A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy. 2020 , 4, 3886-3893	8
339	Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost-effectiveness analysis. 2020 , 9, 5312-5319	4
338	Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. 2020 , 17, 595-610	56
337	Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications. 2020 , 147, 1979-1986	2
336	T cell-engaging therapies - BiTEs and beyond. 2020 , 17, 418-434	124
335	A Microfluidic Single-Cell Cloning (SCC) Device for the Generation of Monoclonal Cells. 2020 , 9,	1
334	Initial Treatment of High Tumor Burden Follicular Lymphoma. 2020 , 34, 673-687	
333	The investigation and management of follicular lymphoma. <i>British Journal of Haematology</i> , 2020 , 191, 363-381	4-5 5
332	Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?. 2020 , 136, 4-6	37
331	Antibody Therapy Maintenance in Follicular Lymphoma. 2020 , 34, 689-699	
330	Recurrent Campylobacter Enteritis in Patients with Hypogammaglobulinemia: Review of the Literature. 2020 , 9,	7
329	O-GlcNAcylation of light chain serine 12 mediates rituximab production doubled by thiamet G. 2020 , 43, 863-875	
328	Rituximab in Ocular Adnexal Lymphoma and Orbital Inflammatory Disease. 2020 , 60, 63-75	
327	Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma. 2020 , 6, eaaz9798	17

326	Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma. 2020 , 20, 563-571	7
325	Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer. 2020 , 25, 853-858	12
324	Rituximab. 2021 , 330-338.e3	
323	Surveillance of the current situation regarding influenza vaccination according to medical oncologists in Japan. 2021 , 112, 433-443	
322	Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease. 2021 , 73, 347-354	7
321	Anti-CD20 treatment for B-cell malignancies: current status and future directions. 2021 , 21, 161-181	6
320	Gene Therapy and Gene Editing for Cancer Therapeutics. 2021 , 116-204	
319	Bleeding Associated with Thrombocytopenia. 2021 , 141-156	
318	Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma. 2021 , 33, 405-416	1
317	A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial. 2021 , 5, 984-993	3
316	Immunotherapy for Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2021 , 39, 343-345	2.2 1
315	Nano-Oncologicals: A Tortoise Trail Reaching New Avenues. 2009860	4
314	Targeted multi-epitope switching enables straightforward positive/negative selection of CAR T cells. 2021 , 28, 602-612	1
313	Does COVID-19 Vaccination Warrant the Classical Principle "??". 2021 , 57,	5
312	Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. 2021 , 204, 209-221	30
311	Targeted alpha immunotherapy of CD20-positive B-cell lymphoma model: dosimetry estimate of Ac-DOTA-rituximab using Cu-DOTA-rituximab. 2021 , 35, 639-647	2
310	Efficacy of Low-Dose Rituximab on Neuromyelitis Optica-Associated Optic Neuritis. 2021 , 12, 637932	1
309	Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. 2021 , 22, 678-689	24

308	BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL. 2021 , 138, 1843-1854	3
307	Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar. 2021 , 35, 459-468	2
306	[Rituximab immunomonitoring in autoimmune diseases: a support tool in clinical practice?]. 2021 , 42, 384-391	0
305	A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions. 2021 , 12, 681984	4
304	Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail. 2021 , 13,	11
303	Vaccination in Patients with Chronic Lymphocytic Leukemia: Current Problems. 2021 , 20, 91-106	
302	Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma. 2021 , 11, 55-66	1
301	SARS-CoV-2 vaccination efficacy and B-cell depletion therapy in systemic lupus erythematosus: Description of a case. 2021 , 30, 1698-1699	0
300	Biological Therapy in Primary Sjögren's Syndrome: Effect on Salivary Gland Function and Inflammation. 2021 , 8, 707104	2
299	The future of antibody therapy in chronic lymphocytic leukemia. 2021 , 26, 323-336	0
298	Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions. 2021 , 8, e593-e604	3
297	Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 148, 523-532.e8	11.5 4
296	[The molecular tumor board]. 2021 , 92, 1011-1015	2
295	A case of polymorphic dermal angitis in a B-cell chronic lymphocytic leukemia patient during rituximab therapy. 2021 , 33,	0
294	Production and Application of CAR T Cells: Current and Future Role of Europe. 2021 , 8, 713401	4
293	Breaking the Silence of Tumor Response: Future Prospects of Targeted Radionuclide Therapy. 2021 ,	0
292	Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy.. 2022 , 8, 26-43	1
291	Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies. 2021 , 39, 1297-1299	29

290	The tetraspan MS4A family in homeostasis, immunity, and disease. 2021 , 42, 764-781	5
289	Impact of rituximab on COVID-19 outcomes. 2021 , 100, 2805-2812	9
288	Prognostic Indicators of Survival in Sinonasal Diffuse Large B-Cell Lymphoma: A National Cancer Database Analysis. 2021 ,	0
287	Role of ceramide/sphingomyelin (SM) balance regulated through "SM cycle" in cancer. 2021 , 87, 110119	8
286	Separation of recombinant monoclonal antibodies IgG201 from a cell culture supernatant using an integrated aqueous two-phase system with thermo-separating EOPO. 2021 , 275, 119246	0
285	Rare Thyroid Cancers. 2006 , 393-402	1
284	The indolent B-cell lymphomas. 2006 , 131, 89-120	2
283	Vaccine therapies for non-Hodgkin's lymphomas. 2006 , 131, 283-315	1
282	Monoclonal antibodies in the treatment of malignant lymphomas. 2008 , 610, 155-76	3
281	Monoclonal Antibodies in Cancer Therapy. 2007 , 453-484	1
280	Monoclonal Antibodies: From Structure to Therapeutic Application. 2013 , 143-178	2
279	Orbital and Ocular Adnexal Lymphoma. 2015 , 145-153	1
278	Analysis of Humoral Immune Responses in Vaccine Trials. 2004 , 543-561	1
277	Monoclonal Antibodies. 2008 , 547-561	3
276	Monoclonal antibody therapy. 2009 , 303-406	3
275	Regulatory process for approval of biologicals for cancer therapy. 2009 , 613-629	0
274	Antibody-Based Therapies for Solid Tumors. 2011 , 245-256	1
273	Monoclonal antibody therapy. 2003 , 329-390	2

272	Application of Fluorescence in Studying Therapeutic Enzymes. 2019 , 1148, 105-114		2
271	Non-Hodgkin's Lymphoma. 2008 , 2371-2404		3
270	Malignant Diseases in Human Immunodeficiency Virus Infection. 2010 , 1765-1779		1
269	Follicular Lymphoma. 2006 , 348-373		1
268	Rituximab. 2003 , 235-258		2
267	Chronic lymphocytic leukemia/small lymphocytic lymphoma. 81-102		1
266	Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL.		1
265	Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2001 , 112, 1085-6	4.5	26
264	High Dose Cyclophosphamide Plus Recombinant Human Granulocyte-colony Stimulating Factor (rhG-CSF) in the Treatment of Follicular, Low Grade Non-Hodgkin's Lymphoma: CALGB 9150. <i>Leukemia and Lymphoma</i> , 2001 , 42, 1255-1264	1.9	2
263	Rituximab Toxicity in Patients with Peripheral Blood Malignant B-cell Lymphocytosis. <i>Leukemia and Lymphoma</i> , 2001 , 42, 1329-1337	1.9	26
262	Immunotargeting and therapy of cancer by advanced multivalence antibody scaffolds. 2020 , 28, 1018-1033		2
261	Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer. 1999 , 11, 187-90		12
260	Treatment of follicular and other indolent lymphomas. 1999 , 11, 333-8		2
259	Biologic therapy for lymphoma. 1999 , 11, 343-50		6
258	Radioimmunotherapy for lymphoma. 1999 , 11, 375-80		37
257	Monoclonal Antibody Therapy for Genitourinary Oncology: Promise for the Future. 2002 , 2615-2623		1
256	Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. 2000 , 22, 295-301		56
255	Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells. 1999 , 68, 1588-96		39

254	Hodgkin's disease and non-Hodgkin's lymphoma. 1999 , 6, 205-15	4
253	Advances in the immunotherapy of hematologic malignancies: cellular and humoral approaches. 1999 , 6, 222-8	6
252	Chronic lymphocytic leukemia. 1999 , 6, 253-61	9
251	Clinically useful monoclonal antibodies in treatment. 2002 , 55, 81-5	26
250	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. 2020 , 8,	3
249	Immunotherapy of lymphomas. 2020 , 130, 1576-1585	14
248	Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. 2011 , 121, 4268-80	125
247	Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects. 2007 , 226-32	23
246	Managing Indolent Lymphomas in Relapse. 2000 , 2000, 166-179	1
245	Rituximab treatment results in impaired secondary humoral immune responsiveness. 2002 , 100, 2257-2259	16
244	Rituxan in the Treatment of Cold Agglutinin Disease. 1998 , 92, 3490-3491	2
243	Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. 2000 , 95, 3052-3056	2
242	Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. 2000 , 95, 3900-3908	102
241	Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. 2000 , 96, 4055-4063	42
240	Targeting CD20: teaching an old dog new tricks. 2019 , 2019, 273-278	4
239	A Case of Rituximab-Induced Acute Thrombocytopenia in a Patient with Splenic Marginal Zone Lymphoma and Chronic Hepatitis C Virus Infection. 2019 , 20, 1394-1397	1
238	Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement. 2014 , 9, e100324	46
237	Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay. 2017 , 12, e0178544	21

236	Chronic Lymphocytic Leukemia. 1999 , 4, 352-369	30
235	A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer. 2016 , 7, 71536-71547	4
234	A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment. 2017 , 8, 113895-113909	11
233	Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development. 2018 , 9, 4020-4033	30
232	Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma. 2015 , 6, 27816-31	18
231	90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity. 2016 , 7, 7597-609	25
230	Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells. 2013 , 4, 218-30	19
229	Principle of Express Selection of Leading Producing Clones of Monoclonal Antibodies in the Development of Stable CHO-Based Cell Lines. 2019 , 35, 65-72	2
228	Therapy of gastric mucosa associated lymphoid tissue lymphoma. 2007 , 13, 3554-66	36
227	Current trends in management of hepatitis B virus reactivation in the biologic therapy era. 2011 , 17, 3881-7	47
226	Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue lymphoma. 2014 , 20, 2751-9	17
225	Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab. 2010 , 25, 86-92	24
224	Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP. 2019 , 34, 885-893	3
223	Biologics in dermatology: an integrated review. 2014 , 59, 425-41	15
222	Rituximab maintenance in follicular lymphoma patients. 2011 , 2, 281-8	6
221	Relapsed follicular lymphoma sequentially treated with rituximab and 90Y-ibritumomab tiuxetan. Case report. 2007 , 151, 109-12	3
220	Next generation of antibody therapy for cancer. 2011 , 30, 293-302	8
219	Fatal adenoviral hepatitis after rituximab therapy. 2006 , 130, 1557-60	18

218	Rituximab use for lymphoplasmacytic lymphoma during continuous renal replacement therapy. 2019 , 31, 258-261	0
217	Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature. 2020 , 9,	3
216	Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells. 2013 , 1, e31	17
215	Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome. 2021 , 1	0
214	Managing Indolent Lymphomas in Relapse. 2000 , 2000, 166-179	
213	Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. 2000 , 96, 1259-1266	6
212	Immunomodulation Strategies in Xenotransplantation. 2001 , 357-388	
211	Non-Hodgkinâs Lymphoma. 2001 , 310-322	
210	Immunology of Cancer. 2001 , 1641-1657	
209	Antibody-Targeted Gene Therapy. 2002 , 81-94	
208	A Case of Follicular Lymphoma with Cutaneous Infiltration.. 2002 , 64, 194-199	
207	Innovations in Cancer Therapeutics. 2002 , 93-116	
206	Akute lymphatische Leukämie bei älteren Patienten. 2002 , 421-436	
205	The Rise of Antibodies as Therapeutics. 2002 , 427-469	
204	Non-Hodgkin-Lymphome. 2003 , 1079-1093	
203	Drug immunoconjugates. 2003 , 435-446	
202	Non-Hodgkinâs Lymphoma. 2003 , 295-318	
201	New Developmental Agents and Directions in the Treatment of Acute Myelogenous Leukemia. 2003 , 153-160	

200 Cancer biotherapy: 2003 disease-related activity. **2003**, 615-674

199 Monoclonal Antibody Therapy in Chronic Lymphocytic Leukemia. **2004**, 269-298

198 Maligne Lymphome. **2004**, 1711-1774

197 Role of Radiotherapy in Lymphomas. **2004**, 229-240

196 Chemotherapy of Chronic Lymphocytic Leukemia. **2004**, 241-254

195 Non-Hodgkin lymphomas. **2004**, 575-616

194 Present Status and Perspectives of Antibody Therapy against Cancer. **2005**, 2, 15-21

1

193 Principles of Bioimmunotherapy. **2005**, 69-91

192 Biological Therapy of Non-Hodgkin's Lymphomas. **2006**, 249-277

191 Follikuläres Keimzentrums-Lymphom (zentroblastisch-zentrozytisches Lymphom). **2006**, 2899-2927

190 Hämoblastosen. **2006**, 630-713

189 Horizons for Cancer Chemotherapy (and Nonchemotherapy). **2006**, 445-457

188 Addition of Rituximab Significantly Improves Outcomes in Patients with Diffuse Large B-cell Lymphoma – A Single-center, Retrospective Study. **2007**, 50, 113-118

187 Fungal Rhinosinusitis. **2007**, 197-214

1

186 Monoclonal Antibodies as Therapeutic Agents. **2008**, 107-126

185 Therapeutic Antibodies and Immunologic Conjugates. **2008**, 531-544

184 Systemic Therapy. **2008**, 449-483

183 POEMS Syndrome and Other Atypical Plasma Cell Disorders. **2008**, 571-623

- 182 Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. **2008**, 141-164
- 181 Drug Immunoconjugates. **2009**, 451-462
- 180 Biological therapy of B and T cell lymphoproliferative disorders. **2009**, 693-709
- 179 Targeted Approaches to Drug Development. **2009**, 57-98 0
- 178 Pharmaceutical Perspectives of Cancer Therapeutics: Current Therapeutic Uses of Monoclonal Antibodies. **2009**, 321-363
- 177 Cell-Targeted Biologics and Emerging Targets: Rituximab, Abatacept, and Other Biologics. **2009**, 947-961
- 176 TRANSPLANT MEDICINE. **2009**, 1269-1294
- 175 Immunotherapy of Cancer. **2009**, 209-240 1
- 174 Lymphomas and Chronic Lymphocytic Leukemia. **2009**, 173-187
- 173 Biologic Therapies for Chronic Lymphocytic Leukemia. **2009**,
- 172 Biologic Therapies For Non-hodgkin Lymphoma And Hodgkin Disease. **2009**,
- 171 Monoclonal Antibody Therapy for Hematologic Malignancies. **2010**, 493-536
- 170 Multidisciplinary Treatment of Cancer. **2009**, 28-42
- 169 Ocular Adnexal Lymphoproliferative Disease. **2010**, 1-19
- 168 Primary Orbital Cancers in Adults. **2010**, 3-12 1
- 167 Overview of the Lymphoid Neoplasms. **2012**, 3-39
- 166 Overview of Therapy for Glomerular Disease. **2011**, 1278-1296
- 165 Brazilian experience using high dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation for malignant lymphomas. **2011**, 33, 432-8 1

164 Infections in Patients with Hematologic Malignancies Treated with Monoclonal Antineoplastic Therapy. **2011**, 47-66

163 Special Situations: Management of Elderly Patients and Chronic Lymphocytic Leukemia in Transformation. 327-337

162 Chronic Lymphocytic Leukemia (CLL). **2012**, 67-96

161 Ocular Adnexal Lymphoproliferative Disease. **2012**, 959-992

160 Maintenance treatment of follicular lymphoma: evidence from recent clinical trials. **2011**, 1, 1707-1716

159 Radiopharmaceuticals and Medical Imaging: Development of Radioimmunoconjugates for Radioimmunoimaging and Radioimmunotherapy of Malignant Diseases.

158 Non-Hodgkinian Lymphomas. **2012**, 115-157

157 Tumor Immunology and Immunotherapy. **2012**, 720-741

156 Development of Immunonconjugates for in Vivo Delivery: Cancer Diagnosis, Imaging, and Therapy. 57-81

155 Lymphomas. **2013**, 153-187

154 From Transplant to Tablets: A paradigm shift in Oncology. **2012**, 12, 402-5

o

153 Biological Treatments (Antibodies). **2013**, 915-948

152 Understanding the Mechanisms of Resistance to Rituximab: Paving the Road for the Development of Therapeutic Strategies to Overcome Rituximab-Resistance. **2013**, 73-92

151 Monoclonal Antibodies in Cancer. **2013**, 337-359

o

150 Cell-Targeted Biologics and Targets. **2013**, 978-1000

149 Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Prototype. **2013**, 93-124

148 mAbs targeting CD20 and other lymphocyte CD markers in lymphoma treatment. **2013**, 6-19

1

147 Historic Outline of the Development of Drugs Targeting B Cells. **2014**, 1-10

- 146 Chronic Lymphocytic Leukemia. **2014**, 1958-1978.e7
- 145 Therapeutic Antibodies and Immunologic Conjugates. **2014**, 508-518.e7 0
- 144 Lymphomes : principes thfapeutiques et imagerie post-thfapeutique. **2014**, 265-298
- 143 Hematologic Malignancies. **1999**, 4, 287-292
- 142 Monoclonal antibodies in chronic lymphocytic leukemia: facts and expectations. **2015**, 136-154
- 141 Impact of Diseases, Comorbidity, and Target Physiology on ADME, PK, and PK/PD of Therapeutic Biologics. 1-22 1
- 140 Diagnostic Applications of Nuclear Medicine: Lymphomas. **2016**, 1-42
- 139 Bleeding Associated with Thrombocytopenia. **2016**, 103-117
- 138 Monoclonal Antibodies in Pediatric Acute Lymphoblastic Leukemia. **2017**, 201-237
- 137 Diagnostic Applications of Nuclear Medicine: Lymphomas. **2017**, 353-393
- 136 COMPARISON IMMUNOCHEMOTHERAPY AND CHEMOTHERAPY EFFICASY IN FOLLICULAR LYMPHOMA. **2017**, 16, 24-31
- 135 Rituximab-Related Late-Onset Neutropenia in Kidney Transplant Recipients Treated for Antibody-Mediated Acute Rejection. **2017**, 15, 414-419 4
- 134 Alkylating Agent-Induced ER Stress Overcomes Microenvironmental Resistance to Lymphoma Therapy.
- 133 Anticorps monoclonaux en oncologie : dclencher une rponse immunitaire en plus de la rduction tumorale spcifique.. **2018**, 202, 707-735
- 132 Weight Parameters and Green Tea Effect; A Review. **2018**, 3, 104-107
- 131 Resistance to Monoclonal Antibody Therapeutics in Lymphoma. **2019**, 27-55
- 130 Molecular and clinical progress in follicular lymphoma lacking the t(14;18) translocation (Review). *International Journal of Oncology*, **2020**, 56, 7-17 4-4
- 129 Antibody Therapy in Follicular Lymphoma. **2020**, 189-206

- 128 Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma. **2020**, 159-212
- 127 VIII. Adult Nephrotic Syndrome: Treatment with Rituximab. **2020**, 109, 933-938
- 126 Ocular Adnexal Lymphoproliferative Disease. **2021**, 769-816 1
- 125 PepSeA: Peptide Sequence Alignment and Visualization Tools to Enable Lead Optimization.
- 124 Long Non-Coding RNAs in Diffuse Large B-Cell Lymphoma. **2020**, 7, 2
- 123 Chapter 33: Therapeutic Applications of Radioactive Agents. **2020**,
- 122 COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge. **2021**, 12, 763412 5
- 121 The Malignant Lymphomas. **2000**, 353-380
- 120 Chronic Lymphocytic Leukemia and Related Chronic Leukemias. **2006**, 1210-1228
- 119 The Non-Hodgkin's Lymphomas. **2006**, 1256-1284
- 118 Immun- und Gentherapie bei malignen Erkrankungen. **2006**, 285-290
- 117 Neue Arzneimittel. 37-107
- 116 Dawn of a new era in molecular cancer therapeutics. **2005**, 63, 1-17 1
- 115 Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. **2006**, 131, 221-50 1
- 114 Monoclonal Antibody Therapy of Cancer. **2007**, 321-342 1
- 113 Lymphoma. **2006**, 107-115
- 112 Monoclonal Antibodies in Lymphomas. **2007**, 511-536
- 111 Antibody Therapy of Cancer. **2008**, 371-412

110	Targeted Therapy in Chronic Lymphocytic Leukemia. 2008 , 61-86	
109	Targeted Therapy in Lymphoma. 2008 , 157-182	
108	Non-Hodgkin-Lymphome niedriger Malignität. 342-384	
107	Monoclonal Antibodies for Cancer Immunotherapy. 2021 , 273-312	1
106	Remission of cold hemagglutinin disease induced by rituximab therapy. 2001 , 164, 1405	1
105	Biological response modifiers in cancer. 2006 , 8, 33	4
104	Targeted radio-immunotherapy with Bexxar produces durable remissions in patients with late stage low grade non-Hodgkin's lymphomas. 2004 , 115, 255-72	2
103	Tumor targeting using liposomal antineoplastic drugs. 2008 , 3, 21-9	40
102	Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects. 2007 , 1, 215-27	13
101	B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis. 2009 , 3, 225-32	4
100	I-Tositumomab in lymphoma. 2009 , 16, 32-47	6
99	Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma. 2010 , 35, 148-57	77
98	Rituximab: a review of dermatological applications. 2009 , 2, 29-37	23
97	Rituximab maintenance in relapsed or refractory follicular non-Hodgkin's lymphoma: the evidence of its therapeutic value. 2007 , 2, 121-9	
96	Radioimmunotherapy of non-Hodgkin's lymphoma: from the 'magic bullets' to 'radioactive magic bullets'. 2011 , 84, 391-407	37
95	Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma. 2011 , 84, 381-9	32
94	C-MOPP: the forgotten regimen plus Rituximab for untreated and relapsed follicular lymphoma. 2011 , 1, 204-14	1
93	Predicting success or failure of immunotherapy for cancer: insights from a clinically applicable mathematical model. 2012 , 2, 204-13	8

92	Advances and application of radioimmunotherapy in non-Hodgkin lymphoma. 2012 , 2, 86-97	7
91	Cancer therapy with bispecific antibodies: Clinical experience. 2010 , 12, 340-9	42
90	Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy. 2015 , 4, 143-51	24
89	Efficacy and safety of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma: a meta-analysis. 2015 , 8, 17515-22	9
88	CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas. 2016 , 6, 403-24	18
87	Fulminant Colitis Following Rituximab Therapy. 2016 , 12, 58-60	4
86	Physicochemical Evaluation of Lyophilized Formulation of -SCN-Bn-DOTA- and -SCN-Bn-DTPA-rituximab for NHL Radio Immunotherapy. 2016 , 15, 295-302	
85	Combination of celecoxib (Celebrex) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas. 2017 , 6, 27-42	2
84	Pre-treatment partial-volume-corrected TLG is the best predictor of overall survival in patients with relapsing/refractory non-hodgkin lymphoma following radioimmunotherapy. 2018 , 8, 407-414	5
83	[Clinical efficacy of modified rituximab combined with fresh frozen plasma and methylprednisolone in the treatment of 9 patients with chronic lymphocytic leukemia with thrombocytopenia as the main manifestation]. 2019 , 40, 243-245	
82	Follicular lymphoma with paraneoplastic pemphigus as the first symptom: a case report and review of the literature. 2020 , 13, 1915-1923	3
81	[Rituximab-induced acute thrombocytopenia in a patient with splenic marginal zone lymphoma: a case report and literature review]. 2021 , 42, 338-342	
80	NCCN Guidelines [®] Insights: B-Cell Lymphomas, Version 5.2021. 2021 , 19, 1218-1230	10
79	Theranostics of Hematologic Disorders. 2022 , 359-432	
78	Clinical development of IDH1 inhibitors for cancer therapy.. 2021 , 103, 102334	1
77	Diagnostische und therapeutische Antikörper in der Onkologie âState of the Art. <i>Acta Chirurgica Austriaca</i> , 2000 , 32, 260-263	
76	Intensive Safety Monitoring of Rituximab (Biosimilar Novex and the Innovator) in Pediatric Patients With Complex Diseases.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 785770	5.6 0
75	Off-the-shelf PSCA-directed chimeric antigen receptor natural killer cell therapy to treat pancreatic cancer.. <i>Gastroenterology</i> , 2022 ,	13.3 5

74	The Enhanced Cytotoxic Effects in B-Cell Leukemia and Lymphoma Following Activation of Prostaglandin EP4 Receptor and Targeting of CD20 Antigen by Monoclonal Antibodies.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	
73	Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review).. <i>International Journal of Oncology</i> , 2022 , 60,	4.4	0
72	The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma.. <i>Leukemia and Lymphoma</i> , 2022 , 1-10	1.9	1
71	Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma.. <i>Bone Marrow Transplantation</i> , 2022 ,	4.4	0
70	Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer: A Systematic Review and Meta-analysis.. <i>JAMA Oncology</i> , 2022 ,	13.4	0
69	Journal Club Review of "Comparison of Two Rituximab Induction Regimens for Antineutrophil Cytoplasm Antibody-Associated Vasculitis: Systematic Review and Meta-Analysis".. <i>ACR Open Rheumatology</i> , 2022 ,	3.5	
68	Antibody response to COVID-19 vaccination in patients with lymphoma.. <i>International Journal of Hematology</i> , 2022 , 1	2.3	0
67	PepSeA: Peptide Sequence Alignment and Visualization Tools to Enable Lead Optimization.. <i>Journal of Chemical Information and Modeling</i> , 2022 ,	6.1	
66	Practical Guidance for the Diagnosis and Management of Secondary Hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees.. <i>Journal of Allergy and Clinical Immunology</i> , 2022 ,	11.5	2
65	Characterization of the canine CD20 as a therapeutic target for comparative passive immunotherapy.. <i>Scientific Reports</i> , 2022 , 12, 2678	4.9	0
64	Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering.. <i>Communications Biology</i> , 2022 , 5, 229	6.7	0
63	Signaling domains of cancer-associated glycolipids.. <i>Glycoconjugate Journal</i> , 2022 , 39, 145	3	0
62	Rituximab-treated lymphoma patients develop strong CD8 T-cell responses following COVID-19 vaccination.. <i>British Journal of Haematology</i> , 2022 ,	4.5	0
61	Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab.. <i>Clinical and Experimental Medicine</i> , 2022 ,	4.9	1
60	Tumor Microenvironment of Lymphomas and Plasma Cell Neoplasms: Broad Overview and Impact on Evaluation for Immune Based Therapies.. <i>Frontiers in Oncology</i> , 2021 , 11, 719140	5.3	0
59	Patient parameters and response after administration of rituximab in pediatric mature B-cell non-Hodgkin lymphoma.. <i>Pediatric Blood and Cancer</i> , 2021 , e29514	3	0
58	Epitope Mapping of an Anti-CD20 Monoclonal Antibody (CMab-60) Using Enzyme-Linked Immunosorbent Assay.. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2021 , 40, 250-254	4.9	0
57	Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200088	2.2	4

56	Prompt Hematological Recovery in Response to a Combination of Pegylated Interferon α 2a and Rituximab in a Profoundly Immuno-Suppressed Hairy Cell Leukemia Patient with a Mycobacterial Infection at Onset: Benefits and Drawbacks of Rapid Immune Reconstitution.. <i>Hematology Reports</i> , 2022 , 14, 135-142	0.9	0
55	Follicular lymphomas. 338-366		
54	Treatment approaches to MALT/marginal zone lymphoma. 404-409		
53	Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma.. <i>Leukemia Research Reports</i> , 2022 , 17, 100319	0.6	
52	A Fatal Breakthrough Coronavirus Disease 2019 Case Following Bendamustine-Rituximab Therapy.. <i>International Journal of Infectious Diseases</i> , 2022 ,	10.5	0
51	Rheumatoid arthritis: current therapeutics compendium.. <i>Endocrine Regulations</i> , 2022 , 56, 148-162	1.9	
50	FDG PET/CT and Dosimetric Studies of Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?. <i>Molecular Imaging and Biology</i> , 2022 ,	3.8	0
49	Treatment of indolent lymphoma.. <i>Blood Research</i> , 2022 , 57, 120-129	1.4	
48	Template-Assisted Crystallization Behavior in Stirred Solutions of the Monoclonal Antibody Anti-CD20: Probability Distributions of Induction Times. <i>Crystal Growth and Design</i> ,	3.5	1
47	Cancers of the Blood. 2022 , 67-131		
46	Rituximab and future biological therapies. 2013 , 333-341.e3		1
45	Diagnostic Applications of Nuclear Medicine: Lymphomas. 2022 , 1-45		
44	Ocular adnexal lymphoma: A single-institution retrospective study. <i>Saudi Journal of Ophthalmology</i> , 2021 , 35, 230	0.9	
43	Recent Developments in the Immunotherapeutic Approaches for Cancer Treatment. 2022 , 413-449		
42	Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies. <i>Frontiers in Oncology</i> , 12,	5.3	0
41	Biological impediments to monoclonal antibody-based cancer immunotherapy. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 1493-1501	6.1	40
40	General Principles of Medical Cancer Treatment.		
39	Antibody-mediated depletion of programmed death 1-positive (PD-1+) cells. <i>Journal of Controlled Release</i> , 2022 , 349, 425-433	11.7	

38	Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 1693-1699 ^{6.1}	2
37	A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 1559-1564	6.1 10
36	Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review. 2022 , 18, 2943-2966	1
35	Secondary rituximab-associated versus primary immunodeficiencies: The enigmatic border.	0
34	Late-onset toxicities of monoclonal antibodies in cancer patients. 2022 , 14, 1067-1083	0
33	Immunoglobulin Superfamily Receptor Translocation Associated 2 Protein on Lymphoma Cell Lines and Hairy Cell Leukemia Cells Detected by Novel Monoclonal Antibodies. 2005 , 11, 87-96	14
32	Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway. 13,	1
31	The Evolution of Antibodies into Versatile Tumor-Targeting Agents. 2005 , 11, 129-138	7
30	Anti-viral efficacy of a next-generation CD4-binding site bNAb in SHIV-infected animals in the absence of anti-drug antibody responses. 2022 , 25, 105067	0
29	Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences. 2022 , 155, 335	0
28	Diagnostic Applications of Nuclear Medicine: Lymphomas. 2022 , 431-474	0
27	Diagnostic Accuracy of Four Serological Tests for COVID-19 and Differences in Antibody Positivity Rates Based on the Need for Treatment or Ventilator Support. 2022 , 13, 29-37	0
26	Drug Allergy: A 2022 Practice Parameter Update. 2022 ,	1
25	Low Cost Immunosuppressive Strategies in Renal Transplantation.	0
24	Off-Label Uses of Rituximab in Dermatology.	1
23	Treatment of Indolent Cutaneous B-Cell Lymphoma with Intralesional or Intravenous Rituximab. 2022 , 14, 4787	1
22	Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review.	2
21	Molecular Diagnostics in Cancer. 1-14	0

20	Monoclonal Antibody and Targeted Toxin Therapy. 1-31	0
19	Determinants of Antibody Response to SARS-CoV-2 Vaccines in Liver Transplant Recipients: The Role of Immunosuppression Reduction. 2022 , 10, 1827	0
18	The effects of COVID-19 infection on the mortality of patients receiving rituximab therapy.	0
17	Seroconversion among rituximab-treated patients following SARS-CoV-2 vaccine supplemental dose. 2022 , 245, 109144	0
16	Transitioning immunotherapy in neuromyelitis optica spectrum disorder –when and how to switch. 1-12	0
15	Efficacy and safety of rituximab for primary nephrotic syndrome with acute kidney injury: A two-center prospective cohort study. 2022 , 109211	0
14	The unmet need for COVID-19 treatment in immunocompromised patients. 2022 , 22,	2
13	Radio-immunotherapy by ¹⁸⁸ Re-antiCD20 and stable silencing of IGF-IR in Raji cells, new insight in treatment of lymphoma.	0
12	Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives. 2023 ,	1
11	Flashback Foreword: Chimeric Anti-CD20 Monoclonal Antibody Therapy. 2023 , 41, 151-152	0
10	Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. 2023 , 22,	0
9	Immunotherapy for Hematological Cancers. 2023 , 1-15	0
8	Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab. 2023 ,	0
7	The efficacy of the rituximab-containing rescue-regimen for severe hemophilia A inhibitor children who relapsed following successful immune tolerance induction with rituximab in China. 2023 , 223, 123-126	0
6	Intérêt du dosage des anticorps antimédicaments dans les rhumatismes inflammatoires. 2022 , 179-189	0
5	Computational and Experimental Evaluation of Linker Peptides and Thioredoxin Fusion Tag in CD20-rituximab Specific Interactions. 2023 , 21,	0
4	Opposite Functions of Mono- and Disialylated Glycosphingo-Lipids on the Membrane of Cancer Cells. 2023 , 151-169	0
3	Application of a Novel Aptamer Beacon for Rapid Detection of IgG1 Antibody Drugs.	0

- 2 Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey.
- 1 Targeted therapy. **2023**, 413-458